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Summary 
 
Cell growth is a tightly regulated process, where a cell adapts its growth 
according to nutrient availability and cellular stress. Tor (Target Of Rapamycin) is an 
evolutionary conserved protein kinase and central controller of cell growth.  It is found in 
two functionally distinct protein complexes termed TORC1 and TORC2. Rapamycin-
sensitive TORC1 mediates temporal control of cell growth whereas rapamycin-
insensitive TORC2 mediates spatial control of cell growth. Although many cellular 
processes regulated by TORC1 have been identified, the molecular mechanisms by which 
TORC1 signals to these diverse processes are not well understood. For example, only few 
substrates of either TORC1 or its direct effector SCH9 are known in the yeast S. 
cerevisiae. To identify novel TORC1 targets in a global manner, a quantitative 
phosphoproteomic strategy was established, which allowed to reproducibly relative 
quantify more than 2,500 phosphorylation sites in untreated and rapamycin-treated cells. 
In parallel, a proteomic study was performed to monitor changes in protein abundances 
induced by rapamycin treatment. In total 55 and 78 proteins were significantly less 
respectively more phosphorylated upon rapamycin treatment in the phosphoproteomic 
analysis. Among them there were many proteins already linked to the TORC1 signaling 
pathway, which functioned as internal control. Many regulated proteins were 
transcription factors or kinases, which are often present at low copy number in the cell, 
suggesting an in-depth analysis of the yeast phosphoproteome. Among the 
hypophosphorylated phosphopeptides the PKA consensus motif was significantly over-
represented suggesting a cross-talk between the TORC1 and PKA signaling pathways. 
This hypothesis was further supported at the molecular level for the protein Maf1, Ksp1 
and Ypk3. In addition, to validate and better characterize the phosphoproteomic data, 
more targeted experiments for some of the regulated phosphoproteins were performed. 
This revealed the involvement of novel proteins (like Hal5, Isw2, Kkq8, Ldb19, Mtc1, 
Noc2 and Vtc2) in TORC1 signaling. On these proteins, several rapamycin-regulated 
phosphorylation sites were mapped and their absolute phosphorylation occupancy was 
estimated. Interestingly, rapamycin-regulated phosphorylation sites usually exhibited low 
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to moderate stoichiometries. Subsequent mutagenesis experiment will address the 
involvement of those specific phosphorylation sites in TORC1 signaling. 
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Abbreviations 
 
8-Br-cAMP 8- Bromoadenosine- 3', 5'- cyclic monophosphate 
CID  collision-induced dissociation 
cpm  counts per minute 
HA  haemagglutinin 
IMAC   immobilized metal affinity chromatography 
kDa  Kilodalton 
λPPase λ protein phosphatase 
LC-MS/MS  liquid chromatography coupled to mass spectrometry 
LTQ   linear trap quadrupole 
m/z   mass-to-charge ratio 
MS   mass spectrometry 
MW  molecular weight 
PKA   protein kinase A 
PP242  2-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-1H-indol-5-ol 
RP-HPLC reverse-phase high-performance liquid chromatography 
SDS-PAGE  sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SILAC  stable isotope labeling with amino acids in cell culture 
(m)Tor  (mammalian) Target of rapamycin 
TORC1 Tor complex 1  
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1. Introduction 
 
1.1. Posttranslational Modifications Increase Proteome Complexity 
 
The global complement of genes encoded by an organism is known as the 
genome. Accordingly, in 1994 the term proteome was coined by Marc Wilkins to 
describe the global set of all proteins encoded by the genome. Both genome size and the 
number of genes encoded in the genome can vary dramatically from species to species. 
For example, the human genome contains an estimated 25,000 to 30,000 genes while the 
genome of the yeast S. cerevisiae encodes approximately 6,100 genes. However, the 
complexity of proteomes usually exceeds many times the complexity of genomes. This is 
due to transcriptional, translational and posttranslational modifications. Posttranslational 
modifications can be divided into three broad categories. The first and probably most 
common is the covalent attachment of chemical groups to amino acid side chains. The 
second is the hydrolytic cleavage of a precursor polypeptide into two or more mature 
proteins. The third category is protein splicing [1], in which internal protein segments 
(inteins) are excised from a precursor protein, followed by ligation of the flanking 
segments (exteins). The first two types of posttranslational modifications require specific 
enzymes like kinases, acetylases, methylases, glycosydases or proteases, while protein 
splicing is an autocatalytic reaction and does not require external enzymes. Interestingly, 
there are very stable posttranslational modifications because of  thermodynamic reasons 
or of lack of enzymes capable of reversing them. And there are unstable modifications 
which can be reverted very quickly. Among the last there are reversible modifications 
such as phosphorylation, acetylation, glycosylation and ubiquitination that allow a protein 
to oscillate between two different states (e.g. active/inactive). For this reason, a cell 
usually contains counteracting enzymes for the addition/removal of phosphates 
(kinases/phosphatases), acetyl groups (acetyltransferares/deacetylases), glycans 
(glycosyltransferases/glycosidases) and ubiquitin (ubiquitin ligases/isopeptidases). 
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The pervasiveness of posttranslational modifications is reflected by the high 
number of enzymes necessary to catalyze these modifications. To date, more than 500 
kinases have been estimated to be encoded by the human genome [2]. In the genome of 
the yeast S. cerevisie protein kinases represent the largest gene family with approximately 
130 genes [2] and similar proportions have been found in the fly D. melanogaster (~240 
kinase genes) and the worm C. elegans (~450 kinase genes) genomes [2]. However, the 
number of enzymes catalyzing posttranslational modifications is not the only factor 
explaining the high complexity of proteomes. A second important parameter is that 
several different protein substrates can be targeted by the same modifying enzyme. 
Therefore, if one assumes that the 500 kinases present in the human genome 
phosphorylate on average five proteins at five different phosphorylation sites, 12,500 
different proteomes might be produced in total. This is still an underestimation of the real 
impact of protein phosphorylation because there are proteins known to be phosphorylated 
at dozens of sites. For example, more than 15 different phosphorylation sites have been 
identified in the insulin receptor, which means that at least 32,768 different variants of 
the receptor could be generated just by differential phosphorylation! Finally, since a 
protein is often multiply modified with different types of modifications, enormously high 
numbers of variants of the same protein might exist. 
The functional consequences of posttranslational modifications vary from protein 
to protein, but some common traits can be identified. The introduction of negatively 
charged groups (e.g. by phosphorylation or sulfation) or the removal of positively 
charged groups (e.g. by acetylation), for example, dramatically influences the protein 
microenvironment due to electrostatic interactions. Or the introduction of certain groups, 
phosphates for instance, can promote protein/protein interactions. Finally, some 
posttranslational modifications lead to changes of subcellular localization. This is the 
case for polyubiquitination that targets proteins to the proteasome or lipidation of serines 
and glycines, which often cause proteins to associate with membranes. 
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1.2. Protein Phosphorylation  
 
 The most frequent and versatile posttranslational modification is protein 
phosphorylation. It occurs in eukaryotes and less frequently in prokaryotes. The residues 
phosphorylated in eukaryotic cells are mostly serines, threonines and tyrosines, whose 
nucleophilic hydroxyl groups attack the electrophilic γ-phosphate of ATP or, less 
frequently, GTP. In prokaryotes the phosphorylated residues are typically histidines and 
aspartic acids. In the so called bacterial two-component system [3], signal transduction 
occurs through the transfer of a phosphate group from ATP to the sensor kinase, a 
histidine kinase. The activated histidine kinase catalyses the subsequent transfer of the 
phosphate group to an aspartic acid residue on the response regulator, which stimulates or 
represses the expression of specific target genes.  
It is estimated that a third of all eukaryotic proteins are phosphorylated at some 
stage in their life cycle and that approximately 2% of all genes in a eukaryotic genome 
encode protein kinases [2, 4]. This clearly underlines the importance of protein 
phosphorylation and suggests a tight crosstalk between kinases and their substrates. To 
fulfill the many complex tasks, a protein kinase must bind to and recognize complex 
specificity determinants in the substrate besides just binding the phosphorylatable 
residue. This is reflected by the high variation in the substrate binding site architecture of 
the different protein kinases.  
 
 
1.2.1. The Biological Rationale of Protein Phosphorylation 
 
Phosphorylation is a versatile modification that can significantly alter the function 
of a target protein. It can modulate the catalytic activity of enzymes, it can lead to 
changes in subcellular localization, affect the half-life of proteins or promote 
protein/protein interactions. The last case can be illustrated by the epidermal growth 
factor (EGF) signaling. Binding of EGF to its cognate receptor triggers dimerization of 
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the receptor to induce trans-phosphorylation at multiple tyrosine residues. This in turn 
generates specific phosphotyrosine motifs that recruit additional EGF signaling 
components like the Grb2 adaptor protein through the binding of its SH2 domain to the 
phosphorylated receptor. In addition to Grb2, phosphatidylinositol 3-kinases (PI3Ks) 
bind to the phosphorylated EGF receptor via their SH2 domains to locally induce the 
production of PtdIns(3,4,5)P3, which is necessary for the recruitment of Pdk1 and Akt to 
the plasma membrane. Finally, phospholipase Cγ also binds to phosphorylated EGF 
receptor via its SH2 domain leading to local production of diacylglycerol and Ins(1,4,5)P3 
(IP3). Again, the relevance of such phosphorylation-induced protein/protein interaction is 
underlined by the number and types of domains devoted to specifically recognize certain 
phosphorylation motifs [5]. The PTB domain also binds phosphotyrosine motifs, while 
14-3-3 proteins and the WW and WD40 domains are necessary to bind specific motifs 
within phosphoserine residues.  
Besides affecting protein/protein interactions, phosphorylation also induces 
changes in subcellular localization. This is well illustrated by many yeast transcription 
factors whose nucleo-cytoplasmic distribution is influenced by TORC1-dependent 
phosphorylation (see below) [6]. For example, phosphorylated Gln3 is kept in the cytosol 
by binding to its cytoplasmic repressor Ure2, but it rapidly translocates to the nucleus 
upon dephosphorylation [7]. Protein phosphorylation can also promote ubiquitin-
mediated degradation of proteins. This is especially important for cell cycle proteins that 
must be quickly synthesized and efficiently degraded to ensure that a cell traverses the 
cell cycle in a regulated and unidirectional way. The yeast proteins Sic1, Far1, Cdc6, 
Cln1, Cln2 and Swe1 are recognized by an E3 ubiquitin protein ligase called the Skp1-
Cdc53-F-box complex (SCF) only after they have been phosphorylated by the Cln-Cdc28 
kinase [8]. Phosphorylation primes these proteins for subsequent degradation and ensures 
that the constitutively active SCF complex only degrades a specific subset of proteins, i.e. 
those that have been previously phosphorylated by the Cln-Cdc28 kinase.   
Another interesting consequence of protein phosphorylation is the binding of 
positively charged ions to store cations. Phosvitin, an antioxidant protein that accounts 
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for more than 50% of the total proteins of egg yolk, contains more than 120 
phosphoserines, which chelate iron to prevent the oxidation of yolk lipids [9]. 
 
 
1.2.2. Regulation of Protein Phosphorylation 
 
Considering the pervasiveness and physiological relevance of protein 
phosphorylation it is expected that the biocatalyst responsible for this modification is 
tightly controlled to prevent aberrant phosphorylation/dephosphorylation. Likewise, it is 
not surprising that constitutively active protein kinases are responsible for several 
malignancies (e.g. Bcr-Abl kinase) and are exploited by some viruses to invade a host 
cell (e.g. v-Src kinase).  
Protein kinases are almost always constitutively inactive and they are “switched 
on” only in response to specific stimuli. They are often subjected to multiple control 
mechanisms. A notable exception is the constitutively active casein kinase 2 which 
amazingly enough, phosphorylates more than 300 substrates [10]. There are multiple 
synergistic modes for keeping protein kinases silent in the basal, un-stimulated state. 
Some kinases have regulatory and catalytic domains in separate subunits. For example, 
protein kinase A (PKA) is a tetramer formed by two catalytic (C) and two regulatory (R) 
subunits. In its inactive state, all four subunits form the inactive R2C2 complex while 
binding of cAMP to the R subunits leads to dissociation of the regulatory subunits to 
liberate the active C subunits [11]. A similar logic is used by other kinases where 
regulatory and catalytic subunits or domains are in cis. In these kinases activation 
typically leads to conformational rearrangements to allow access of ATP to the active 
site. Also, regulatory subunits can act as activators instead of repressors of the kinase 
activity. This mechanism is used by cyclin-dependent kinases that, as the name implies, 
are active only when the cyclin subunits are bound to kinase subunits [12].  
The aforementioned processes are often insufficient to fully activate a protein 
kinase. Frequently, protein kinases must be phosphorylated for full activity. This has 
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been extensively documented for AGC kinases, which are phosphorylated at three well-
conserved positions: the activation loop (T-loop), the hydrophobic motif (HM) and the 
turn motif (TM). The activation loop is a protein segment that connects the N- and C-
lobes of the kinase and is in close proximity to the ATP-binding pocket. This loop is 
connected to the N-lobe through an α-helix known as αC-helix. Phosphorylation of the 
activation loop by an upstream kinase (Pdk1 in mammals and Pkh1/2 in yeasts) leads to a 
conformational change in the αC-helix that allows the formation of hydrogen bond 
interactions crucial for the catalytic activity [13, 14]. Furthermore, phosphorylation of the 
hydrophobic motif by kinases other than Pdk1 (Pkh1/2), allows it to fold back in a 
hydrophobic pocket in the N-lobe, which leads to further stabilization of the αC-helix in 
the active conformation [14, 15]. Finally, turn motif phosphorylation helps stabilizing the 
rearrangements of the hydrophobic motif and therefore results in an even increased 
catalytic activity. 
In summary, regulation of a protein kinase occurs only under specific 
circumstances. The many different requirements a protein kinase has to meet before 
becoming fully activated guarantee multiple-safe mechanisms to prevent aberrant 
phosphorylation. 
 
 
1.3. The Eukaryotic Kinome 
 
In analogy to the proteome, the term kinome is referred to the whole complement 
of kinases encoded by an organism [2]. Sequencing of the major eukaryotic genomes 
allows to classify the kinome into groups, families and subfamilies. Based on sequence 
similarities of the catalytic domains, the eukaryotic protein kinases can be divided into 8 
groups: AGC, CaMK, CK1, CMGC, RGC, STE, TK and TKL [2]. The human AGC 
kinase group contains more then 60 different kinases, whereas the yeast genome encodes 
around 20 AGC kinases. The acronym “AGC” comes from three important and closely 
related kinase families: the protein kinase A, protein kinase G and protein kinase C. 
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Interestingly, the activity of all three kinases is allosterically regulated by second 
messengers [16]. PKC is usually activated by calcium ions and diacylglycerol (DAG) 
[17], whereas PKA and PKG respond to intracellular cAMP [11] and cGMP [18] levels, 
respectively. PKB, another important member of the AGC group is regulated by 
PtdIns(3,4,5)P3 and PtdIns(3,4)P2 [19]. The hallmark of the second group, the 
Ca2+/calmodulin-dependent protein kinase (CaMK) group, is the regulation of the 
catalytic activity by calcium/calmodulin. The casein kinase (CK1) and the receptor 
guanylate cyclases (RGC) groups contain only a few but fundamental kinases. The RGC 
group is an evolutionary recent group since yeast and other lower eukaryotes do not 
encode RGC kinases. Interestingly both CK1 and RGC groups are enormously expanded 
in the worm kinome, containing around 80 and 30 different kinases, respectively [2]. The 
CMGC group owes its name to cyclin-dependent kinases (CDKs), mitogen-activated 
protein kinases (MAP kinases), glycogen synthase kinases (GSKs) and CDK-like kinases. 
This rather large group contains several essential kinases, whose aberrant expressions are 
often associated with pathological conditions [20]. The STE kinase group owes its name 
to the budding yeast Ste7, Ste11 and Ste20 kinases which are important regulators of the 
MAPK cascade. The tyrosine kinase (TK) group contains kinases that catalyze phosphate 
transfer onto tyrosine residues, a function which emerged only late in evolution. As a 
result, fungi do not encode these enzymes, although tyrosine phosphorylation exists due 
to the presence of dual specificity kinases. Finally, the tyrosine kinase-like (TKL) group 
comprises S/T kinases named so because of their close sequence similarity to tyrosine 
kinases. Like their close relatives, they are not present in fungi but they constitute the 
largest group in the plant kinome. 
 
 
1.4. TOR, an Atypical Protein Kinase 
 
In the eukaryotic kinome there are four additional kinase groups which do not 
share clear sequence similarity with the kinase groups introduced before. They are 
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therefore named atypical kinases. Among them is the phosphatidylinositolkinase-related 
protein kinase (PIKK) group. It contains kinases whose catalytic domain resembles the 
catalytic domain of lipid kinases (PI3K and PI4K) although they do not exhibit lipid 
kinase activity. The founding members of the PIKK group are Tor1 and Tor2, two protein 
kinases identified as target of the immunosuppressive drug rapamycin (hence the name 
Target Of Rapamycin). It is only thanks to rapamycin that these two protein kinases 
could be originally identified and characterized. Rapamycin, a macrocyclic lactone 
produced by the bacterium S. hygroscopicus, was initially classified as an antifungal 
agent but due to its immunosuppressive effects its use as an antifungal drug was 
abandoned. Remarkably, some years later rapamycin attracted much attention due to the 
discovery of its inhibitory activity on proliferating tumor cells. This made rapamycin 
very promising for clinical use but it was crucial to identify its cellular target and mode of 
action before submitting the compound to clinical trials. Since both yeast and mammalian 
cell growth was inhibited by rapamycin, yeast could be exploited to identify the cellular 
target of the drug. Therefore, a genetic screen in the yeast S. cerevisiae was performed to 
identify rapamycin resistant mutants [21]. Interestingly, the screen identified three 
different types of mutants: fpr1, tor1 and tor2 mutants. After some additional 
experiments it became finally clear that rapamycin was targeting and inhibiting Tor1 and 
Tor2 kinase activity upon formation of a complex with the proline isomerase Fpr1.  
Biochemical purification of yeast Tor1 and Tor2 revealed that these proteins form 
two structurally and functionally different multiprotein complexes in the cell, TORC1 
and TORC2 [22]. Both complexes are conserved in higher eukaryotes and they perform 
essential functions. Yeast TORC1 contains either Tor1 or Tor2 and the three proteins 
Lst8, Kog1 and Tco89 [22-24], whereas TORC2 contains Tor2 together with Lst8, Avo1, 
Avo2, Avo3 and Bit61 [22-24]. Interestingly, only the function of TORC1 is inhibited by 
rapamycin, which is probably the consequence of steric hindrance between the TORC2-
specific components and the rapamycin/Fpr1 complex. But what is the function of the 
Tor kinases? 
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1.4.1. TOR, a Central Controller of Cell Growth  
 
In the late 90s it became clear that TOR (Tor1 and Tor2) is involved in the control 
of cell growth [25]. This was a surprise as it was initially thought that cell growth was a 
passive process, in which a cell simply increases biomass in response to the availability 
of nutrients. Nowadays it is commonly accepted that both TORC1 and TORC2 are 
activated by nutrients and promote the accumulation of biomass via stimulation of 
anabolic processes and repression of catabolic processes. The anabolic processes favored 
by TORC1 are ribosome biogenesis, translation initiation, and nutrient import, whereas 
autophagy and stress response are among the catabolic processes inhibited by TORC1.  
Arguably, ribosome biogenesis is the main anabolic process promoted by TORC1. 
In terms of energy consumption, ribosome biogenesis is a very “expensive process”, 
since actively growing yeast cells produce on average 2,000 ribosomes per minute [26], 
requiring the coordinate synthesis and assembly of  78 different ribosomal proteins (RPs) 
and four rRNA molecules. This in turn necessitates the coordinate action of both RNA 
Pol I and RNA Pol III as well as additional factors, so-called ribosome biogenesis (RiBi) 
factors, to process, assemble and export to the cytosol the ribosomal subunits. RP and 
RiBi gene expression is dependent on RNA Pol II transcription. Therefore it is very 
reasonable that this process is tightly regulated in response to nutrient cues and, for 
instance, inhibited under unfavorable growth conditions. The regulation of ribosome 
biogenesis mainly occurs at the transcriptional level via the action of different 
transcription factors. Rrn3 is a RNA Pol I transcription factor and interestingly it was 
found to be degraded upon rapamycin treatment [27], therefore reducing RNA Pol I-
mediated synthesis of rRNAs. TORC1 also controls the expression of RP genes via 
regulation of Fhl1 activity [28-30]. When TORC1 is active, the transcription factor Fhl1 
binds to Ifh1 and stimulates RP gene transcription, while under unfavorable growth 
conditions Fhl1 associates with the corepressor Crf1, which blocks RP gene expression 
[28] (Figure 1.1). The activity of Crf1 is in turn controlled by TORC1 via the PKA/Yak1 
signaling pathway [28]. Besides Fhl1, TORC1 regulates RP and RiBi gene expression via 
the transcription factor Sfp1, whose function is regulated at the level of subcellular 
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localization [31]. Active TORC1 directly phosphorylates Sfp1 and promotes its nuclear 
translocation, where Sfp1 associates with RP and RiBi gene promoters and stimulates 
their transcription [32] (Figure 1.1). Interestingly it seems that the Rab escort protein 
Mrs6 is further needed to allow Sfp1 nuclear translocation [32]. Finally TORC1 also 
regulates RP and Ribi gene expression via the kinase Sch9, which phosphorylates the 
transcription factors Dot6, Tod6 and Stb3 [33] (Figure 1.1). When TORC1 is active, 
Dot6, Tod6 and Stb3 are phosphorylated and inactive. Upon TORC1 inactivation they 
become dephosphorylated and bind RP and RiBi gene promoters to repress their 
transcription [33]. Furthermore, Sch9 and thus TORC1, positively regulates RNA Pol III-
dependent tRNA transcription by phosphorylating and inactivating the Maf1 repressor 
[34, 35].  
Besides promoting ribosome biogenesis, TORC1 positively affects translation 
initiation. Upon nutrient starvation, the phosphatase Sit4 is no longer repressed by 
TORC1 and it dephosphorylates and activates the Gcn2 kinase (Figure 1.1). This in turn 
promotes the phosphorylation of the α-subunit of the translation initiation factor eIF2, 
which down-regulates general mRNA translation and stimulates the selective translation 
of the transcription factor Gcn4 [36, 37]. Gcn4 translocation to the nucleus promotes the 
transcription of a group of genes coding for amino acid synthesis and amino acid 
permeases (see below). In addition, it seems that TORC1 is also involved in the 
regulation of Eap1 [38], an eIF4E-interacting protein resembling the mammalian 4E-BPs 
(Figure 1.1). All these processes also impinge indirectly on ribosome biogenesis, because 
processing of the 35S rRNA precursor into 25S, 18S, and 5.8S rRNAs requires ribosomal 
proteins [39]. As a consequence, reduced ribosome biogenesis is caused by both, 
decreased general translation and decreased rRNA processing. 
In accordance with the involvement of TORC1 in promoting cell growth, it is not 
surprising that this complex also controls cellular nutrient uptake. This is accomplished 
by the coordinate expression of more than 250 different membrane transporters and 
permeases [40]. The involvement of TORC1 in the regulation of permease gene 
expression has been initially demonstrated by transcriptomic experiments [41, 42] and 
further characterized by more targeted experiments, which revealed that active TORC1 
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promotes, via inhibition of Sit4, the cytoplasmic retention of the GATA transcription 
factors Gln3, Gat1 and Dal81 [6, 43-45] (Figure 1.1). As soon as TORC1 senses nutrient 
starvation, the GATA transcription factors translocate to the nucleus where they stimulate 
expression of the so-called nitrogen catabolite repression (NCR) genes (e.g. low-affinity 
permeases, enzymes involved in allantoin and urea metabolism, etc.). Moreover, active 
TORC1 also regulates the stability of amino acid permeases at the plasma membrane. 
When TORC1 is inhibited, the phosphatase Sit4 dephosphorylates and activates the Npr1 
kinase which in turn stabilizes the general amino acid permease Gap1 at the plasma 
membrane [46, 47] (Figure 1.1). Vice versa, many high-affinity permeases like the 
tryptophane-specific permease Tat2 are degraded by ubiquitin-mediated endocytosis. 
Furthermore, TORC1 inactivation leads to the selective translation of Gcn4 mRNA, a 
transcription factor involved in the expression of amino acid biosynthesis and permease 
genes [36]. 
TORC1, via the transcription factors Rtg1 and Rtg3, also regulates the cellular 
balance of glutamate and glutamine, two fundamental metabolites necessary for the 
synthesis of amino acids. Under favorable growth conditions, Rtg1 and Rtg2 are 
sequestered in the cytosol upon binding to Mks1 and the 14-3-3 proteins Bmh1/2 (Figure 
1.1) [48-50]. When TORC1 is inactive, the protein Rtg2 binds to the Rtg1/Rtg3/Mks1 
complex to liberate Rtg1/3 which subsequently enter the nucleus, where they promote the 
expression of the so-called retrograde response pathway (RTG) genes. These genes are 
particularly important when yeast cells grow in the presence of glucose and nitrogen 
compounds requiring α-ketoglutarate for assimilation. 
As already mentioned, TORC1 not only promotes anabolic processes but also 
prevents catabolic processes. Among the latter is autophagy that guarantees the recycling 
of nutrients from degradation of non-essential cellular components. This is vital for the 
cell to endure and survive periods of nutrient limitation and TORC1 is an important 
modulator of this process. Under favorable growth conditions TORC1 promotes Atg13 
phosphorylation, which leads to its dissociation from the Atg1 kinase and to suppression 
of autophagy (Figure 1.1) [51]. On the contrary, TORC1 inactivation leads to 
Introduction 
 
 19
dephosphorylation of Atg13 and its subsequent binding to Atg1, an essential requirement 
for the induction of autophagy [52]. 
TORC1 also negatively regulates stress response by nutrient limitation. The stress 
response is mainly regulated at the transcriptional level via expression of proteins 
required to survive periods of stress [53]. This is accomplished by the transcription 
factors Msn2 and Msn4, which are usually retained in the cytoplasm when TORC1 is 
active [6]. They quickly translocate to the nucleus in response to nutrient starvation, via a 
Sch9-dependent activation of the Rim15 kinase [54, 55] (Figure 1.1). 
In conclusion, there is ever-increasing evidence of the positive effects of TORC1 
on cell growth, which directly or indirectly controls the activity of kinases and 
phosphatases and the nucleo-cytoplasmic distribution of transcription factors. However, 
considering the central role of the TORC1 pathway in regulating cell growth, it is likely 
that TORC1 signaling is connected to other major signaling pathways. It integrates many 
cellular inputs into a large network for the control of cellular homeostasis (see below).  
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1.4.2. TOR, a Signaling Pathway by its Own? 
 
Evidence supporting the view that the TORC1 is connected to other signaling pathways 
stems from genetic studies showing a connection between TORC1 and PKA signaling. 
For example, the Sch9 kinase, one of the few direct substrates of TORC1, has been 
originally characterized as a multi-copy suppressor of the PKA mutants cdc25-1, cyr1∆, 
ras1∆ras2∆ and tpk1∆tpk2∆tpk3∆ [56]. In accordance with these findings, other genetic 
studies showed that cells with a hyperactive PKA pathway (e.g. ira1∆ira2∆, bcy1∆ or 
RAS2V19) are more resistant to rapamycin. Also, the repression of RP genes induced by 
rapamycin in such cells is less prominent than in wild type cells [57]. Conversely, cells 
with impaired PKA signaling (e.g. tpk1∆, tpk1∆tpk2∆, tpk1∆tpk3∆) are more susceptible 
to rapamycin and have impaired RP gene expression [57]. In addition, deletion of MSN2 
and MSN4 in combination or alone [58] and deletion of RIM15 [59] rescues the growth 
defect of yeast mutants with reduced PKA signaling [58]. Similarly, the localization of 
the transcription factors Msn2 and Msn4 is affected by both TORC1 and PKA signaling 
[6, 58, 60] (Figure 1.1). Indeed, both rapamycin treatment and impaired PKA activity 
lead to their nuclear translocation with subsequent expression of stress-inducible (STRE) 
genes. Furthermore, the interplay between TORC1 and PKA becomes more explicit 
considering that rapamycin treatment causes a rapid accumulation of the PKA catalytic 
subunit Tpk1 in the nucleus [61].  
Additional support for the idea of a connection between TORC1 and PKA 
signaling comes from the nucleo-cytoplasmic distribution of Sfp1 and Crf1 (Figure 1.1). 
As mentioned above, Sfp1 is mainly nuclear under favorable growth conditions but 
quickly translocates to the cytosol when TORC1 is inhibited. Interestingly, in bcy1∆ 
cells, Sfp1 remains in the nucleus even after rapamycin treatment [31]. Nevertheless, 
Sfp1 can still partially localize to the nucleus in cells with down-regulated PKA signaling 
and its localization is still sensitive to rapamycin, which means that TORC1 and PKA act 
on Sfp1 in a different way [31]. Similarly, the corepressor Crf1 is mainly nuclear when 
rapamycin is added to yeast cells but this is no more the case in both bcy1∆ and RAS2V19 
cells [28]. Finally, there is evidence showing that Maf1, Atg13 and Rim15 are all 
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common targets of TORC1 and PKA (Figure 1.1). Inhibition of either TORC1 or PKA 
leads to Maf1 dephosphorylation and its nuclear translocation and both TORC1 and PKA 
independently modulate Atg13 phosphorylation [62]. Rim15 is also targeted by both 
TORC1 and PKA. TORC1 promotes the cytosolic retention of Rim15 and PKA 
inactivates Rim15 by direct phosphorylation [59, 63]. 
 
 
1.4.3. Direct Versus Indirect TORC1 Targets 
 
In spite of the many biological processes controlled by TORC1, the identification 
of direct TORC1 substrates has lacked behind. Today, only three direct targets of TORC1 
have been identified in yeast, while around ten substrates have been found in mammalian 
cells. The three direct TORC1 targets in yeast are Tap42, Sch9 and Sfp1 (Figure 1.1) [32, 
64-67]. Tap42 is a regulator of PP2A and PP2A-like phosphatases and is responsible for 
controlling the phosphorylation state of Npr1 [47], Rtg1 and Rtg3 [68], Gln3 [69], Gat1 
[44], Msn2 and Msn4 [60], and Gcn2 [36]. Sch9 is an AGC kinase that directly 
phosphorylates Rim15 [63], Maf1 [34] and the repertoire of Sch9 targets has recently 
been extended to Stb3, Dot6 and Tod6 [33]. Sfp1 is a transcription factor involved in the 
regulation of RP and RiBi genes [32]. Sch9 and Tap42 are by far the best characterized 
targets of TORC1 and genetic evidence suggests that they represent the major signaling 
branches downstream of TORC1. Indeed, cells co-expressing the tap42-11 and SCH9DE 
alleles are hyperresistant to rapamycin [34]. 
The exact mechanism through which TORC1 phosphorylates and regulates the 
activity of Tap42 is not well understood. The model that fits the observations best 
suggests that TORC1 phosphorylates Tap42 to enhance its interaction with the catalytic 
subunits of PP2A (i.e. Pph21 and Pph22) and PP2A-like (i.e. Sit4) phosphatases, which 
results in inhibition of the phosphatase activity [64]. This model nevertheless, has its 
caveats. Firstly, yeast cells contain ten times more PP2A phosphatases than Tap42, which 
means that Tap42 cannot be a stoichiometric inhibitor of the PP2A phosphatases. 
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Secondly, Tap42 dephosphorylation following rapamycin treatment has a much slower 
kinetic (50% reduction after 30 minutes) than phosphatase inactivation (< 10 minutes). A 
possible answer to these conflicting findings is that Tap42 is a positive rather then a 
negative regulator of PP2A and PP2A-like phosphatases [70]. In this model rapamycin 
treatment induces a release of phosphorylated Tap42 from TORC1, which is then free to 
bind and activate the phosphatases. The signal response is eventually terminated by slow 
dephosphorylation of Tap42. This model is supported by the fact that Tap42 associates at 
the membrane with TORC1 and quickly (< 10 minutes) dissociates from the membrane 
upon rapamycin treatment [70]. Furthermore, it has been shown that once in the cytosol, 
dephosphorylation of Tap42 and Tap42-PP2A disassembly occurs with comparable 
kinetics (about 30 minutes) [70].   
Regulation of phosphatases by TORC1 has been further complicated by the 
discovery of Tip41 [71]. Tip41 is a negative regulator of TORC1 signaling. Deletion of 
TIP41 confers rapamycin resistance, suppresses the growth defect of a TAP42 mutant 
(tap42-11), prevents dissociation of Tap42 from Sit4, causes Npr1 hyperphosphorylation 
and promotes Gln3 retention in the cytoplasm [71]. However, since deletion of TIP41 has 
no effect on cell growth it is unlikely that it is a central regulator of TORC1 signaling. In 
addition, active TORC1 results in phosphorylation of Tip41 and reduced binding of 
Tip41 to Tap42, suggesting that Tip41 must first be dephosphorylated to interact with 
Tap42. However, it has never been demonstrated that (i) Tip41 dephosphorylation occurs 
with the same kinetics as activation of the phosphatases and (ii) that Tip41 becomes 
directly phosphorylated by TORC1.  
 The regulation of the second TORC1 substrate, Sch9, is much better understood 
[66]. There is evidence showing that TORC1 phosphorylates Sch9 in vivo and in vitro on 
at least six different positions (S711, T723, S726, T737, S758 and S765) clustered in the 
C-terminus of the protein [66]. These data show that the sequence determinants leading to 
substrate phosphorylation by TORC1 are less stringent than those used by other kinases. 
TORC1 seems to have a preference for serines and threonines surrounded by bulky 
hydrophobic residues at the -4, +1 and +2 position. Similar to Tap42, Sch9 is an 
important regulator of cell growth and ribosome biogenesis [66]. 
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1.5. The Search for Protein Kinase Substrates  
 
Even though a number of direct TOR targets have been identified, it is 
conceivable that the TOR proteins must have many more substrates to fulfill the 
multitude of tasks associated with the control of cellular growth and homeostasis. The 
search for kinase substrates has proven to be difficult. Many methods exist such as 
genome-wide screening of kinase substrates spotted on proteome arrays using 
recombinant protein kinases [72] or the KESTREL (kinase substrate tracking and 
elucidation) method [73]. In a KESTREL assay a cell lysate is fractionated, typically via 
anion exchange chromatography, to reduce sample complexity and the resulting fractions 
are incubated in presence radioactive ATP with the exogenously added kinase. The major 
problem associated with the KESTREL assay is that a cell lysate contains endogenous 
kinases which are able to phosphorylate several substrates upon incubation with 
radioactive ATP, which is causing a high background. An interesting alternative to the 
KESTREL is the “chemical genetic” approach developed by the Kevan Shokat’s 
laboratory [74]. Briefly the kinase of interest is mutated by substituting a conserved bulky 
residue in the ATP-binding pocket with a smaller residue that allows the mutant kinase to 
use a bulky radioactive ATP analogue for phosphate transfer. In this way only the 
target(s) of the mutant kinase are phosphorylated thereby reducing background 
phosphorylations. This technique has been further improved by using ATP analogues that 
lead to tiophosphorylation instead of phosphorylation of the target substrates. In this way 
the tiophosphorylated proteins are digested and the resulting thiophosphorylated peptides 
can be enriched using iodoacetyl-agarose beads for LC-MS/MS analysis [75]. 
In spite of all these technological improvements, it remains a cumbersome task to 
screen and identify the physiological substrates of protein kinases. Recent developments 
in mass spectrometry have shifted the focus towards the sampling of phosphoproteomes 
from cells treated with specific protein kinase inhibitors to identify differentially 
phosphorylated kinase effectors. Several elaborate workflows exist for the quantitative 
analysis of phosphoproteomes from untreated and inhibitor-treated cells. They are often 
relying on phosphoprotein or phosphopeptide enrichment strategies coupled with high-
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resolution mass spectrometry. These large-scale phosphoproteomic workflows have 
caused a true data explosion over the past decades in regards to the analysis of 
phosphorylation events in cells. Nevertheless, before becoming a robust and reliable 
methodology, a number of obstacles needed to be solved. 
Analysis of protein phosphorylation by mass spectrometry remains a challenge for 
at least three reasons. First of all the stoichiometry of protein phosphorylation is usually 
low. Consequently, only a fraction of the total protein population in a cell carries the 
modification. To make things worse, certain proteins, especially transcription factors and 
signaling proteins, are only present in low copy numbers. Moreover, proteins are usually 
heterogeneously phosphorylated, which means that at any moment in a cell multiple 
isoforms of the same phosphoprotein coexist. As a result, phosphorylation analysis of 
complex samples usually leads to the identification of only major phosphorylation sites 
from highly expressed proteins. To circumvent this problem, several strategies have been 
developed over the last two decades. In the following two sections these strategies will be 
reviewed. The first section centers on advances achieved in phosphoprotein and 
phosphopeptide enrichment aimed at tracing low stoichiometry phosphorylation sites. 
The second section reviews mass spectrometric advances in analyzing phosphopeptides. 
 
 
1.5.1. The Search for the Needle in the Haystack 
 
 Over the years many techniques have been developed to trace low stoichiometry 
phosphorylation sites in complex digests of proteins. These are either aimed at enriching 
phosphoproteins or phosphopeptides. Although the goal of both approaches is the same, 
there are substantial differences between the enrichment of phosphoproteins and 
phosphopeptides. First of all, the enrichment of phosphopeptides generates less complex 
mixtures than the digests of enriched phosphoproteins. At first sight phosphopeptide 
enrichment is preferred over phosphoprotein enrichment. On the other hand, it implies 
that the identification of the corresponding proteins after phosphopeptide enrichment 
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critically hinges on the identification of just the phosphopeptides and therefore requires 
very stringent search criteria. Phosphoprotein enrichment has also some intrinsic 
drawbacks. In the first place, the amount of phosphate groups per protein is much lower 
than the amount of phosphate groups per peptide, which makes the enrichment of 
phosphopeptides more selective. Moreover, in contrast to phosphopeptides, working with 
phosphoproteins is complicated by their instability at high and low pH, high temperatures 
and their susceptibility to organic solvents. As a result, nowadays more alternatives exist 
for phosphopeptide enrichment in comparison to phosphoprotein-based enrichment 
strategies.  
Enrichment of phosphoproteins is usually performed with phospho-specific 
antibodies. The use of antibodies is usually restricted to the analysis of tyrosine 
phosphorylation because anti-phosphoserine and anti-phosphothreonine antibodies are 
generally of low specificity, probably due to lower immunogenicity of the phosphoserine 
and phosphothreonine epitopes compared to the bulky phosphotyrosine antigen. This 
problem can be circumvented using antibodies that recognize phosphorylated serines or 
threonines surrounded by specific residues, like antibodies to phospho-SQ or phospho-
TQ [76]. Another alternative is the use of protein domains that reversibly bind 
phosphorylated residues, like WW, FHA, SH2 and PTB domains. A third experimental 
strategy enriches phosphoproteins by β-elimination of the phosphate group to generate 
dehydroalanine or dehydroaminobutyric acid which in turn reacts with biotin-labeled 
ethanedithiol [77]. The main advantage of this approach is the ease with which 
biotinylated phosphopeptides can be isolated via avidin affinity purification. The major 
drawback is the production of protein degradation products due to the strong alkaline 
conditions used for β-elimination as well as the occurrence of unwanted side reactions 
that further complicate MS/MS spectra identification (e.g. reaction of cysteines with 
biotin, oxidation of methionines and tryptophanes).  
As already mentioned above, a wider panel of methods is at hands to enrich 
phosphopeptides. Analogous to phosphoproteins, phosphopeptides can be enriched via 
chemical derivatization and much effort has been spent to supply the researcher with a 
variety of methods [78, 79]. However, as with phosphoproteins, these techniques suffer 
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from unwanted side reactions. The most widely used and robust approach to enrich 
phosphopeptides is based on the affinity of phosphate groups for positively charged metal 
ions (typically iron or gallium). Such ions can easily be immobilized on chelators 
covalently coupled to a solid matrix. This approach, which was used in the present study, 
is called Immobilized Metal Affinity Chromatography (IMAC) [80]. All IMAC resins 
suffer from unspecific binding of peptides rich in aspartic and glutamic acid residues. To 
avoid this problem, the acidic side chains in peptides are sometimes esterified with 
methanolic HCl to convert them to uncharged methyl esters [81]. This reaction is, like all 
chemical reactions, prone to side reactions like deamidation of asparagines and 
glutamines. Moreover, the low pH used to methylesterify the peptides and the 
requirement to remove water from the sample can lead to a very low peptide recovery. A 
second very widespread technique to enrich phosphopeptides makes use of metal oxides 
like titanium dioxide or zirconium oxide and is called metal oxide affinity 
chromatography (MOAC). Similar to IMAC, unspecific binding of acidic residues to 
TiO2 and ZrO2 occurs, but can be prevented by methylesterification or by using additives 
during peptide binding [82]. Importantly, both IMAC and MOAC produce 
complementary results and are therefore often used in parallel [83]. Alternatively, they 
can be used sequentially, where IMAC is usually performed as the first step of 
enrichment and the flow-though is further enriched via MOAC [84]. Both enrichment 
techniques, IMAC and MOAC, have been used in conjunction with orthogonal 
fractionation techniques like strong cation exchange (SCX) chromatography or 
hydrophilic interaction chromatography (HILIC). Both techniques already pre-
concentrate phosphopeptides and are very useful to improve the selectivity of IMAC and 
MOAC. Workflows with various combinations like SCX followed by IMAC [85], SCX 
followed by TiO2 [86] or HILIC followed by IMAC [87] have been described that yield 
comprehensive phosphoproteomes from cell cultures and organs. Unfortunately a study 
that systematically compares these different approaches does not exist nowadays and it is 
therefore difficult to objectively conclude which approach yields the best results. 
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1.5.2. Phosphopeptide Analysis by Mass Spectrometry  
 
 Phosphopeptide analysis by mass spectrometry is not straightforward for several 
reasons. The two main challenges are the sequence identification of a phosphopeptide 
and the precise localization of the phosphorylation site within the peptide sequence. In 
fact phosphopeptides do not fragment as well as their unphosphorylated counterparts 
when they are subjected to collision-induced dissociation (CID).  
During CID peptide ions are accelerated in the vacuum followed by a collision 
with inert gas molecules (usually helium or molecular nitrogen), which transforms the 
kinetic energy into vibrational energy necessary to break the chemical bonds. Such a 
fragmentation usually takes place at amide bonds and produces b- and y-ions [88], 
although the exact fragmentation pattern can vary significantly according to the peptide 
sequence, the number of arginines and lysines per peptide and the charge state [89]. 
Fragmentation at amide bonds can be explained by the so called „mobile proton” model 
[90]. This model states that during excitation, protons that were previously sequestered 
by arginines and lysines become mobile and protonates sites that were energetically less 
favored like amide oxigens and nitrogens. These protonation events weaken these bonds 
to induce dissociation and generation of b- and y-ions. In reality, certain amino acids 
affect the proton localization and favor cleavage at specific sites [89]. This means that 
fragmentation spectra are never a product of random cleavages of the amide bonds. The 
„mobile proton” model also explains the atypical fragmentation observed for many 
phosphopeptides, which is characterized by dominant peaks corresponding to the neutral 
loss of phosphoric acid (H3PO4) from the precursor ions and reduced backbone 
fragmentation (Figure 1.2A). The reason of this observation lies in the energetically 
favored reaction leading to phosphate loss compared with backbone fragmentation at the 
amide bond promoted by the “mobile proton”.  
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Figure 1.2: CID MS/MS spectra of the yeast phosphopeptide SRSSVMFK (derived from Bcy1). MS/MS 
spectrum acquired with standard activation parameters (35% normalized collision energy for 30ms) (A) 
without MSA and (B) with MSA. 
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Interestingly, during fragmentation of different phosphopeptides there is 
considerable variation in terms of neutral loss and peptide backbone fragmentation that 
depends on the chemical composition of the phosphopeptide, its charge state and the 
collision energy used to activate the precursor ion. For example, neutral loss ions are 
almost entirely absent in phosphotyrosine-containing peptides because the aromatic ring 
sterically hinders the chemical bond rearrangements required for the neutral loss product. 
In addition, the φ-O bond in phosphotytosine does not readily break because it is 
stabilized by the resonance of the benzene ring. Another important parameter affecting 
neutral loss is the charge state of the precursor ion. Usually the intensity with which 
neutral loss occurs decreases with increasing charge because more “mobile protons” are 
available for backbone fragmentation at higher charge states (Figure 1.3). Moreover, 
since neutral loss formation is favored over backbone fragmentation because it requires 
less energy, it is conceivable that mild excitation methods favor the formation of neutral 
loss over high energy activation methods. This is indeed the case when phosphopeptides 
are fragmented at lower collision energy and longer activation times in an ion trap 
(Figure 1.2A). 
In conclusion, phosphopeptide fragmentation differs from the fragmentation of 
non-phosphorylated peptides. This is a consequence of the neutral loss of H3PO4 from the 
side chains of serines and threonines, which competes with backbone fragmentation. 
Nevertheless, there are many factors influencing the extent to which neutral loss occurs. 
The chemical composition of the ion (phosphotyrosine-containing peptides do not show a 
neutral loss), the charge state and the collision energy all determine the fragmentation 
behavior of phosphopeptides. But which are the consequences of neutral loss on 
phosphopeptide identification? 
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Figure 1.3: Neutral loss intensity decreases with increasing peptide charge state. MS/MS spectra of (A) the 
tryptic Srf1 phosphopeptide KSGSLEALQNAK and of (B) the tryptic Rnr2 phosphopeptide 
AAADALSDLEIKDSK.  
 
 
The major problem is that neutral loss predominates and thereby reduces 
backbone fragmentation. The few available fragment ions hamper peptide sequence 
identification and consequently unambiguous phospho-site localization. Indeed, the 
localization of the site of phosphorylation requires the presence of specific diagnostic 
backbone fragments in a MS/MS spectrum. This is shown in Figure 1.4, where the 
presence of a given set of ions (in red) allows to pinpoint the phosphorylation site to a 
specific residue while excluding a different localization. To circumvent the problem of 
neutral loss, alternative fragmentation methods have been developed for 
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phosphopeptides. The most common is the use of MS3 fragmentation [91, 92], multistage 
activation (MSA) [93], electron capture dissociation (ECD) [94] and electron transfer 
dissociation (ETD) [95]. MS3 fragmentation and MSA are very similar in the sense that 
both methods require two steps of ion activation. In the case of MS3 fragmentation the 
precursor ion that underwent neutral loss is isolated and subsequently fragmented. Since 
neutral loss of H3PO4 can no longer occur, backbone fragmentation is favored. MS3 has 
the disadvantage of increasing the duty cycle and that sometimes contradictory sequences 
are assigned to the same MS2/MS3 spectrum pair. To circumvent this problem MSA was 
developed, where the ion that underwent neutral loss is activated while the fragment ions 
from the precursor are still present in the trap. This results in a composite spectrum that is 
the product of the MS2 and MS3 spectra (Figure 1.2B). Since in MSA the fragment ions 
derived from the precursor ion are trapped together with those generated by the neutral 
loss ion, MSA spectra have increased signal intensities and a greater number of 
structurally diagnostic ions compared to MS3 fragmentation. Interestingly, in a study 
where normal MS2 fragmentation was compared with MS3 and MSA fragmentation it was 
found that all three produce redundant data, therefore reducing the benefits of doing MS3 
and MSA [96]. This is probably a consequence of the increased duty cycle of MS3 and 
MSA over MS2. In addition, even in a MS2 spectrum containing a dominant ion derived 
from neutral loss, weak backbone fragmentation is still present (Figure 1.2A), allowing 
reliable sequence identification and reducing the benefits of performing MSA or MS3 
fragmentations. This phenomenon will probably improve even more over time with the 
development of new ion traps with increased ion trapping capacities.  
Finally, there are two more fragmentation methods said to reduce neutral loss 
while preserving backbone fragmentation: ECD and ETD. The main common feature 
between the two methods is the use of electrons to dissociate peptide ions. As a 
consequence ECD and ETD MS/MS spectra differ significantly from CID MS/MS 
spectra with respect to the type of ions formed. Especially, ECD and ETD spectra contain 
c- and z-ions instead of the usual b- and y-ions observed in CID. A particular advantage 
of ECD/ETD over CID is that much less neutral loss of phosphate occurs so that spectra 
rich in diagnostic backbone ions are generated. This is extremely helpful when a 
phosphorylation site needs to be localized and it seems that ECD and ETD are designed 
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to completely replace CID for phosphopeptide analysis. However, it has been shown that 
ECD/ETD and CID produce complementary results. In a large-scale study comparing 
ECD with CID [97] the results were more in favor of CID concerning the total number of 
phosphopeptide identifications. This puzzling observation can be explained by the use of 
trypsin for protein digestion, which tends to produce doubly charged peptide ions. Since 
the cross-section of an ion that can capture an electron is proportional to the square of its 
charge [98], the doubly charged peptides produced by trypsin cleavage tend to fragment 
suboptimally during ECD/ETD. Another explanation concerning the poor performance of 
ECD/ETD over CID is the fact that the major search engines (e.g. Sequest, Mascot) have 
been initially designed for CID MS/MS spectra obtained in ion traps or time-of-flight 
mass spectrometers. Finally, 50 times more ions are required for ECD than CID, which 
increases the duty cycle and reduces the benefit of ECD for the analysis of complex 
phosphopeptide samples [97]. Nevertheless, even though ECD performed less efficiently 
than CID, its potential for unambiguous phospho-site localization is well appreciated in 
the proteomic community [97]. It should be also considered that ECD is typically 
performed on a Fourier transform ion cyclotron resonance (FTICR) mass spectrometer 
which records spectra with much higher mass accuracy than ion trap mass spectrometers.  
The fact that CID and ECD/ETD produces complementary results, prompted 
researchers to use both fragmentation technologies in a decision-tree-based MS approach 
[99]. In this way the benefit of ETD for the fragmentation of large peptides with high 
charges is combined with the optimal performance of CID for the fragmentation of small 
peptides with low charges. Another way to circumvent the reduced performance of 
ECD/ETD for the fragmentation of ions with low charges is the use of alternative 
proteases, for instance endoproteinase Glu-C and Lys-C [100, 101]. However, the final 
outcome of phosphopeptide identifications by the use of alternative proteases in 
conjunction with ETD was very modest [101]. As a result, the use of CID coupled with 
MSA seems to be so far still the best choice for the analysis of phosphopeptide samples, 
which also explains its wide-spread use for large-scale phosphorylation studies. On the 
other hand, ECD and ETD are being improved continuously and it is foreseeable that 
they will be used more and more as an alternative to CID in future phosphoproteomic 
studies. 
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Figure 1.4: MS/MS spectra of three phospho-isoforms of the same peptide (TSATREDTPLSQNESTR 
derived from Isw2). Detection of specific diagnostic ions (in red) allows to localize in a reliable way the 
residues carrying the phosphate.  
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2. Materials and Methods 
 
2.1. Yeast Strains, Media, and Genetic Manipulations 
 
The S. cerevisiae strains used in this work are listed in Table 2.1. All constructed 
strains are isogenic to TB50. Yeast manipulations, including cell cultures, sporulation, 
tetrad dissections, and genetic techniques, were carried out essentially as described [102]. 
Cells were grown either in rich YPD medium (1% yeast extract, 1% peptone, 2% 
glucose, and 2% agar for solid media) or minimal synthetic medium (6.7 g yeast nitrogen 
base per liter, 2% glucose, relevant amino acids for plasmid maintenance, and 2% agar 
for solid media). If not stated otherwise, the synthetic medium used for plasmid 
maintenance contained all amino acids except uracil. Yeast nitrogen base, yeast extract, 
peptone and agar were purchased from BD Biosciences while amino acids were from 
Sigma. 
 
 
Name Genotype Ref. 
TB50a MATa leu2 ura3 rme1 trp1 his3∆ GAL+ HMLa Lab strain 
TB50a/@ MATa/@ leu2/leu2 ura3/ura3 rme1/rme1 trp1/trp1 his3∆/ his3∆ GAL+/GAL+ HMLa/HMLa Lab strain 
TB105-1c MATa leu2 ura3 rme1 trp1 his3∆ GAL+ HMLa gln3::kanMX4 gat1::HIS3MX6 Lab strain 
AN9-2a MATa leu2 ura3 rme1 trp1 his3∆ GAL+ HMLa tor1::kanMX4 Lab strain 
YPJ2 MATa leu2 ura3 rme1 trp1 his3∆ + HMLa arg4::His3MX6 lys1 ::KanMX4   This study 
YAC1 MATa leu2 ura3 rme1 trp1 his3∆ GAL+ HMLa  hal5::KanMX4 This study 
YAC2 MATa leu2 ura3 rme1 trp1 his3∆ GAL+ HMLa  isw2::KanMX4 This study 
YAC3 MATa leu2 ura3 rme1 trp1 his3∆ GAL+ HMLa  kkq8::KanMX4 This study 
YAC4 MATa leu2 ura3 rme1 trp1 his3∆ GAL+ HMLa  ldb19::KanMX4 This study 
YAC5 MATa leu2 ura3 rme1 trp1 his3∆ GAL+ HMLa  mtc1::KanMX4 This study 
YAC6 MATa leu2 ura3 rme1 trp1 his3∆ GAL+ HMLa  nap1::KanMX4 This study 
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YAC7 MATa leu2 ura3 rme1 trp1 his3∆ GAL+ HMLa  reg1::KanMX4 This study 
YAC8 MATa leu2 ura3 rme1 trp1 his3∆ GAL+ HMLa  ubx7::KanMX4 This study 
YAC9 MATa leu2 ura3 rme1 trp1 his3∆ GAL+ HMLa  vtc2::KanMX4 This study 
YAC10 MATa leu2 ura3 rme1 trp1 his3∆ GAL+ HMLa  vtc3::KanMX4 This study 
YAC11 MATa/@ leu2/leu2 ura3/ura3 rme1/rme1 trp1/trp1 his3∆/ his3∆ GAL+/GAL+ HMLa/HMLa  noc2::KanMX4 This study 
YAC12 MATa/@ leu2/leu2 ura3/ura3 rme1/rme1 trp1/trp1 his3∆/ his3∆ GAL+/GAL+ HMLa/HMLa  sec7::KanMX4 This study 
YAC13 MATa leu2 ura3 rme1 trp1 his3∆ GAL+ HMLa  HAL5-3HA::KanMX4 This study 
YAC14 MATa leu2 ura3 rme1 trp1 his3∆ GAL+ HMLa  ISW2-3HA::KanMX4 This study 
YAC15 MATa leu2 ura3 rme1 trp1 his3∆ GAL+ HMLa  KKQ8-3HA::KanMX4 This study 
YAC16 MATa leu2 ura3 rme1 trp1 his3∆ GAL+ HMLa  LDB19-3HA::KanMX4 This study 
YAC17 MATa leu2 ura3 rme1 trp1 his3∆ GAL+ HMLa  MTC1-3HA::KanMX4 This study 
YAC18 MATa leu2 ura3 rme1 trp1 his3∆ GAL+ HMLa  NAP1-3HA::KanMX4 This study 
YAC19 MATa leu2 ura3 rme1 trp1 his3∆ GAL+ HMLa  REG1-3HA::KanMX4 This study 
YAC20 MATa leu2 ura3 rme1 trp1 his3∆ GAL+ HMLa  RTS3-3MYC::KanMX4 This study 
YAC21 MATa leu2 ura3 rme1 trp1 his3∆ GAL+ HMLa  UBX7-3HA::KanMX4 This study 
YAC22 MATa leu2 ura3 rme1 trp1 his3∆ GAL+ HMLa  VTC2-3HA::KanMX4 This study 
YAC23 MATa leu2 ura3 rme1 trp1 his3∆ GAL+ HMLa  VTC3-3HA::KanMX4 This study 
YAC24 MATa leu2 ura3 rme1 trp1 his3∆ GAL+ HMLa  NOC2-3HA::KanMX4 This study 
YAC25 MATa leu2 ura3 rme1 trp1 his3∆ GAL+ HMLa  SEC7-3HA::KanMX4 This study 
 
Table 2.1: Yeast strains used in this study 
 
 
Yeast strains carrying a plasmid were precultured in selective synthetic medium 
lacking the corresponding amino acids for plasmid maintenance. They were then diluted 
into YPD medium and grown for 5 hours to an OD600 of 0.8.  Metabolic labeling of yeast 
proteins was done by growing cells in synthetic medium supplemented with either 12C6-
arginine and 12C6-lysine (“light” culture) or 13C6-arginine and 13C6-15N2-lysine (“heavy” 
culture) (Cambridge Isotope Laboratories, Andover, MA), each at 30 mg/l. Treatment 
with rapamycin (LC Laboratories, Woburn, MA) was at 200 ng/ml final concentration 
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(added from a 1 mg/ml stock solution in 90% ethanol/10% Tween20) for 20 min. 
Transformation of yeast cells was performed with the LiAc/SS-DNA/PEG method [103]. 
All deletions and genomically tagged strains were constructed by PCR targeting [104]. 
The resulting transformants were checked for proper integration by colony PCR.  
 
 
2.2. Molecular Biology Techniques 
 
The plasmids used in this work are listed in Table 2.2. All plasmids were 
constructed by cloning into the pHAC plasmids pHAC33 and pHAC195. DNA inserts 
were generated by PCR amplification of the target gene with two primers each containing 
a restriction site. The resulting PCR products were gel purified with the NucleoSpin 
Extract II Kit (Macherey-Nagel, Oensingen, Switzerland) according to the 
manufacturer’s protocol. Both insert and plasmid were digested with the appropriate 
restriction endonucleases. The digested plasmid was separated on a 2% agarose gel. DNA 
ligation was done with the T4 DNA ligase kit (Promega AG, Dübendorf, Switzerland) 
according to the manufacturer’s recommendations. The ligation mixture was transformed 
into Top10 E. coli cells (Invitrogen, Lucerne, Switzerland) according to standard 
procedures. Transformants were selected on LB plates containing ampicillin and the 
plasmids were isolated with the GenElute Miniprep Kit (Sigma) according to the 
manufacturer’s instructions. The plasmids were stored in 50 µl water at -20°C. Point 
mutations were constructed using a modified version of the QuikChange Site-Directed 
Mutagenesis System [105]. The PCR reaction was digested over-night with the restriction 
enzyme DpnI (New England Biolabs, Allschwil, Switzerland) and the PCR product was 
subsequently precipitated with 5M potassium acetate and washed with ethanol. After 
drying the PCR product in a Speedvac, it was resuspended in 10 µl dH2O. 5 µl of the 
PCR product were transformed into Top10 E. coli cells according to standard procedures. 
Transformants were selected on LB plates containing ampicillin and plasmids were 
isolated with the GenElute Miniprep Kit. 
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Name  Description Ref. 
pHAC33 CEN, URA3, MCS-3x HA-CYC1 terminator, Amp Lab plasmid 
pHAC195 2µ, URA3, MCS-3x HA-CYC1 terminator, Amp Lab plasmid 
pAC1 pHAC195::HAL5-3HA (2µ, URA3) This study 
pAC2 pHAC195::ISW2-3HA (2µ, URA3) This study 
pAC3 pHAC195::KKQ8-3HA (2µ, URA3) This study 
pAC4 pHAC195::LDB19-3HA (2µ, URA3) This study 
pAC5 pHAC195::MTC1-3HA (2µ, URA3) This study 
pAC6 pHAC195::NAP1-3HA (2µ, URA3) This study 
pAC7 pHAC195::NOC2-3HA (2µ, URA3) This study 
pAC8 pHAC195::REG1-3HA (2µ, URA3) This study 
pAC9 pHAC195::VTC2-3HA (2µ, URA3) This study 
pAC10 pHAC195::VTC3-3HA (2µ, URA3) This study 
pAC11 pHAC33::ISW2-3HA (2µ, URA3) This study 
pAC12 pHAC33::ISW2T1079A-3HA This study 
pAC13 pHAC33::ISW2T1079E-3HA This study 
pAC14 pHAC33::ISW2T1079D-3HA This study 
 
Table 2.2: Plasmids used in this study 
 
 
2.3. Phosphoproteome Analysis 
2.3.1. Protein Extraction, Protein Fractionation and In-gel Digestion 
 
200 mL YPJ2 were grown at 30°C in SD medium supplemented with either light 
or heavy arginine and lysine to an OD600 of 0.8. To the “heavy” culture 40 µL 1 mg/ml 
rapamycin were added and the culture was incubated at 30°C for 20 min. Both cultures 
were then centrifuged at 4,500 g and 4oC for 10 min. Cell pellets were washed once with 
50 ml cold H2O and resuspended in 2 mL cold lysis buffer (100 mM Tris-HCl, pH 7.5, 
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2.5% SDS, 10% glycerol, 1x Roche protease inhibitor cocktail (Roche Diagnostics, 
Basel, Switzerland), 1x phosphatase inhibitor cocktail 1 (Sigma) and 1 mM PMSF 
(AppliChem, Baden-Dättwil, Switzerland)). The cell suspensions from either light or 
heavy cultures were distributed into 2 mL screw cap tubes and glass beads were added 
until the liquid reached the top of the tube. The cells were broken in a bead beater 
(FastPrep Homogenizer FP120, Thermo Savant) with six 30 sec bursts at maximum 
speed. Between each burst the lysates were cooled on ice for 2 min. The lysates were 
centrifuged at 12,000 rpm and 4°C for 10 min and the supernatants were transferred into 
new tubes and the individual protein concentrations were measured with the bicinchonic 
acid assay (Sigma). 2.5mg of each protein extract were mixed to obtain a 1:1 light:heavy 
protein mixture. After adding SDS-PAGE sample buffer the protein mixture was 
incubated at 98°C for 5 min.  
A total of 5 mg proteins (2.5 mg protein from the light and heavy cultures) were 
separated on a preparative 10% SDS slab gel (15 x 13 x 0.15cm). The proteins were 
electrophoresed at 10 mA constant current over-night. After electrophoresis, the gel was 
washed three times for 5 min with H2O, stained with SimplyBlue SafeStain (Invitrogen, 
Lucerne, Switzerland) for 1 hr and distained with H2O water. The gel was then cut 
horizontally into 16 slices, which were further diced into 1 mm3 cubes. The gel pieces 
were distained over-night in 1 mL 50% acetonitrile/50 mM NH4HCO3, dehydrated for 10 
min with 500 µL 100% acetonitrile and dried in a speed-vac. The proteins were in-gel 
reduced at 55°C for 60 min by adding to each dried gel plug 1 mL 10 mM DTT  (in 50 
mM NH4HCO3). The remaining solution was discarded from the gel pieces and 
alkylation was performed in the dark for 30 min by adding 1 mL 50 mM iodoacetamide 
(in 50mM NH4HCO3). To remove unreacted iodoacetamide, the gel pieces were washed 
three times with 1 mL 50% acetonitrile/50 mM NH4HCO3. After the last wash they were 
dehydrated with 500 µL 100% acetonitrile, dried in a speed-vac and then rehydrated on 
ice for 1 h in 1 mL 50 mM NH4HCO3, pH 8.0 containing 15 ng/µL trypsin (Sigma). 
Digestion was performed over-night at 37°C. Supernatants were collected into fresh tubes 
and tryptic peptides were extracted three times with 50% acetonitrile/5% formic acid, 
followed by a final extraction with 100% acetonitrile. The liquid volume was reduced in 
a speed-vac to approximately 10 µl to which 290 µl 1% acetic acid were added. A small 
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drop was spotted onto pH paper and if necessary the pH was adjusted to 2.0-2.5 with 
100% acetic acid. 
 
 
2.3.2. Phosphoproteome Analysis: Peptide Desalting and Phosphopeptide 
Enrichment 
 
Before enriching phosphopeptides by Immobilized Metal Ion Affinity 
Chromatography (IMAC) the digests were desalted on disposable C18 MacroSpin 
columns (500 µl packed resin, The Nest Group, Southborough, MA) according to the 
manufacturer’s instructions. The peptides were eluted from the cartridge with 600 µl 60% 
acetonitrile/1% acetic acid. The eluates were dried down to 10 µl final volume in a speed-
vac and 90 µl IMAC-buffer (30% acetonitrile/250 mM acetic acid) were added. 1 µl of 
each digest was diluted 200-fold with 2% acetonitrile/0.1% acetic acid and 10 µl were 
analysed by LC/MS/MS for expression analysis. 
For phosphopeptide selection, 40 µl IMAC slurry (PHOS-Select, Sigma) were 
washed five times with 1 mL IMAC-buffer to remove glycerol from the beads and then 
loaded into a constricted GELoader tip [106]. The desalted digests were applied to the 
GELoader IMAC columns and the flow-throughs were collected and re-applied five 
times. The columns were washed three times with 150 µl IMAC-buffer and the bound 
phosphopeptides were eluted with three 70 µl desorption steps of 50 mM KH2PO4 (pH 
adjusted to 10.0 with ammonium hydroxide) into 1.5 ml tubes containing 30 µl 10% 
formic acid. The IMAC eluates were desalted on disposable C18 MicroSpin columns 
(100 µl packed resin, The Nest Group, Southborough, MA) according to the 
manufacturer’s instructions. After elution with 200 µl 60% acetonitrile/1% acetic acid, 
the volume was reduced in a speed-vac to about 10 µl and the phosphopeptides were 
diluted with 40 µl 2% acetonitrile/0.1% formic acid for LC-MS/MS analysis. 
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2.3.2. Phosphoproteome Analysis: LC-MS/MS Analysis 
 
LC-MS/MS analysis was performed on an LTQ-Orbitrap hybrid instrument 
(Thermo Scientific, San José, CA). The IMAC eluate was separated by capillary liquid 
chromatography using a trapping 300SB C-18 column (0.3 x 50 mm) (Agilent 
Technologies, Basel, Switzerland) and a separating column (0.1 mm x 10 cm) that had 
been packed with Magic 300Å C18 reverse-phase material (5 µm particle size, Michrom 
Bioresources, Auburn, CA). A linear 80-min gradient from 2 to 50% solvent B (80% 
acetonitrile/0.1% acetic acid and) in solvent A (2% acetonitrile/0.1% acetic acid) was 
delivered with a Rheos 2200 pump (Flux Instruments, Basel, Switzerland) at a flow rate 
of 100 µl/min. A pre-column split was used to reduce the flow to approximately 100 
nl/min. 10 µl of peptide digest were injected with an autosampler thermostatted to 4°C 
(CTC Analytics, Agilent Technologies, Basel, Switzerland). The eluting peptides were 
ionized at 1.7 kV.  
The LTQ-Orbitrap was operated in a data-dependent mode. A survey scan 
between m/z 375-1600 was acquired in profile mode in the Orbitrap at 60,000 resolution, 
followed by 10 MS/MS scans in centroid mode in the LTQ of the 10 most abundant ions. 
Singly charged ions were omitted from fragmentation and previously selected ions were 
dynamically excluded for 25 sec. The normalized collision energy was set to 35% and for 
phosphopeptide analysis multistage activation was enabled. Automatic gain control 
(AGC) was set to 500,000 and 10,000 for Orbitrap and LTQ, respectively. Scan-to-scan 
calibration was allowed by setting the lock mass to m/z 445.120025 (Olsen JV, 2005, 
Mol Cell Proteomics).  
 
 
2.3.3 Phosphoproteome Analysis: Databank Search and Quantitation of SILAC-
Ratios  
 
The raw data from the mass spectrometer were processed with MaxQuant 
(1.0.12.31) [107] and searched with the Mascot search engine (version 2.2.04, Matrix 
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Science, London, UK) [108] against a databank containing 31,426 protein sequences. The 
databank contained forward and reverse (Swiss-Prot) S. cerevisiae sequences as well as 
common protein contaminants. Precursor ion and fragment ion mass tolerances were set 
to 7 ppm and 0.6 Da, respectively. Maximally two missed cleavages with three labeled 
amino acids were allowed. Methionine oxidation and phosphorylation of serine, threonine 
and tyrosine were set as variable modifications, while carbamidomethylation of cysteine 
residues was set to fixed modification. To increase the confidence in protein 
identification only peptides with a Mascot score above 20 were accepted. In addition, the 
posterior error probability (PEP) for each MS/MS spectrum was set to below 0.1 [109].  
To further simplify the MaxQuant output data, oxidized methionines were 
replaced with unmodified methionines and gene products of the Ty retrotransposons and 
the S. cerevisiae virus L-A were removed from the output list. When peptides or 
phosphopeptides matched several proteins, all proteins were joined together in a unique 
protein hit, except if one of the proteins contained additional peptides that were not 
shared by the other proteins. In this case, only those proteins were reported that had the 
highest number of matching peptides. Phosphopeptides with the same phosphorylation 
site(s) but different sequences due to incomplete cleavage were grouped together to 
calculate a unique SILAC ratio. In addition, an average protein SILAC ratio was 
calculated by combining all SILAC ratios for the non-phosphorylated peptides belonging 
to the same protein.  
 
 
2.4. Radioactive Labeling of Yeast Proteins 
 
Yeast extracts were prepared as described above. Purified yeast GST-Npr1 kinase was 
provided by Simon Hauri (Simon K. Hauri, Molecular and Functional Characterization of 
the Yeast Npr1 Kinase, Master Thesis, 2007-2009). 30 µl of yeast proteins (~10 mg/ml) 
were incubated in 20 µl 5x kinase buffer (500 mM Tris-HCl pH 8.0, 2.5% Tween-20, 5 
mM DTT, 50 mM MgCl2, 50% glycerol), 2 µl [γ-32P]-ATP (150 kBq/assay) (Hartmann 
Analytic, Braunschweig, Germany), 2 µl 1 mM ATP, 40 µl of GST-Npr1 (~2 µg) and 6 
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µl H2O. The reaction mixture was incubated at 37°C for 30 min in a thermoshaker. The 
kinase reaction was stopped by adding 20 µl 6x SDS-PAGE sample buffer and boiling at 
95°C for 5 min. The kinase assay was separated by SDS-PAGE. The gel was washed 
three times for 5 min with H2O and stained with SimplyBlue SafeStain (Invitrogen, 
Lucerne, Switzerland) for 1 hr, followed by destaining with H2O. The gel was 
autoradiographed, and radioactively labeled proteins were in-gel digested essentially as 
described above and desalted on disposable C18 MacroSpin columns.  
 
 
2.5. Western Blotting, Phosphatase Treatment and In vitro Kinase 
Assays 
  
 200 ml cells were grown in either YPD or SD medium to an OD600 of 0.8. If 
necessary, at this stage yeasts were treated with rapamycin or vehicle for 20 min. After 
that, cells were harvested by centrifugation at 4,500 rpm and 4°C for 10 min, washed 
with cold water and centrifuged again. Cell pellets were resuspended in 1 ml lysis buffer 
(PBS containing 0.5% Tween 20 and 10% glycerol) containing 1x Roche protease 
inhibitor cocktail, 1 mM PMSF and phosphatase inhibitors (10 mM NaF, 10 mM NaN3, 
10 mM p-nitrophenylphosphate, 10 mM sodium pyrophosphate and 10 mM β-
glycerophosphate) and transferred to a 2 ml screw cap tube. Glass beads were added till 
the liquid reached the top of the tube and the cells were lysed in a bead beater with six 30 
sec bursts. In between the bursts, the cells were cooled on ice for 2 min. Cell debris were 
pelleted at 12,000 rpm and 4°C for 5 min. The protein concentration of the supernatant 
was determined by the Bradford assay and the same amount of protein for each sample 
(between 5-15 mg) was transferred to a 1.5 ml tube. The final volume in the tube was 
adjusted to 800 µl. HA or MYC-tagged proteins were immunoprecipitated over-night on 
an end-over-end rotator with 25 µL of proteinA-Sepharose beads (50% suspension in 
PBS, pH 7.3/0.01% thiomerosal) covalently crosslinked to anti-HA antibody (Santa Cruz 
Biotechnology, 12CA5) or anti-MYC antibody (American Type Culture Collection, 
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CRL-1729). After over-night incubation at 4oC, the Sepharose beads were washed five 
times with 1 ml washing buffer (PBS, pH 7.3 containing 10% glycerol and 0.5% Tween-
20) at 500 g for 1 min at 4°C. After the last wash step, the wash buffer was completely 
removed with a Hamilton syringe. For SDS-PAGE, the tagged proteins were eluted from 
the beads with 25 µl 2x SDS-PAGE sample buffer by boiling at 95°C for 5 min and 
electrophoresed on mini-gels (Bio-Rad, Reinach, Switzerland). The proteins were 
transferred onto nitrocellulose. For western blotting, anti-HA (mouse monoclonal, Cell 
Signaling) and anti-MYC (mouse monoclonal, American Type Culture Collection, CRL-
1729) antibodies were used. 
For λ phosphatase treatment, the pull-downs were washed five times with 1 ml 
washing buffer as described above, followed by two washes with 0.8 ml phosphatase 
buffer (50 mM Tris-Cl pH 7.5, 0.1 mM EDTA, 5 mM DTT, 0.01% BRIJ35, 2 mM 
MnCl2). After the last wash step, the phosphatase buffer was completely removed from 
the beads with a Hamilton syringe and the beads were resuspended in either 20 µL 
phosphatase buffer or in 20 µL phosphatase buffer supplemented with 25 U λ protein 
phosphatase (Sigma). The tubes were incubated on a thermoshaker for 30min at 30°C. To 
stop the reaction 4 µL 6x SDS-PAGE sample buffer were added to each sample and the 
tubes were boiled at 95°C for 5 min. SDS-PAGE, protein transfer and western blotting 
were done essentially as described above.  
 
 
2.6. In vitro Kinase Assay 
 
For in vitro kinase assays, pull-downs from 800 ml yeast cultures were prepared. 
After over-night immunoprecipitation of the tagged proteins, the beads were washed five 
times with 1 ml washing buffer (PBS, pH 7.3 containing 10% glycerol and 0.5% Tween-
20), followed by two washes with 0.8 ml kinase buffer (50 mM HEPES, pH 7.5, 10 mM 
MnCl2, 1 mM EGTA, 0.01% Tween-20 and freshly added 2.5 mM DTT). After that, the 
beads were resuspended in 5 µl 4x kinase buffer, 11.3 µl H2O, 0.7 µl 190 µM PP242 (or 
0.7 µl DMSO), 0.2 µl 100 µM ATP, 0.4 µl [γ-32P]-ATP (150 kBq/assay), 2.4 µl 
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recombinant mTOR (Invitrogen, Lucerne, Switzerland). For the kinase assays, the mTOR 
stock solution was diluted ten fold into 20 mM HEPES, pH 7.5, 0.02% Tween-20, 2 mM 
DTT, 0.1 mg/ml BSA so that 100 ng mTOR was used per assay. The kinase assays were 
incubated on a thermoshaker at 30°C for 30 min and stopped with 4 µl 6x SDS-PAGE 
sample buffer and boiling at 98°C for 5 min. The tubes were then briefly spun and 24 µl 
of the supernatant was loaded on minigels (Bio-Rad, Reinach, Switzerland). The gels 
were washed three times for 5 min with H2O and stained with SimplyBlue SafeStain for 1 
hr. The gel was then destained with H2O, wrapped in Saran foil and exposed on a 
Phosphor Screen for 18 hours (GE Healthcare). The Phosphor Screen was developed on a 
Typhoon FLA 9000 (GE Healthcare). 
 
 
2.7. LC-MS/MS Analysis of Protein Immunoprecipitates 
 
For LC-MS/MS analysis immunoprecipitates from 800 ml yeast cultures were 
prepared. The tagged proteins were immunoprecipitated over-night with 25 µl antiHA-
Sepharose beads essentially as described above. The beads were subsequently washed 10 
times with 1 ml washing buffer (PBS, pH 7.3 containing 10% glycerol and 0.5% Tween-
20) and, after the last wash, the residual liquid was removed with a Hamilton syringe. 
Bound proteins were eluted by incubating the beads with 50 µl 0.2% SDS on a 
thermoshaker for 20 min. After a short spin, the supernatant was transferred to a new 
tube. The proteins were precipitated by adding 12.5 µl 100% TCA and incubation on ice 
for 2 hours. The proteins were pelleted at 12,000 rpm and 4°C for 20 min. The precipitate 
was washed with 1 ml 20% TCA and 1 ml acetone (-20°C). The protein precipitate was 
dried in a speed-vac for 10 min and dissolved in 10 µl of the appropriate resuspension 
buffer (Table 2.3). The proteins were reduced at 37°C with 10 mM TCEP for 30 min and 
alkylated in the dark with 50 mM iodoacetamide for 60 min. Before digestion, the urea 
concentration was reduced to 0.8 M with the appropriate dilution buffer (Table 2.3). The 
proteins were digested over-night with 0.25 µg of the appropriate protease. Protein 
digestion was performed at 37°C, except for the Glu-C digestion that was carried out at 
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25°C. The next day, the digests were acidified by adding 5.3 µl 100% formic acid (final 
concentration of 5%) and they were desalted on C18 Stage Tips (Thermo Scientific, 
Reinach, Switzerland) according to manufacturer’s instructions. Peptides were eluted 
with 30 µl 80% acetonitrile/5% formic acid. The digests were dried in a speed-vac and 
dissolved in 30 µl 0.1% TFA for LC-MS/MS analysis. 
Liquid chromatography was performed using a ProteoCol trap C18 column (0.15 
x 10 mm, 3 µm particle size, 300Å) (SGE Analytical Science, Victoria, Australia) and a 
separating column (0.1 x 100  mm) that had been packed with Magic 300Å C18 reverse-
phase material (5 µm particle size, Swiss Bioanalytics, Birsfelden, Switzerland). The 
columns were connected on line to an Orbitrap FT hybrid instrument (Thermo Finnigan, 
San Jose, CA). The solvents used for peptide separation were 0.1% acetic acid (solvent 
A) and 80% acetonitrile/0.1% acetic acid and in water (solvent B). Peptides were injected 
via a 2 µl loop onto the trap column with the capillary pump of an Agilent 1200 system 
(Agilent Technologies, Basel, Switzerland) set to 5 µl/min. After 15 min, the trap column 
was switched into the flow path of the separating column. A linear gradient from 2 to 
35% solvent B in 60 min was delivered with an Agilent 1200 nano pump at a flow rate of 
500 nl/min. After 60 min the percentage of solvent B was increased to 60% in ten 
minutes and further increased to 80% within 2 min. The eluting peptides were ionized at 
1.7 kV. The mass spectrometer was operated as previously described for the 
phosphoproteome analysis. Briefly, full scans were acquired between m/z 375-1600 in 
profile mode in the Orbitrap at 60,000 FWHM nominal resolution, followed by the 
fragmentation of the 10 most intense ions in the LTQ. Singly-charged ions were not 
fragmentated and dynamically exclusion was set at 25 sec.  
Mass spectral data were searched with Mascot (version 2.2.04) against a databank 
containing 31,426 protein sequences from forward and reverse (Swiss-Prot) S. cerevisiae 
sequences as well as common protein contaminants. The search parameters were as 
described above except that arginines and lysines were kept unmodified. The data were 
filtered using an expectation value below 0.05 and a Mascot score higher than 20. The 
searches were exported in Excel sheets and oxidized methionines were replaced with 
normal methionines. 
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Enzyme Resuspension buffer Dilution buffer 
Trypsin, 
Endoproteinase Lys-C 
500mM Tris-HCl, pH8.6, 8M urea 50mM Tris-HCl, pH 7.4, 5mM CaCl2 
Endoproteinase Asp-N 
250mM sodium phosphate, pH 8.0, 8M 
urea 
50mM sodium phosphate, pH 8.0 
Endoproteinase Glu-C 
250mM ammonium carbonate, pH 8.0, 
8M urea 
25mM ammonium carbonate, pH 8.0 
 
Table 2.3.: List of the appropriate resuspension and dilution buffers for each protease. 
  
 
 
2.8. Phosphomapping of HA-Nap1 
 
2.8.1. In vitro Phosphorylation of HA-Nap1 
 
HA-Nap1 immunoprecipitates were obtained from 4 l yeast cultures as described 
above. The immunoprecipitates were washed five times with 1 ml washing buffer (PBS 
containing 0.5% Tween 20 and 10% glycerol). For Nap1 dephosphorylation, the 
immunoprecipitates were further washed twice with 0.8 ml 1x phosphatase buffer (50 
mM Tris-Cl pH 7.5, 0.1 mM EDTA, 5 mM DTT, 0.01% BRIJ35, 2 mM MnCl2). The 
dephosphorylation reaction was as previously described. After dephosphorylation, the 
beads were washed five times with washing buffer (PBS containing 0.5% Tween 20 and 
10% glycerol), followed by two washes with 0.8 ml 1x kinase buffer (50 mM HEPES, pH 
7.5, 10 mM MnCl2, 1 mM EGTA, 0.01% Tween-20 and freshly added 2.5 mM DTT). 
The in vitro kinase reaction was performed as described above. If necessary half of the 
immunoprecipitates were treated with DMSO (control) and the second half with PP242. 
After in vitro phosphorylation of Nap1 with [γ-32P]-ATP, the beads were washed 
extensively until no radioactivity was detected in the wash. At this stage Nap1 was eluted 
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from the beads by adding 50 µl 0.2% SDS and incubation on a thermoshaker for 20 min. 
Proteins were precipitated with TCA, digestion and peptide desalting were as described 
above, except that the peptides were desalted on disposable C18 MicroSpin columns. 
Radioactively labeled peptides were isolated by C18 reverse-phase chromatography. 
 
 
2.8.2. Reverse-Phase Chromatography  
 
Reverse-phase chromatography was done on a Zorbax SB-C18 reverse-phase 
HPLC column (0.5 x 150 mm, 5.0 µm particle size, Agilent Technologies, Basel, 
Switzerland) connected to an Agilent 1260 Infinity Capillary LC System (Agilent 
Technologies, Basel, Switzerland) at a flow rate of 10 µl/min. The column was 
equilibrated with 98% solvent A (0.1% TFA) and the digest was injected via a micro-
autosampler. After 10 min, the peptides were eluted with a linear 60 min gradient from 
2% to 80% solvent B (80% acetonitrile, 0.09% TFA). The effluent was monitored at 220 
nm and 280 nm and fractions were collected every 2 min with a microtiter plate fraction 
collector. Each fraction was dried in a speed-vac and resuspended in 30 µl 0.1% TFA. 5 
µl were used for liquid scintillation counting and the remaining part was used for LC-
MS/MS as described. 
 
 
2.10 Quantitative Real-time PCR Analysis 
 
Cells were grown in SD medium to an OD600 of 0.8. Cultures were treated with 
drug vehicle or rapamycin (200 ng/ml) for 30 minutes before total RNA was isolated 
using the RNeasy Mini Kit (Quiagen, Magden, Switzerland) according to the 
manufacturer’s instructions. Additionally, to remove genomic DNA DNase I (Quiagen, 
Magden, Switzerland) treatment was performed directly in the RNeasy column. RNA 
purity and quantity were assessed spectrophotometrically. cDNA was generated from 3 
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µg of RNA using SuperScript II reverse transcriptase (Invitrogen, Lucerne, Switzerland) 
and random nonamers (Sigma) according to the manufacturer’s instructions. Each cDNA 
sample was diluted ten fold with nuclease-free water (Ambion, Rotkreuz, Switzerland). 
The cDNA was then analyzed by qPCR in a StepOnePlus real-time PCR machine 
(Applied Biosystems, Zug, Switzerland) using the SYBR Green method. Gene-specific 
primers (Table 2.4) were designed with the Beacon Designer software. The reaction was 
set up by mixing 2 µl cDNA template with 7.5 µl 2x Power SYBR Green PCR Master 
Mix (Applied Biosystems, Zug, Switzerland), 5 µl nuclease-free water and 0.3 µl of each 
forward and reverse primer (200 nM each). All reactions were run in duplicate. The 
qPCR conditions were 95°C for 10 minutes, followed by 40 cycles with denaturation at 
95°C for 15 seconds and annealing/elongation at 60°C for 1 minute. Expression for each 
target gene was normalized to actin and the reference sample (TB50a untreated) was 
normalized to 1.  
 
 
Name Sequence 
INO1_fwd TTAATGGTTCACCGCAGAATAC 
INO1_rev GCCAGAACAGACTTCAACTTG 
SIP4_fwd GCTCCTCTAACGCAATCACTG 
SIP4_rev AGGGAAGTCAATTTTCGCACAG 
ACT1_fwd ATGGATTCTGAGGTTGCTG 
ACT1_rev CCTTGGTGTCTTGGTCTAC 
 
Table 2.4: Primers used for qPCR analysis 
 
 
2.9. Glycogen Staining 
 
Staining of intracellular glycogen was performed with iodine vapor as previously 
described [25]. 
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3. Results  
 
3.1. Establishing a Workflow for the Qualitative Analysis of the 
Rapamycin-Sensitive Yeast Phosphoproteome  
 
Although it is known that TORC1 regulates many cellular processes, the 
molecular mechanisms by which TORC1 signals to diverse processes are not well 
understood. To date, only Tap42 [65], Sch9 [66] and Sfp1 [32] have been identified as 
direct TORC1 substrates. For a global understanding of the phosphorylation sites 
regulated by TORC1 and for the identification of novel TORC1 targets, 
phosphoproteomes obtained from untreated or rapamycin-treated yeast cells were 
compared. In particular, those phosphorylation events that are decreased following 
rapamycin treatment can in principal, be regarded as direct substrates of TORC1. 
In a first comparison of the phosphoproteomes, proteins from untreated or 
rapamycin-treated yeast cells were digested with trypsin in solution, and phosphopeptides 
were enriched via IMAC. The resulting phosphopeptides were analysed by LC-MS/MS 
and the proteins were identified by databank searching. Surprisingly, except for 
phosphopeptides of highly expressed proteins, the total number of identified 
phosphopeptides was disappointingly low (results not shown). This is attributable to the 
high complexity and the extremely large dynamic range of the peptides present in the 
digest that leads to the fragmentation of only the most abundant phosphopeptides in the 
mass spectrometer. Therefore, it was obvious that the yeast extract needed to be 
fractionated in some way to reduce sample complexity and to increase proteome 
coverage. To date several separation techniques to fractionate entire proteomes have been 
used independently or in combination, such as strong cation exchange chromatography 
(SCX [91]), hydrophilic interaction liquid chromatography (HILIC [87]), and SDS-
PAGE [110]. SCX and HILIC fractionations are done at the peptide level and involve 
separations according to peptide charge and hydrophilicity, respectively. Therefore they 
are very useful to further concentrate the negatively-charged and hydrophilic 
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phosphopeptides. On the other side, SDS-PAGE fractionation is a convenient method 
because it allows to directly lyse the cells in SDS buffer. Due to the strong denaturing 
effect of SDS, inadvertent dephosphorylation of proteins by phosphatases can be 
effectively suppressed. For this reason and for the inherent simplicity of gel 
electrophoresis, the proteomes from control and rapamycin-treated yeast cells were 
separated by SDS-PAGE. Two preparative SDS-gels were run in parallel, one for the 
separation of an extract from untreated and the other for the separation of an extract from 
rapamycin-treated cells. The two gels were sliced individually into horizontal bands and 
the gels slices were digested with trypsin. Before phosphopeptide enrichment, tryptic 
peptides were desalted on C18 reverse-phase columns. Several column formats were 
tested to make sure that the maximal binding capacity of the packing material was not 
exceeded. The use of MacroSpin columns containing 200 µl bed volume of C18 material 
was optimal for the desalting of the tryptic peptides generated from a single gel slice 
(~400 µg), since no peptide losses were observed in the column flow-through (data not 
shown).  
After desalting, the phosphopeptides were enriched via immobilized metal ion 
affinity chromatography (IMAC [80]). At this stage two types of enrichment procedures 
were tested. In one case, Fe(III)IMAC resin was added directly to one half of the peptide 
pool and phosphopeptide enrichment was done by incubating the solution on a shaker for 
one hour (“In-solution IMAC” [110]). The other half of the peptide pool was loaded onto 
a micro-column packed into a constricted GeLoader tip (“IMAC column” [106]). The 
phosphopeptide enrichment on the micro-column was far better than in-solution 
enrichment, since the number of identified phosphopeptides was two times higher (Figure 
3.1A). The effect of the peptide to resin ratio on the selectivity of the IMAC enrichment 
was also evaluated. Tryptic digests from individual gel slices were spiked with 
radioactively labeled yeast phosphopeptides and the distribution of the radioactivity in 
the flow-through and the eluate of the IMAC micro-column was measured. The 
radioactive phosphopeptides were obtained after digesting a mixture of yeast proteins 
previously phosphorylated by the Npr1 kinase. Such a heterogeneous mixture of 
radiolabelled phosphopeptides was favored over a mixture of a few standard 
phosphopeptides because it more closely resembles the complex mixture obtained from 
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yeast cells. The radiolabeled phosphopeptide pool contained about 60,000 cpm in total 
from which 2,000 cpm were used for each tracer experiment. The highest recovery of 
radiolabelled phosphopeptides in the eluate was observed when a ratio between 0.1 to 1 
mg peptide per 30 µl packed IMAC resin was used (Figure 3.1B). Notably, a constant 
amount of radioactivity was always present in the flow-through, even at very low peptide 
to IMAC ratios. This is perhaps due to extremely basic phosphopeptides that are unable 
to bind to the Fe3+ of the IMAC resin. However, no significant radioactivity was detected 
in the washing steps once the phosphopeptides had bound to IMAC, which indicates that 
most of the phosphopeptide losses occur during the binding step. In addition, at all 
peptide to IMAC resin ratios a discrete amount of radioactivity corresponding to 20% of 
the total loaded radioactivity was lost in the flow-through and the eluate. These 
phosphopeptides most likely bind irreversibly to IMAC. 
The IMAC eluates from the gel slices were analyzed individually by LC-MS/MS 
on an LTQ-Orbitrap hybrid mass spectrometer. To fragment as many different peptides 
as possible, after each survey scan, ten precursor ions were subjected to fragmentation in 
the LTQ part of the instrument (Top10 strategy [111]). Also, to reduce peptide co-elution, 
a shallow LC-gradient of less than 0.3 % solvent B change per minute was applied. 
Moreover, phosphopeptides are known to undergo intense neutral-loss of H3PO4 upon 
collision induced dissociation. As a consequence, a predominant signal corresponding to 
the dephosphorylated peptide and reduced backbone fragmentation is observed [111]. To 
obtain richer fragmentation spectra that yield unambiguous identifications during 
databank searching, multistage activation [111] was performed on the selected precursor 
ions. Figure 3.2A summarizes the overall procedure to qualitatively analyze the 
phosphoproteomes from both control and rapamycin-treated cells. 
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Figure 3.1: (A) Comparison between on-column and in-solution phosphopeptide enrichment. (B) Influence 
of the peptide to resin ratio on the selectivity of the IMAC enrichment. The phosphopeptide distribution 
between flow-through and eluate was monitored by measuring the radioactivity of 32P-labeled 
phosphopeptides. 
 
 
In total 850 unique phosphoproteins (1,683 unique phosphopeptides) from 
vehicle-treated cells versus 803 phosphoproteins (1,661 unique phosphopeptides) from 
rapamycin treated cells were identified (Figure 3.2B and Appendix I-II). The ratio of 
pSer:pThr:pTyr was 61:8:1 and 65:10:1 for untreated and rapamycin treated cells, 
respectively (Figure 3.2B). This compares well to previously reported pSer:pThr:pTyr 
ratios in mammalian cells (79:17:4) [112]. The tyrosine phosphorylation detected in this 
study probably is caused by dual-specificity kinases in yeast [113]. Interestingly, a 
relationship was observed between incompletely cleaved peptides and phosphorylated 
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peptides identified in the phosphoproteome. In the untreated and rapamycin-treated 
samples there were 35% and 33% incompletely cleaved phosphopeptides, respectively, 
while these values were much lower for the non phosphorylated peptides (15% and 12%, 
respectively). This is very likely due to inhibition of the protease cleavage site by the 
neighboring phosphorylated residue (Figure 3.2C). Indeed, most of the incompletely 
cleaved phosphopeptides had phosphorylation sites in close proximity to arginine and 
lysine residues when compared to fully cleaved phosphopeptides. The average peptide 
length in the untreated and rapamycin-treated phosphoproteomes was 14 and 13 amino 
acids, respectively. These values do not differ significantly from previously published 
phosphoproteomes, where SCX instead of SDS-PAGE was used for fractionation [92]. 
This is surprising as one would assume that in-gel digestion tends to release small 
peptides from the gel matrix, while large peptides do not diffuse out of the 
polyacrylamide matrix. However, the fact that in both studies a comparable average 
peptide length was observed could be attributable to the reverse-phase desalting step that 
tends to bind very long peptides irreversibly. 
In the phosphoproteomes from both untreated and rapamycin-treated cells, the 
majority of the phosphopeptides (80%) carried one phosphate, while 17% were doubly 
phosphorylated peptides (Figure 3.2B). This distribution agrees well with the findings of 
Bodenmiller et al. (84% singly and 15% doubly phosphorylated peptides) [83]. This 
distribution is specific to IMAC selection, since it was reported that other enrichment 
procedures like titanium dioxide (TiO2) enrich almost only singly phosphorylated 
peptides [83]. Another interesting observation is that the highest number of 
phosphopeptides was detected in the high mass range of the gel and it decreased steadily 
towards the low mass range. In both phosphoproteomes 85% of all phosphopeptides were 
contained in gel slices above 40 kDa. A possible explanation is the exceedingly high 
concentration of ribosomal proteins in the lower part of the gel. The high concentration of 
peptides derived from ribosomal proteins can effectively compete and eventually displace 
phosphopeptides from low-abundance phosphoproteins present in these bands.  
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Figure 3.2: (A) Schematic overview for the qualitative TORC1 phosphoproteome of S. cerevisiae. (B) 
Summary of the results from a single phosphoproteomic experiment. The numbers in the white and black 
boxes represent phosphoproteins/phosphopeptides/phosphorylation sites from untreated or rapamycin 
treated cells, respectively. The pie charts (white: untreated; black: rapamycin-treated) illustrate the number 
of phosphorylation sites per phosphopeptide (C) Amino acids between phosphorylation and cleavage sites. 
1 means that the phosphorylation site is adjacent to the cleavage site. 
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 Interestingly, the qualitative phosphoproteome contained several known 
components of the TORC1 signaling pathway (Figure 3.3 and Appendix I-II). For 
example, several transcription factors involved in RP and RiBi gene expression like Fhl1, 
Ifh1, Tod6, Dot6 and Stb3 could be identified [28-30, 33]. Several phosphatase subunits 
(Cdc55, Rts1, Tpd3, Sap155, Sap190) and the kinase Sch9 were also present [64-66]. 
Moreover, a number of transcription factors indirectly controlled by TORC1 could also 
be identified in the present phosphoproteomic analysis: Gat1, Gis1, Maf1, Mks1, Msn2/4 
and Rtg1/3. Many phosphorylation sites of the rapamycin-activated protein kinase Npr1, 
which plays a crucial role in the trafficking of Gap1 to the plasma membrane [46, 47] 
were detected. The permease Gap1 itself along with other nutrient permeases (Agp1, 
Bap2, Can1, Dal4, Dip5, Fui1, Gnp1, Put4 and Tat2) was found phosphorylated in the 
phosphoproteome. Also heavily phosphorylated was the protein Atg13, a key regulator of 
autophagy [51]. Several phosphorylation sites mapping to various proteins functioning in 
translation initiation were also identified, for instance Gcn2, eIF2α, Eap1 and several 
subunits of the eIF2B and eIF2 complexes. Finally, phosphorylation sites on Tco89 and 
Bit61, two subunits of TORC1 and TORC2, were also found in the phosphoproteomic 
analysis [22-24]. Interestingly, components of other signaling pathways known to interact 
with the TORC1 pathway were also well represented in the phosphoproteome. For 
example, several phospho-sites from the PKA subunits Bcy1 and Tpk3 and from the 
upstream PKA regulators Gpr1, Gpa2, Ira2 and Cyr1 could be mapped. Likewise, the 
phosphoproteome contained phosphopeptides from the Snf1 kinase, its effectors Adr1, 
Sip4 and Mig1 as well as its upstream regulators Reg1, Sak1 and Elm1. Considering all 
these findings, the phosphoproteomic workflow established in the present work allows 
the tracking of rapamycin-sensitive phosphorylation events associated with many 
components of the TORC1 signaling pathway. 
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Figure 3.3: Schematic overview of the TORC1 signaling network. Proteins in orange are found 
phosphorylated in the qualitative phosphoproteome. The inserts illustrate the single protein components of 
PKA and the eIF2 and eIF2B complexes.  
Results 
 
 58
3.2. The Quantitative Rapamycin-Sensitive Phosphoproteome of S. 
cerevisiae 
 
In the first section a qualitative phosphoproteomic strategy was presented, which 
enables the detection of several physiologically relevant phosphorylation sites known to 
be regulated by TORC1. Interestingly, for some of these proteins a qualitative difference 
in phosphorylation following rapamycin treatment could already be seen. For example, 
T273 phosphorylation on Sch9 and S232/S233 phosphorylation of the Sch9 substrate 
Rps6 were detected only in untreated cells (Appendix I-II), which agrees well with the 
fact that TORC1 directly phosphorylates and activates Sch9 (the activating phospho-sites 
are S711, T723, S726, T737, S758 and S765 [66]), which in turn phosphorylates Rps6 at 
S232 and S233 [66]. Likewise, many phosphorylation sites on Atg13 (S355, T379, S382, 
S461, S644 and S646) and Gat1 (S291 and S399) were present only in untreated cells 
(Appendix I-II) [51]. However, for other TORC1-regulated proteins the effect of 
rapamycin treatment was not evident. For example, the same phosphorylation sites 
between control and rapamycin-treated cells were found in Maf1, Msn2/4, Npr1 and 
Rim15 (Appendix I-II). This, however, does not exclude regulation on these sites. 
Previous studies revealed down-regulation of a number of phosphorylation sites on Npr1 
following rapamycin treatment [114]. Therefore, it is important to be able to quantitate in 
relative terms the effect of rapamycin on the site occupancy of all observable 
phosphorylation sites.  
 In a first attempt to quantitate relative changes of phosphorylation, the tryptic 
peptides obtained from each gel slice were chemically derivatized with the isobaric 
iTRAQ reagent [115]. Even though quantitative derivatization of all peptides was 
achieved with the iTRAQ reagent (Appendix III), the total number of peptides and 
phosphopeptides was much lower than in the unlabeled phosphoproteome (164 vs. 1,683 
unique phosphopeptides). The low yield of peptides, observed also by other laboratories, 
is probably a consequence of the higher charge state of iTRAQ-modified peptides in 
comparison to the unlabeled counterparts. This leads to very complex fragmentation 
spectra that are difficult to identify by data bank searching [116]. A similar trend, 
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although much less pronounced, was also observed in the present study, where the 
percentage of doubly, triply and higher charged ions was 88%, 11%, 1% versus 83%, 
15%, 2% for the unlabeled and iTRAQ-labeled phosphopeptides, respectively. Since the 
iTRAQ approach was unsatisfactory, it was decided to perform relative quantification by 
stable isotope labeling with amino acids in cell culture (SILAC [117]). 
In contrast to iTRAQ, SILAC has the distinct advantage that the protein extracts 
from control and rapamycin-treated cells are mixed in equal amounts before 
fractionation, thus reducing experimental variation, time and number of samples to be 
processed. Similar to the original qualitative phosphoproteomic workflow, 
phosphopeptides from in-gel digested proteins were enriched by IMAC, and the resulting 
phosphopeptide pools were sequentially analyzed by LC-MS/MS (Figure 3.4A). To 
increase the phosphoproteome coverage and, equally important, to obtain statistically 
sound results, four independent biological replicates were processed. The advantage of 
performing different experiments to increase phosphoproteome coverage is illustrated in 
Figure 3.4C. Essentially, only 50% of the total phosphopeptides have been identified and 
quantified in three or more experiments and 20% of the total hits have been found in just 
one out of four experiments. 
Even though a complete set of phosphopeptides could only be obtained with 
repeated runs, the reproducibility of the SILAC ratios was very high. The SILAC ratios 
of each phosphopeptide from each individual experiment were compared to the average 
ratio of all other combined experiments and in all four cases high correlation values were 
obtained (Figure 3.4D). In total 2,487 unique phosphopeptides and 2,607 unique 
phosphorylation sites mapping to 972 phosphoproteins were quantified (Figure 3.4B and 
Appendix IV). These values agree well with previously published yeast 
phosphoproteomes: Gruhler et al. quantified 729 phosphorylation sites (from 503 S. 
cerevisiae phosphoproteins), while in more recent studies up to 2,887 quantitative 
phosphorylation sites had been reported [92, 100, 110, 118]. 
The abundance of the quantified phosphoproteins was compared to the protein 
abundance of all yeast open reading frames (ORFs), which were estimated in a previous 
study from genome-wide protein affinity purification experiments [119]. For this, the 
cumulative percentages of all yeast ORFs and of the proteins quantified in the 
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phosphoproteome were plotted. The two curves were perfectly superimposable (Figure 
3.4E), indicating that the dynamic range of the SILAC-labeled phosphoproteins closely 
follows the previously determined expression levels in yeast. Equally important, the data 
suggest that there is no bias in the phosphoproteome towards highly expressed proteins so 
that low abundant phosphoproteins are equally well quantified than high abundance 
phosphoproteins. This is important when considering the many effects TORC1 exerts on 
signaling proteins such as transcription factors, protein kinases and phosphatases, which 
are typically present in low copy numbers in yeast cells.  
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Figure 3.4: (A) Overview of the experimental approach for the quantitative TORC1-regulated 
phosphoproteome of S. cerevisiae. (B) Summary of the unique phosphoproteins/phosphopeptides that were 
quantified from four biological replicates. (C) Venn diagram for the overlap of quantitated phosphoproteins 
from the four biological replicates. (D) Evaluation of the biological reproducibility. The SILAC ratios from 
each single experiment were compared to the average ratios of all combined experiments. (E) Comparison 
between the protein abundances of all S. cerevisiae open reading frames (blue line) and the 
phosphoproteins quantified in this study (red line). Protein abundance data were retrieved from a genome-
wide protein affinity purification study [119].  
 
 
To identify those proteins whose changes in phosphorylation were significantly 
affected by rapamycin, four biological replicates for sound statistical significance were 
performed. For estimating the experimental variance, a control experiment was devised 
by mixing a light and a heavy cell culture without rapamycin treatment so that 
theoretically all SILAC ratios should be equal to 1. Any deviation from a ratio of 1.0 is 
caused by experimental variation so that a proper threshold for the rapamycin-treated cell 
cultures can be set. Since the SILAC ratios obtained from MaxQuant range from 0 to 1 
for down- and from 1 to infinite for up-regulation, all ratios were log2-transformed to 
obtain a symmetrical distribution. For the control experiment, an average SILAC ratio of 
0.02 with a standard deviation of 0.28 was obtained. Based on these values, the threshold 
for a significant up- or down-regulation of the four biological replicas following 
rapamycin treatment was set to twice the standard deviation of the control experiment (± 
0.56). However, some phosphopeptides were observed in only one experiment (Figure 
3.4C) but had a large change in the extent of phosphorylation. For such potentially 
interesting phosphorylation sites, the threshold was set to four times the standard 
deviation of the control experiment (± 1.12). With the above filters 78 proteins had up-, 
and 55 proteins had down-regulated phosphorylation following rapamycin treatment 
(Table 3.1 and 3.2).   
In the present phosphoproteome many significantly up- or down-regulated 
phosphoproteins have previously been linked to TORC1 signaling (Table 3.1 and 3.2). 
Consistent with the first qualitative phosphoproteome and previously published data, a 
clear decrease in phosphorylation of Atg13 and Sch9 was observed [51, 66]. In contrast 
to the qualitative phosphoproteome, the effect of rapamycin on the phosphorylation of 
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other TORC1-regulated proteins, like Maf1, Npr1 and Rim15 became now clearly 
apparent (Table 3.1 and 3.2) [34, 47, 59].  
It should be noted that not all changes observed in the phosphoproteome are 
caused by specific phosphorylation events. Previous reports have shown that a very short 
treatment with rapamycin (<20 min) already induces substantial transcriptional changes 
of specific sets of genes [41, 42]. As a result, a change in the extent of phosphorylation of 
a given protein could be just as well the consequence of the altered mRNA level. To 
discriminate between changes in gene expression or phosphorylation induced by 
rapamycin, the present phosphoproteomic data were compared with previously published 
microarray data obtained from rapamycin-treated yeast cells [42]. A comparison of the 
two data sets showed that in 25% of all proteins the regulation was probably a 
consequence of altered transcriptional levels rather than altered phosphorylations (third 
column in Table 3.1 and 3.2). However, for 13% of the proteins an inverse correlation 
between the change in phosphorylation and mRNA levels was observed (third column in 
Table 3.1 and 3.2). This clearly rules out that these changes in phosphorylation were an 
indirect effect of a change in gene expression. Obviously altered mRNA levels do not 
necessarily correspond to changes in protein levels. This is because not only protein 
synthesis but also protein stability and degradation are important determinants affecting 
the overall protein abundance. Furthermore, the mRNA needs to be processed and 
translated before alterations on protein expression become evident. Therefore, a 
comparison between phosphoproteomic and transcriptomic data does not always allow 
deciding whether a phosphorylation change is due to a change in protein abundance or 
not. To see if a change in the extent of phosphorylation is a consequence of altered 
translation/degradation or phosphorylation, an aliquot of each sample was analyzed by 
LC-MS/MS before IMAC selection to quantitate the proteins in relative terms. In theory, 
based on the intensity of the ensemble of peptides belonging to the same protein, it 
should be possible to see if the expression of this protein is altered or not. Unfortunately, 
because of the enormous peptide complexity, only 34% of the proteins which were 
identified in the phosphoproteome could be traced in the LC-MS/MS runs of the digests 
prior to IMAC enrichment (Appendix V). In spite of the low proteome coverage, it was 
possible to monitor the relative expression levels of 1,328 yeast proteins (fourth column 
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in Table 3.1 and 3.2 and Appendix V). Interestingly, only 1.2% of the observed proteins 
had up- or down-regulated protein expression in response to rapamycin (Table 3.3), 
which means that the transcriptional effects exerted by rapamycin usually take more than 
20 minutes to alter protein expression. Among the regulated proteins, 12 had higher, and 
4 lower expression levels following rapamycin treatment (Table 3.3). Consistent with 
published microarray data [42], among the up-regulated proteins there were several 
permeases (Agp1, Can1, Dip5, Gap1, and Ptr2) as well as the enzyme Dur1,2 responsible 
for urea catabolism. Moreover, in accordance with the negative control of TORC1 on 
glycogen synthesis, the expression of the glycogen synthase enzymes Gsy1/2 was found 
to be significantly increased after rapamycin treatment.  
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Hyperphosphorylated proteins (part I) 
  
Phospho Site 
(Av. Ratio ± SD) 
mRNA Protein     
Phospho Site  
(Av. Ratio ± SD) 
mRNA Protein 
CAN1 S 38 (2.92 ± 1.19) ↑ ↑   
LSB3 
T 298, S 303 (3.00) * 
↑  
CDC33 S 30 (12.90) *  →   S 300, S 303 (2.35) * 
CIN5 
S 196 (2.29 ± 0.49)  
 
  LYP1 S 87, T 90 (2.30) *   
T 198 (1.96 ± 0.20)    
MDG1 
S 287 (9.00) * 
↑  CLA4 T 447 (1.74 ± 0.08)  →   S 288 (3.37 ± 1.87) 
DAL81 S 860, S 862 (2.52) *     S 291 (6.17) * 
DBF2, 
DBF20 
T 544 (2.68) *   
  
MEP2 
S 484, S 487, S 490, 
S 491 (2.23) * 
↑  
DCS2 
S 63 (2.49 ± 0.11) 
↑  
  S 487, S 490, S 491 (2.43) * 
T 64 (2.73 ± 0.38)   S 490, S 491 (2.44 ± 0.66) 
DED1 
S 535, S 539 (21.480) * 
↓  
  T 459 (3.21 ± 0.72) 
S 535 (5.90 ± 1.69)   MLF3 S 74 (2.73) *   
S 539 (6.93 ± 3.14)   MRE11 S 560 (1.52 ± 0.03) ↑  
DIP5 
T 10, S 11 (2.36) * 
↑  
  MSC3 S 363 (1.99 ± 0.10)   
S 11 (3.64 ± 0.08)   MTC1 S 75 (4.42 ± 1.48)  → 
S 11, S 17 (4.21) *   NCL1 S 424 (2.81 ± 0.27) ↓ → 
T 12 (3.36 ± 1.43)   NEW1 S 1181 (1.94 ± 0.27) ↓ → 
S 13 (3.57 ± 0.96)   NOC2 S 70 (2.62 ± 0.85) ↓ → 
S 17 (2.36 ± 0.16)   
NSG2 
S 90, S 93 (3.27 ± 1.17)  
→ 
S 18 (2.28 ± 0.19)   S 90 (2.01 ± 0.35)  
S 22 (2.12 ± 0.46)   S 93 (2.51 ± 0.71)  
EAF1 T 971 (1.84 ± 0.18)     S 49 (1.87 ± 0.14)  
ECM3 S 338 (4.76) * ↓    NUS1 S 60 (4.55) *   
EFR3 S 735 (1.94 ± 0.43) ↓    
ORM1 
S 29, S 32 (3.25 ± 0.21)  
 
ELP4 S 222 (1.96 ± 0.06) ↓ →   S 29, S 34 (3.50) *  
GCS1 S 157 (2.08 ± 0.39)  →   S 32, S 34 (2.82 ± 0.60)  
GDH2 S 482 (2.64 ± 1.42) ↑    S 32 (2.04 ± 0.40)  
GIN4 S 666 (2.14 ± 0.21)  →   S 35, S 36 (3.19) *  
GIS1 
S 694, S 696 (2.12 ± 0.17)  
 
  
OSH3 
T 352 (2.56 ± 0.54)  
 
S 425 (2.50 ± 1.02)    S 209 (2.08 ± 0.33)  
GPH1 T 31 (2.33 ± 0.59) ↑ ↑   PAN1 S 1003 (1.78 ± 0.23)  → 
GYP5 S 834 (1.77 ± 0.00)     
PAR32 
S 246 (3.11 ± 0.88) 
↑  
HAL5 
S 17 (1.80 ± 0.22)  
 
  S 36, S 39 (4.90) * 
S 17, S 19 (3.95) *    S 39 (2.50 ± 0.89) 
HBT1 
S 303 (2.24) * 
↑  
  PCL7 S 58 (2.62) * ↑  
S 956, S 959, S 962 
(1.56 ± 0.03) 
  
PDR12 S 56 (2.93 ± 1.49)  → 
HOM3 
S 332, S 344 (6.77) *  
→ 
  PDR16 S 346 (2.25 ± 0.26)  → 
T 333, S 344 (4.82) *    PSP2 S 340 (2.03 ± 0.26)   
IGO1 S 64 (2.43 ± 0.57)     
PTR2 
S 39, S 45 (1.71 ± 0.20) 
↑  
ISW2 T 1079 (1.83 ± 0.29)     S 6, S 9 (1.83 ± 0.05) 
ITR1 
S 46 (4.70 ± 1.97)  
→ 
  S 36, S 39, S 45 (1.97 ± 0.11) 
T 12, S 26, S 31 (1.66 ± 0.05)    Y 49, S 54 (3.16 ± 0.19) * 
KEL1 S 613, S 621 (4.08) *  →   Y 49 (3.71) * 
KIN2 S 888 (3.19 ± 0.65) ↓    S 52, S 54 (2.97) * 
KKQ8 S 21 (1.98 ± 0.05)     S 52 (3.00 ± 0.05) * 
  S 75 (2.96) *     PUT4 S 47 (4.30) * ↑  
LDB19 T 795 (6.64 ± 0.58)     RAS2 T 227 (4.19) * ↑ → 
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Hyperphosphorylated proteins (part II) 
  
Phospho Site  
(Av. Ratio ± SD) 
mRNA Protein 
    Phospho Site 
(Av. Ratio ± SD) 
mRNA Protein 
RSC2 
T 243 (3.29 ± 1.06)  
 
 
 TSL1 
T 75, S 77 (10.10) * 
↑ 
 
S 682 (2.36 ± 0.7)   S 77 (1.72 ± 0.32)  
RTS3 
S 47, S 50 (5.68) * 
↑  
 
YBR287W 
S 228 (5.74 ± 2.58)   
S 47 (3.03) *  S 231, S 234 (2.96 ± 0.06)   
S 238 (8.84) *  S 231 (7.09) *   
S 241 (8.06 ± 3.81)  YBT1 S 936 (8.98 ± 1.7) *  → 
RTT107 T 532 (2.45 ± 0.74)    YGR125W S 149 (2.40) *   
SCP160 T 50 (1.51 ± 0.03) ↓ →  YGR237C T 638 (2.55 ± 0.71) ↑ → 
SEC7 S 772 (7.08 ± 0.28)  →  
YLR152C 
S 287 (4.78) * 
↑ 
 
SMI1 
S 200, S 201 (1.79 ± 0.2)    S 273 (1.64 ± 0.05)  
S 202, S 203 (2.21) *    
YLR257W 
S 7 (6.42) * 
↑ 
 
SPN1 T 15 (1.89 ± 0.19)  →  T 44 (10.680 ± 5.29)  
SSD1 
S 480 (3.03 ± 0.2)  
→ 
 S 137 (2.92 ± 1.89)  
T 482 (2.90 ± 0.39)   
YOR051C 
S 30, S 33 (2.86) * 
↓ 
 
SSK2 S 39 (2.18 ± 0.01)    S 30, T 34 (3.04 ± 0.67)  
TCB3 
S 1340, T 1350 
(1.73 ± 0.14) 
 → 
 
S 33 (2.46) * 
 
TEA1 T 755 (1.82 ± 0.16)    
YPR172W  
S 99, T 103 (2.45 ± 0.18) 
↑ 
 
TIF4632 T 196 (1.91 ± 0.31)  →  T 101 (2.57) *  
TIF5 T 191 (3.90 ± 1.1) ↓ →  T 103 (3.14) *  
TPS3 S 148 (1.68 ± 0.22) ↑ →  
YSC84  
S 301, S 311 (1.86 ± 0.09)  
→ 
TSL1 
S 147 (3.84 ± 1.11) 
↑ 
  S 274 (2.71 ± 0.36)  
S 73, S 77 (5.24 ± 1.11) *   ZEO1 S 25 (1.85 ± 0.24) ↑ → 
 
 
Table 3.1: Rapamycin-induced increase of phosphorylation. For each protein the regulated phosphorylation 
site(s) and the fold-increase (Av. Ratio ± SD) is given. Significantly increased (↑) or decreased (↓) mRNA 
levels after rapamycin treatment [42] are indicated. The fourth column shows increased (↑) or unchanged 
(→) protein expression measured in the proteomic analysis. An asterisk (*) marks phosphopeptides 
identified only in one experiment.  
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Hypophosphorylated proteins 
Protein 
Phospho Site 
(Av. Ratio ± SD) 
mRNA Protein 
  
Protein 
Phospho Site 
(Av. Ratio ± SD) 
mRNA Protein 
AMD1 
T 136 (0.38 ± 0.09)   
→ 
  NAP1 T 24 (0.59 ± 0.00)   → 
S 138 (0.31 ± 0.09)     
NPR1 
S 255, S 260 (0.30) * 
↑ 
  
ATG13 
S 554 (0.09) *       S 353, S 356 (0.33 ± 0.16)   
S 649 (0.29 ± 0.19)       S 257, S 260 (0.10) *   
S 346, S 348 (0.08 ± 0.01)       ORC2 S 188 (0.54 ± 0.05) ↓   
S 379 (0.28 ± 0.12)       
PCT1 
S 16, S 19 (0.31 ± 0.04) 
↑ → 
BNI4 S 43 (0.43) *       S 19 (0.52 ± 0.02) 
BOI1 S 147 (0.46) *     
  PPH21, 
PPH22 
S 272 (0.37) * 
    
BUL1 S 195 (0.47 ± 0.11)       PTR2 S 594 (0.35) * ↑ ↑ 
CCR4 S 281, T 285 (0.63 ± 0.03)       RCN2 S 198 (0.41) *     
CLB3 S 33 (0.37) *       REG1 S 570 (0.41 ± 0.04)     
DNF3 S 908 (0.27) *       RIM15 S 1047 (0.52 ± 0.00)     
DOT6 
S 245 (0.33 ± 0.04)       
RPC82 
S 392 (0.47 ± 0.12) 
↓ 
  
S 247 (0.44) *       S 394 (0.46 ± 0.10)   
EAP1 
S 281 (0.51 ± 0.07)       RPH1 S 587 (0.33) *     
S 282 (0.57 ± 0.15)       RPL12A S 38 (0.57 ± 0.08) ↓ → 
ESF1 S 223 (0.65 ± 0.02) ↓ →   SCH9 S 726 (0.22 ± 0.11) ↓   
FIN1 S 36 (0.51 ± 0.09) ↑     
SER33 
S 20 (0.28 ± 0.05)   
→ FRA1 S 56 (0.48 ± 0.16)       S 22, S 29 (0.08 ± 0.04)   
GAT1 S 270 (0.34 ± 0.16) ↑     S 22 (0.33 ± 0.10)   
GCN2 
S 577 (0.18 ± 0.02)       SKY1 S 445 (0.55 ± 0.05)     
S 569, S 572 (0.07 ± 0.02)       SLA2 S 308 (0.55 ± 0.08)   → 
GIN4 S 502 (0.30) *   →   
SSD1 
S 155 (0.37) *   
→ 
GNP1 
S 111 (0.35 ± 0.09) 
↓ 
    S 164 (0.56 ± 0.07)   
S 113 (0.27 ± 0.05)     STB3 S 337 (0.43 ± 0.12)     
IRA2 S 631 (0.02) *       STM1 S 55 (0.29) * ↓ → 
KCS1 
S 581 (0.37 ± 0.05)       SWI5 T 490, S 492 (0.37) *     
S 537 (0.42) *       TGL1 T 460 (0.44) *     
KSP1 
T 526, S 529 (0.35 ± 0.05)       UBR1 T 291, S 296 (0.62 ± 0.04)     
S 827 (0.27 ± 0.01)       UBX7 S 388 (0.53 ± 0.08)     
S 883, S 884 (0.11) *       
URK1 
S 14, S 17 (0.14) * 
↓ 
  
S 884 (0.40) *       S 14 (0.12 ± 0.04)   
LHP1 S 19 (0.51 ± 0.13) ↓ →   
VTC2 
S 196 (0.40) *   
→ MAF1 
S 90 (0.25 ± 0.08)       S 583 (0.24 ± 0.03)   
S 209 (0.29) *       S 182, S 187 (0.07) *   
MET2 T 272 (0.31) *       S 182 (0.37 ± 0.02)   
MKS1 S 518 (0.43 ± 0.18)       VTC3 S 592 (0.54 ± 0.15)   → 
MOB2 S 38 (0.61 ± 0.04)       YBR028C T 82 (0.23) *     
NAP1 
T 20, T 24, S 27 (0.10) *   
→ 
  YJL016W S 350 (0.50 ± 0.02)   → 
T 20, T 24 (0.47 ± 0.10)     YML119W S 72 (0.39) *     
T 20 (0.42) *     ZUO1 S 50 (0.58 ± 0.14) ↓ → 
 
Table 3.2: Rapamycin-induced decreased of phosphorylation. For each protein the regulated 
phosphorylation site(s) and the fold-decrease (Av. Ratio ± SD) are given. Significantly increased (↑) or 
decreased (↓) mRNA levels after rapamycin treatment [42] are indicated. The fourth column shows 
increased (↑) or unchanged (→) protein expression measured in the proteomic analysis. An asterisk (*) 
marks phosphopeptides identified only in one experiment. 
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Increased abundance 
  Av. Ratio ± SD mRNA 
AGP1 2.39 * ↑ 
CAN1 3.47 * ↑ 
CIS3, HSP150, PIR1, PIR3, YJL160C 2.27 ± 0.43 ↑ 
DIP5 2.86 ± 1.20 ↑ 
DUR1,2 3.14 ± 1.20 ↑ 
GAP1 5.66 ± 1.80 ↑ 
GSY1, GSY2 1.61 ± 0.10 ↑ 
INO1 3.01 * ↑ 
MSC1 2.15 ± 0.56 ↑ 
OM45 1.73 ± 0.10 ↑ 
PTR2 2.13 ± 0.37 ↑ 
REP1 2.50 ± 0.43   
   
   
Decreased abundance 
  Av. Ratio ± SD mRNA 
PHO84 0.55 ± 0.08 ↓ 
UFD2 0.31 *   
YLL054C 0.26 ± 0.26   
YNR021W 0.35 *   
 
Table 3.3: Rapamycin-induced increase or decrease in protein abundance. For each protein the fold-change 
in protein quantity (Av. Ratio ± SD) is shown. Increased (↑) or decreased (↓) mRNA levels after rapamycin 
treatment [42] are indicated. An asterisk (*) marks proteins identified in only one experiment. 
 
 
 
To determine if TORC1 controls phosphorylation of specific sequence motifs, the 
sequences surrounding the rapamycin-regulated phospho-sites were analysed with the 
Motif-X algorithm (Figure 3.5 [120]). For sites whose extent of phosphorylation did not 
change, no clear kinase consensus was found except acidic sites (data not shown), which 
is a consequence of preferential binding of acidic phosphopeptides to the IMAC resin. 
For the peptides whose extent of phosphorylation was down-regulated upon rapamycin 
treatment, the top scoring motif was RRxS (the phosphorylated residue is underlined). 
The same motif was underrepresented in the phosphopeptides whose phosphorylation 
was up-regulated (Figure 3.5). In addition, the related motif RxxS appeared in both the 
up- and down-regulated phosphopeptides (Figures 3.5). Finally, the two motifs SP and 
SxxS were also present, but only in the up-regulated phosphopeptides. The same result 
was obtained when the rapamycin-sensitive phosphoproteome from Huber et al. was 
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analysed by Motif-X [34]. From this analysis, it appears that the RRxS consensus site is a 
primary target motif for TORC1-dependent phosphorylation. 
Notably, the RRxS/T consensus becomes specifically phosphorylated by protein 
kinase A (PKA [121, 122]). Out of the 55 proteins whose phosphorylation was decreased 
upon rapamycin-treatment, 10 had decreased phosphorylation at PKA sites (Fra1, Gcn2, 
Kcs1, Ksp1, Lhp1, Maf1, Mks1, Ssd1, Vtc2, and Yjl016w). Interestingly, Fra1, Ksp1, 
Lhp1, Maf1, and Ssd1 have been shown to be PKA targets in vitro [72, 121] and Maf1 is 
phosphorylated and negatively regulated by PKA and TORC1 in vivo [34, 35, 123, 124]. 
Moreover, the localization of the serine/threonine protein kinase Ksp1 is affected by PKA 
[125], and Gcn2, Kcs1, Ksp1, Lhp1, Mks1, and Ssd1 have been linked to TORC1 and 
PKA signaling either genetically or biochemically (www.yeastgenome.org). These 
observations suggest that the PKA and TORC1 pathways are interconnected and that 
TORC1 may modulate PKA activity. It is important to note that not all PKA target motifs 
in our phosphoproteome were affected by rapamycin treatment, like the PKA sites in the 
two well-known PKA targets Msn2 and Nth1.  
To confirm these findings, targeted analyses were performed for some PKA 
substrates, with particular emphasis on the effect of rapamycin treatment on the in vivo 
phosphorylation of the known or suspected PKA substrates Ksp1, Maf1 and Ypk3 (also 
known as Ybr028c and Kbn8). The regulated phosphorylation sites on these three 
proteins that were identified in the phosphoproteome are listed in Table 3.4 (the 
phosphorylation sites in bold conform to the PKA consensus site).  
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Figure 3.5: Motif analysis of the peptide sequences surrounding the rapamycin down- (left panel) and up-
regulated (right panel) phosphorylation sites. For the Motif-X algorithm, the phosphorylation sites were 
extended by 7 residues on each side. The height of the residues is proportional to their binomial 
probabilities based on the background database (SGD). The red lines represent a p-value of 0.01 (after 
multiple hypothesis correction) and the blue lines represent the significance threshold used in the Motif-X 
analysis. Motifs are ranked from top to bottom. 
 
 
 
Protein Description (SGD) Regulated phospho-site (Av. Ratio ± SD) Direction 
Ksp1 Ser/Thr protein kinase required for haploid filamentous growth. 
T526, S592 (0.35 ± 0.05) 
Decreased 
S827 (0.27 ± 0.01) 
S883, S884 (0.11) 
S884 (0.40) 
Maf1 Negative regulator of RNA polymerase III in response to nutrients and stress. 
S 90 (0.25 ± 0.08) 
Decreased S 209 (0.29) 
Ypk3 AGC kinase phosphorylated by PKA. 
T 82 (0.23) 
Decreased 
S 207 (0.67 ± 0.05) 
 
Table 3.4: Proteins chosen to investigate the in vivo effect of rapamycin on the PKA consensus sites. All 
three proteins were found to be regulated in the phosphoproteome at sites with a perfect PKA consensus 
motif (phospho-sites in bold). The average fold change in phosphorylation and the corresponding standard 
deviation (SD) was calculated from all four phosphoproteomic experiments (Appendix IV).  
Results 
 
 71
To investigate the effect of rapamycin treatment on the in vivo phosphorylation of 
Maf1, Ksp1 and Ypk3, phosphorylation of these proteins was probed with an antibody 
specific for the phosphorylated consensus PKA target motif (anti-RRxS/T). As reported 
previously [123], PKA-dependent Maf1 phosphorylation was reduced after rapamycin 
treatment (Figure 3.6A), which agrees well with the phosphoproteome data (Table 3.4). 
Other reports, however, show activation of Maf1 by PKA via the TORC1 effector Sch9. 
Since Sch9 is a member of the AGC kinase family, it can directly phosphorylate the PKA 
consensus sites in Maf1 [34, 35]. To demonstrate that TORC1 activates PKA to 
phosphorylate Maf1, the cell permeable, phosphodiesterase resistant cAMP analogue 8-
Bromo-cAMP [126] was used to activate PKA in rapamycin-treated yeast cells, in which 
TORC1 and Sch9 are inactive (Figure 3.6B). As expected, TORC1 inactivation upon 
rapamycin treatment resulted in a strong reduction of Maf1 phosphorylation at PKA sites 
and addition of 8-Br-cAMP to the cells restored Maf1 phosphorylation at the same sites 
(Figure 3.6B). Likewise, phosphorylation of both Ksp1 and Ypk3 at PKA consensus 
site(s) decreased upon rapamycin treatment (Figure 3.6A), which again agrees with the 
phosphoproteomic data (Table 3.4). Moreover, like Maf1, but to a lesser extent, 
activation of PKA with 8-Br-cAMP counteracted the inhibitory effect of rapamycin on 
the phosphorylation of Ypk3 at PKA sites (Figure 3.6B). Similar experiments were 
performed for the PKA substrates Cdc25, Cki1, Msn2, and Yak1. For Cdc25, Yak1, and 
Cki1 no phosphorylation by LC/MS/MS was detected at their PKA sites and for Msn2, 
no change in phosphorylation was found at the site residing in the PKA motif. 
Accordingly, no change in phosphorylation upon rapamycin treatment was detectable 
using the anti-RRxS/T antibody (Figure 3.6C). Thus, both large scale and targeted 
analyses suggest that TORC1 activates PKA towards a specific subset of substrates (e.g. 
Ksp1, Maf1 and Ypk3). 
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Figure 3.6: Influence of TORC1 inhibition on in vivo PKA substrate phosphorylation. (A) Rapamycin 
negatively affects the phosphorylation state at PKA sites of Maf1, Ypk3 and Ksp1. The blots were probed 
with an antibody against the HA tag (@ HA) or against the phosphorylated PKA consensus sequence (@ 
RRxS/T). (B) Constitutive PKA activation with 8-Br-cAMP compensates the rapamycin-induced 
dephosphorylation at PKA sites of Maf1 and Ypk3. The blots were probed as in (A). (C) Effect of 
rapamycin treatment on PKA substrates whose consensus sequence phosphorylation was not altered. The 
blots were probed as in (A). 
 
 
3.3. Validation of the Phosphoproteomic Data  
 
In 2009 another yeast rapamycin-regulated phosphoproteome was published [34]. 
A comparison of the two studies revealed surprisingly little overlap. Although the total 
number of rapamycin-regulated phosphoproteins was very similar in the two studies (133 
vs. 129), only 29 phosphoproteins (13 down- and 16 up-regulated) were common (Figure 
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3.7). Among the phosphoproteins identified exclusively in this study, there are many 
which have already been shown to be clearly involved in TORC1 signaling (Gcn2, Npr1, 
Rim15 and Ssd1). Other phosphoproteins represented in this study were shown to have 
altered sensitivity to rapamycin, caffeine or wortmannin resistance upon gene deletion 
(Figure 3.7). This clearly shows that depending on the approach and conditions used, 
complementary phosphoroteomes are obtained. Nevertheless, this also means that a 
thorough validation of the phosphoproteomic data is required, especially regarding those 
proteins that were found in just one of the two studies. Moreover, the observation that a 
protein contains rapamycin-sensitive sites is definitely an important indicator of its 
involvement in TORC1 signaling, but it needs further validation by additional 
experiments. Indeed, even a significantly regulated phospho-site may have no functional 
consequence. This is because the phosphorylation changes measured in the 
phosphoproteome are relative rather than absolute changes. In addition, the protein 
coverage in the phosphoproteome is typically low due to the high dynamic range and the 
complexity of the sample. As a consequence, additional regulated phospho-sites could be 
missing for each phosphoprotein identified in the phosphoproteome. For these reasons, it 
was important to further investigate some of the identified rapamycin-sensitive 
phosphoproteins to check whether they were real TORC1 effectors.  
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Figure 3.7: Overlap between the present and a previously published rapamycin-sensitive phosphoproteome 
[34]. The regulated phosphoproteins common to both studies are listed on the left while regulated 
phosphoproteins unique in the present study are listed on the right of the Venn diagrams. (rap +) and (rap -) 
indicate increased  or decreased resistance to rapamycin in the corresponding null mutants. 
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Twelve proteins that were found to be significantly affected in phosphorylation by 
rapamycin were chosen for further investigation. This choice was based on the following 
criteria: firstly, we focused only on phosphoproteins identified in the present study. 
Secondly, priority was given to those phosphoproteins that were found to be regulated in 
at least three out of four independent experiments. Thirdly, proteins whose biological 
functions could be linked to TORC1 downstream signaling were preferred over less well-
characterized proteins. 
Twelve proteins were chosen for additional investigation, eight of them (Hal5, 
Isw2, Kkq8, Ldb19, Mtc1, Noc2, Rts3, and Sec7) were more phosphorylated following 
rapamycin treatment, and four had decreased phosphorylation upon rapamycin treatment 
(Nap1, Reg1, Vtc2, and Vtc3) (Table 3.5). Hal5 and Kkq8 are members of a class of 
serine/threonine kinases involved in regulating various plasma membrane transporters. 
They are homologous to the Npr1 kinase, which has already been shown to be a target of 
TORC1 signaling [47]. Noc2 is a plausible target of TORC1 signaling since it is involved 
in the intranuclear transport of ribosomal precursors [127], an important step in ribosome 
biogenesis.  Ldb19 is implicated in the regulation of stability of plasma membrane 
permeases [128], which may explain its involvement in nutrient uptake and TORC1 
signaling. Nap1 was particularly interesting due to its physical interaction with TORC1 
[129] and because its deletion affects the localization of the kinase Gin4 [130], another 
protein found to be significantly affected by rapamycin (Table 3.1 and Table 3.2). Vtc2 
and Vtc3 are subunits of the vacuolar transporter chaperone complex. They are attractive 
candidates because TORC1 has been shown to localize to the vacuolar membrane [131]. 
Isw2 is interesting because it represses INO1 expression [132] and its protein product is 
also increased upon rapamycin treatment in the proteomic analysis (Table 3.3). The 
regulatory subunit Reg1 of the Glc7 phosphatase is required for the dephosphorylation 
and inactivation of the kinase Snf1, which had been shown to become more 
phosphorylated at T210 upon rapamycin treatment [133, 134]. Rts3 is a putative 
component of the protein phosphatase type 2A (PP2A) and it is interesting because 
TORC1 controls the activity of PP2A and PP2A-like phosphatases [64]. Finally, the 
proteins Mtc1 and Sec7, even though unrelated to TORC1 at a first glance, were included 
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for validation as they had reproducibly large changes in phosphorylation following 
rapamycin treatment (Mtc1: 4.24 ± 0.93; Sec7: 7.08 ± 0.28).  
 
 
Protein Description (SGD) Regulated phospho-site (Av. Ratio ± SD) Direction 
Hal5 Putative protein kinase involved in the regulation of Trk1/Trk2 transporters. 
S17 (1.77 ± 0.26) 
Increased 
S17, S19 (3.95) 
Isw2 ATP-dependent DNA translocase involved in 
chromatin remodeling. T1079 (1.83 ± 0.29) Increased 
Kkq8 Putative S/T kinase. Member of the Npr1/Hal5 protein kinase family 
S21 (1.98 ± 0.05) Increased 
S75 (2.96) 
Ldb19 
Protein involved in regulating the endocytosis of 
plasma membrane proteins by recruiting the ubiquitin 
ligase Rsp5 to its target. 
T795 (6.64 ± 0.58) Increased 
Mtc1 Protein of unknown function. Interacts with ribosomes. S75 (4.42 ± 1.48) Increased 
Nap1 
Involved in the transport of H2A and H2B histones to 
the nucleus. Involved in regulating mictotubule 
dynamics during mitosis. Controls bud morphogenesis. 
T20 (0.42) 
Decreased T20, T24 (0.47 ± 0.10) 
T20, T24, S27 (0.10) 
T24 (0.59 ± 0.00) 
Noc2 Protein that mediates intranuclear transport of 
ribosomal precursors S70 (2.62 ± 0.85) Increased 
Reg1 Regulatory subunit of the protein phosphatase Glc7. Negatively regulates glucose-repressible genes. S570 (0.41 ± 0.04) Decreased 
Rts3 Putative component of the protein phosphatase type 2A 
complex. 
S47 (3.03) 
Increased S47, S50 (5.68) 
S238 (8.84) 
S241 (8.06 ± 3.81) 
Ses7 GEF factor for ARF proteins involved in proliferation 
of the Golgi. Regulates ER-to-Golgi transport. S772 (7.08 ± 0.28) Increased 
Vtc2 
Subunit of the vacuolar transporter chaperone (VTC) 
complex involved in membrane trafficking, 
microautophagy and non-autophagic vacuolar fusion. 
S182 (0.37 ± 0.02) 
Decreased S182, S187 (0.07) 
S196 (0.40) 
S583 (0.24 ± 0.03) 
Vtc3 
Subunit of the vacuolar transporter chaperone (VTC) 
complex involved in membrane trafficking, 
microautophagy and non-autophagic vacuolar fusion. 
S592 (0.54 ± 0.15) Decreased 
 
Table 3.5: Phosphoproteins whose extent of phosphorylation was significantly altered by rapamycin 
treatment selected for further studies. Protein functions were retrieved from SGD 
(http://www.yeastgenome.org/).  
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To check the role of the above proteins in TORC1 signaling, (1) the rapamycin 
sensitivity and (2) the glycogen accumulation of the corresponding deletion mutants were 
investigated; (3) their SDS-PAGE mobility was monitored to check if rapamycin 
treatment was able to induce a shift in migration; and (4) an in-depth LC-MS/MS analysis 
was performed to confirm the regulated phosphorylation sites identified in the 
phosphoproteome and to check for the presence of additional rapamycin-sensitive sites.    
 
 
3.3.1. Rapamycin Sensitivity, Glycogen Accumulation and Electrophoretic Mobility 
Shift 
 
The rapamycin sensitivity of the null mutants was compared with the one of the 
wild-type strain TB50a (Figure 3.8A).  This is an important indicator, because many 
known TORC1 effectors cause sensitivity or resistance to rapamycin when deleted (e.g. 
gln3∆, kog1∆, lst8∆, msn4∆, npr1∆, rim15∆, sch9∆, sfp1∆, tco89∆, tor1∆). Similarly, the 
strains isw2∆, reg1∆, hal5∆ and ldb19∆ are more sensitive to rapamycin because they 
mimic the tor1∆ phenotype. Interestingly, while reg1∆, hal5∆ and ldb19∆ have been 
shown to be less sensitive to rapamycin in strains with a different background, it has 
never been shown that ISW2 deletion confers sensitivity to rapamycin. Moreover, in 
contrast to the published rapamycin sensitivity [135], no change in rapamycin resistance 
of the nap1∆ mutant was observed. The rapamycin sensitivity of sec7∆ and noc2∆ could 
not be investigated, because both null mutants were not viable (Figure 3.8B). 
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Figure 3.8: (A) Sensitivity of the null mutants against increasing concentrations of rapamycin. The null 
mutants were compared to the rapamycin sensitivity of the wild-type strain TB50a and the hypersensitive 
tor1∆ mutant. (B) Tetrad dissection of heterozygous sec7∆/sec7 and noc2∆/ noc2 mutants. The 
homozygous deletion strains are not viable.  
 
 
 To cope with stress, such as nitrogen starvation, yeast cells typically increase the 
synthesis of the storage carbohydrates glycogen and trehalose [136]. Because nitrogen 
starvation causes inactivation of TORC1, tor1∆ mutants accumulate more glycogen than 
wild type cells [25]. Therefore, altered accumulation of glycogen upon deletion of a gene 
is a good indication whether a protein is involved in TORC1 signaling or not. For 
example, deletion of KOG1, TCO89, and NPR1 leads to increased glycogen 
accumulation, and individual deletions of ATG1, ATG13, ATG17, and RIM15 accumulate 
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less glycogen than wild type cells [137]. However, it is also known that pathways other 
than TORC1 impinge on glycogen synthesis, such as the PKA and Snf1 pathways. For 
example, both bcy1∆ cells with constitutively active PKA signaling and snf1∆ cells have 
reduced glycogen accumulation [138, 139]. Therefore, altered glycogen accumulation 
and rapamycin sensitivity are indicators (but by no means certain) that a gene is part of 
the TORC1 signaling pathway.  
Concerning the mutants selected for the phosphoproteome validation, ldb19∆, 
hal5∆, reg1∆ and isw2∆ deletions clearly increased glycogen accumulation, which was 
even more pronounced after rapamycin treatment (Figure 3.9). reg1∆ was expected to 
cause increased glycogen accumulation due to its role in targeting the Glc7 phosphatase 
to the Snf1 kinase. Dephosphorylation inactivates the kinase activity of Snf1 and snf1∆ 
cells accumulate less glycogen than the wild type [139]. As a result, REG1 deletion 
should lead to an increase in phosphorylation and activation of Snf1 and therefore 
increase glycogen levels.  
The observation that deletion of ISW2, a chromatin remodeling factor, has 
increased glycogen accumulation is more difficult to explain.  This mutation is probably 
only indirectly related to glycogen metabolism, because glycogen levels are also affected 
by cellular stress, which may be caused by perturbation of chromatin structure. 
Nevertheless, it has also been shown that ino1∆ cells accumulate less glycogen and INO1 
transcription is repressed by Isw2. This has been clearly observed in the proteomic 
analysis as well, where the Ino1 protein level was significantly increased upon rapamycin 
treatment (Table 3.3). Consequently, ISW2 deletion should relieve the repression on 
INO1 expression and as a result lead to increased glycogen accumulation.  
Ldb19 is a protein involved in endocytosis of plasma membrane permeases and, 
as such, abnormal glycogen accumulation in ldb19∆ could be a consequence of decreased 
nutrient uptake impinging on TORC1. Less clear is the phenotype of hal5∆, a protein 
involved in the regulation of Trk1/2 potassium transporters. Maybe the abnormal 
phenotype observed in ldb19∆ is a consequence of cellular stress because it is known that 
hal5∆ mutants are more susceptible to various types of stresses (e.g. hyperosmotic, ionic, 
doxorubicin and cisplatin hypersensitivity). 
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Figure 3.9: Glycogen accumulation of rapamycin- or vehicle-treated yeast cells. Glycogen accumulation of 
the individual deletion mutants was compared to the wild-type TB50a strain and the tor1∆ strain.  
 
 
Next, the gel migration of the selected candidates was checked since protein 
phosphorylation often induces a shift in electrophoretic mobility [140]. For the majority 
of the tested proteins, no shift in electrophoretic migration following rapamycin treatment 
was seen. This can in part be explained by the high molecular weight of the proteins 
tested. Also, a migration shift is unlikely to occur if the change of phosphorylation 
induced by rapamycin is small or if the overall site occupancy is low (see 3.2.2). 
Nevertheless, rapamycin treatment of Ldb19-HA and Kkq8-HA led to shifts in migration, 
and interestingly, an increase in protein abundance upon rapamycin treatment (Figure 
3.10A). The expression of Rts3-MYC was also up-regulated probably by an increase in 
the mRNA level (Fig. 3.9A, Table 3.1) [41, 42]. Since for Ldb19 and Kkq8 no change in 
mRNA abundance was reported [41, 42], the observed increase in protein abundance 
could be due to increased protein stability perhaps brought about by phosphorylation. The 
mobility shift of Ldb19-HA and Kkq8-HA was reversed with λ protein phosphatase 
treatment (Figure 3.10B). Notably, for Ldb19-HA two isoforms approximately 7-8 kDa 
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apart were detected (Figure 3.10A-B). The mass shift conforms to a modification of 
Ldb19 by ubiquitin. This protein was reported to be ubiquitinated at K486 by the E3 
ubiquitin ligase Rsp5 [128]. Interestingly, it seems that both isoforms are affected by 
treatment with rapamycin. Similar to Ldb19-HA, the change in the electrophoretic 
mobility of Kkq8-HA induced by rapamycin could be better appreciated when the protein 
was treated with λ protein phosphatase (Figure 3.10B). In conclusion for all proteins 
except Ldb19-HA and Kkq8-HA, no clear change in migration was observed. In the case 
of Ldb19-HA, Kkq8-HA and Rts3-MYC a change in protein abundance was also 
apparent. Finally, for Sec7-HA a slight change in migration was observable, but it was 
evident only for a degradation product of Sec7-HA and not for the intact protein. 
 
 
 
 
 Figure 3.10: (A) Comparison of the electrophoretic migration of HA-/MYC-tagged candidate proteins 
isolated from untreated (-) or rapamycin-treated (+) cells.  (B) In addition to rapamycin treatment, the 
immunoprecipitates of Ldb19 and Kkq8 were further treated with (+) or without (-) λ protein phosphatase.  
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3.3.2. In-depth LC-MS/MS Analysis of Selected Regulated Phosphoproteins 
 
Mapping phosphorylation sites on a system-wide scale yields a wealth of 
information that can be used to better define signaling cascades. Nevertheless, often a 
discrepancy exists between the data obtained from in-depth LC-MS/MS analysis of 
isolated proteins and those found in large-scale mapping projects inasmuch as more 
phosphorylation sites are usually found in isolated systems. Therefore, for each candidate 
protein, the presence of additional phosphorylation sites was investigated by in-depth LC-
MS/MS analysis. This type of analysis also addresses a second question namely the lack 
of mobility shift of the proteins selected for validation.  
The in-depth LC-MS/MS analysis consisted in the isolation of each protein by 
immunoprecipitation from untreated and rapamycin-treated cells, protein digestion using 
different proteases to increase protein coverage, and subsequent LC-MS/MS analysis. 
Typically, the immunoprecipitates were first checked by data-dependent MS/MS to 
confirm the presence of the phosphorylation sites found in the quantitative 
phosphoproteome and to search for additional phosphorylation sites. This was then 
followed by a targeted LC-MS/MS experiment to better localize the phosphorylation 
site(s) in the peptides. Inclusion lists allow acquiring many more MS/MS spectra per 
phosphospeptide so that many MS/MS scans can be added for a much safer localization 
of the site of phosphorylation. Finally, single-reaction monitoring of specific precursor 
ion/fragment ion transitions was sometimes performed to be able to quantify 
phosphorylation changes of coeluting phosphopeptide isoforms. Notably, in all these 
experiments no phosphopeptide enrichment was performed so that an estimate of the site 
occupancy of a given phosphorylation site could be done.  
To quantify the occupancy of a phosphorylation site, the ion intensity of the 
phosphopeptide was normalized to the sum of the ion intensities of the phosphopeptide 
and the corresponding non-phosphorylated peptide. Assuming equal efficiency of 
ionization of the unphosphorylated and its phosphorylated counterpart, this ratio should 
reflect the absolute occupancy of a given phospho-site, i.e. its phosphorylation 
stoichiometry. To determine site occupancy, the detection and identification of two ion 
signals, one for the phosphorylated and the other for the non-phosphorylated peptide, is 
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required. This is in contrast to SILAC quantitation that compares the signal intensities of 
only the phosphopeptides from treated and untreated cells. To estimate the fold change in 
phosphorylation at a given site, the normalized values for each phosphopeptide from 
control and rapamycin treated samples were then divided by each other. Since the value 
from the rapamycin treated sample was divided by the value from the untreated sample, a 
ratio greater than 1 indicates increased phosphorylation in the presence of rapamycin, and 
vice versa (Figure 3.11).  
In-depth analysis of the proteins selected for validation yielded the same 
phosphorylation sites as identified in the phosphoproteome (Figure 3.11 [phospho-sites in 
red] and Table 3.6). Not surprisingly, the in-depth LC-MS/MS analysis revealed 
additional phosphorylation sites that escaped detection in the phosphoproteome (Figure 
3.11 [phospho-sites in black] and Table 3.6). This is particularly evident for Kkq8-HA, 
where nine additional phospho-sites were quantified (Table 3.6). It is remarkable that the 
majority of the phosphorylation sites responding to rapamycin treatment have low to 
moderate site occupancy (Figure 3.11). Two different factors might account for this 
observation. First of all, as already mentioned, the calculation of the phospho-site 
stoichiometry assumed that the phosphorylated and unphosphorylated peptides ionize 
equally well. It is, however, not known for all instances if, and how much, the presence 
of a negatively charged phosphate affects the ionization of peptide. Obviously, in case the 
phosphorylated peptide ionizes less efficiently than the unphosphorylated cognate, the 
stoichiometry of phosphorylation can be grossly underestimated. A second reason 
explains why the rapamycin-regulated sites do not have high site occupancy, which is due 
to technical issues related to the presence of multiple phosphorylations in the same 
peptide. This can be well illustrated by the calculation of the stoichiometry of T619 in 
Ldb19-HA, which was assessed using the ion tracing of the phosphopeptide 
GHVLT619PHSTR and the peptide GHVLTPHSTR. However, in the same sample the 
incompletely cleaved phosphopeptides GHVLT619PHST623RDIR and GHVLTPHST623R- 
DIR could be identified as well. Since the stoichiometry of T619 was calculated 
comparing only the completely cleaved phosphopeptide/peptide pair, it was probably 
underestimated because part of the peptides containing this phosphorylation was present 
as incompletely cleaved phosphopeptide GHVLT619PHST623RDIR.  
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Figure 3.11: Phospho site occupancy as a function of rapamycin treatment of selected HA-tagged proteins. 
The site occupancy is expressed as the percentage of the LC/MS signal of the phosphorylated peptide 
versus the sum of the signals of the phosphopeptide and its unphosphorylated counterpart. The sites marked 
in red were found in the quantitative phosphoproteome.  
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Protein 
Only in the 
phosphoproteome 
Only in the in-depth LC-MS/MS Common 
Isw2-HA  S19, S1073, S1082 S831, T1079 
Ldb19-HA  T93, T619 T795 
Mtc1-HA 
S336, S337, S339, S340, 
S342, S436 
S75*, T266, S273 S72* 
Noc2-HA   S70 
Kkq8-HA S21, S75 
S63 or S66, S81 or S83, S111, S131, S212, 
S232, S238 or S241, S304, S348 
S37 
 
Table 3.6: Comparison of the phosphorylation sites found in the quantitative phosphoproteome and in the 
in-depth LC-MS/MS analysis. Residues in bold are sensitive to rapamycin treatment. An asterisk indicates 
conflicting site assignment between the phosphoproteome (italic bold) and the in-depth analysis (italic). 
 
 
As can be seen from Table 3.6, for Mtc1 and Kkq8 some phospho-sites previously found 
in the phosphoproteome were missing in the in-depth LC-MS/MS analysis. For Mtc1, six 
phospho-sites (S336, S337, S339, S340, S342 and S436) have been exclusively identified 
in phosphoproteomic analysis and are localized in the peptides 
EADATPDDDRS336S337IS339S340NS342NK and QKESEDEDEDDEIIDPS436EWVK. Both 
peptides are exceptionally acidic and are particularly well enriched by IMAC because of 
the clustered glutamic and aspartic acids. It is therefore possible that these missing 
phospho-sites were not identified in this approach because the phosphorylated peptides 
are not abundant enough and can only be detected after phosphopeptide selection. The 
missing phospho-sites S75 and S21 of Kkq8 could be identified but not quantified in the 
in-depth LC-MS/MS analysis. This is due to the proximity of these phosphorylation sites 
to lysines and arginines, which prevent cleavage by trypsin. As a result, incompletely 
cleaved phosphopeptides are generated, whose sequences differ from the completely 
cleaved unphosphorylated peptides. As a consequence, the ion tracing between the 
phosphopeptide and its unphosphorylated counterpart cannot be compared. This is 
particularly obvious for S75 in Kkq8, which is located one residue down-stream of the 
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trypsin cleavage site. However it was rather puzzling that S21 blocks the trypsin cleavage 
site located three residues down-stream of the protease cleavage site (R18). Indeed, as 
shown in Figure 3.2C, the phosphorylation site can hinder the cleavage by the protease 
when it is less than three residues apart from the cleavage site, which was not the case for 
S21 in Kkq8. However, a careful inspection of the LC-MS/MS raw data revealed that the 
serine immediately following the trypsin cleavage site (S19) was also phosphorylated 
(Figure 3.12), which is located exactly after R18.  
 
 
 
 
Figure 3.12: Effect of positional phospho-site isomers on phospho-site quantitation. The tryptic peptide 
containing the phosphorylation sites for S19 and S21 of Kkq8 occur in different forms depending on the 
site of phosphorylation. For site-specific quantitation the signal of phosphorylated S19 splits into two ion 
tracings, S19FSESFK (middle panel) and VRS19FSESFK (left panel) generated by incomplete cleavage by 
trypsin. Ion signals in blue could be assigned to b- or y-ions, while signals in red are those allowing the 
localization of the phosphorylation site. 
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 Recently, the phosphorylation stoichiometry in S. cerevisiae was assessed on a 
system wide level [141]. A comparison of the present and the system wide study revealed 
striking similarities at least for the few common sites (Table 3.7). The stoichiometries for 
the in-depth LC-MS/MS analysis were slightly lower, suggesting that the 
phosphopeptides are probably ionized with a slightly lower efficiency in comparison with 
the non-phosphorylated peptides. However, this minor discrepancy in the two data sets 
could be also a consequence of the phosphopeptide dephosphorylation performed by Wu 
et al. which, in case of multiple phosphorylated peptides, leads to a sum of all 
stoichiometries and therefore to an overestimation of the stoichiometry of the singly 
phosphorylated peptide. 
 
 
 
  Stoichiometry (%) 
Protein Phospho-Site 
In-depth LC-MS/MS  
(no rapamycin)  
Wu et al. 
Isw2-HA S831 65.3 87 
Mtc1-HA 
S72 
S75 
0.1 
5.4 
7 
7 
Nap1-HA* 
S76 
S82 
0.7 
1.0 
1 
1 
Noc2-HA S70 0.4 2 
 
 
Table 3.7: Comparison of the phosphorylation stoichiometries obtained in the in-depth LC-MS/MS 
analysis and in the published large-scale study [141]. Note that in the large-scale analysis precise 
localization of the sites of phosphorylation is not possible. * For the in-depth LC-MS/MS analysis of Nap1 
see section 3.3.3.  
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Having established that the phosphorylation stoichiometry in our study is correct 
in a first approximation, the lack of a shift of SDS-PAGE migration of some candidate 
proteins can be easily explained (Figure 3.10). For example, S831 of Isw2 is the site with 
the highest phosphorylation occupancy but its extent of phosphorylation does not change 
upon rapamycin treatment (Figure 3.11). On the other hand, the phosphorylation of 
T1079 of Isw2 changes dramatically by rapamycin treatment, but its site occupancy is 
quite low. Dephosphorylation, even though extensive, probably does not translate into an 
observable band shift. If this is the case, dephosphorylation of the major site of 
phosphorylation by λ protein phosphatase treatment of Isw2 should induce a mobility 
shift during SDS-PAGE. For this, Isw2-HA was immunoprecipitated from control and 
rapamycin-treated cells and one half of the immunoprecipitates was subjected to 
dephosphorylation by λ protein phosphatase while the other half was mock-incubated 
(Figure 3.13). After complete dephosphorylation of Isw2-HA by λ protein phosphatase a 
pronounced mobility shift was seen during SDS PAGE, despite its high molecular weight 
of 130 kDa. In contrast, both the phosphoproteomic analysis and in-depth LC-MS/MS 
analysis revealed the presence of a single low-stoichiometry phospho-site in Noc2-HA 
that was unable to induce a band shift following rapamycin treatment (Figure 3.10). This 
supports the hypothesis that band shifts only occur when high stoichiometry phospho-
sites become altered by rapamycin treatment.  
 
 
 
 
 
Figure 3.13: Band shift assay of Isw2-HA. Rapamycin treatment leads to a decrease of the phosphorylation 
of low-stoichiometry sites while phosphatase treatment removes the phosphate from all, including high 
stoichiometry sites. λPPase indicates phosphatase treatment. 
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Even though the phosphorylation stoichiometries measured in the in-depth LC-
MS/MS analysis were relatively low, T1079 in Isw2 showed quite a remarkable change 
upon rapamycin treatment (from 9% to 29% phosphorylation occupancy). Since ISW2 
deletion has been shown to confer higher sensitivity to rapamycin, it was interesting to 
mutate T1079 into alanine (ISW2T1079A-HA), aspartic acid (ISW2T1079D-HA), or glutamic 
acid (and ISW2T1079E-HA) and check the rapamycin sensitivity of such point mutants. As 
shown in Figure 3.14A the strains expressing the mutant protein from a centromeric 
plasmid were all functional but, surprisingly, the rapamycin sensitivity of the three point 
mutant strains was comparable to the one of the WT strain (Figure 3.14B). It should be 
noted that a slightly higher sensitivity to rapamycin was observed in the ISW2T1079A-HA 
strain. These data suggests that T1079 may not be the primary site, which TORC1 
impinges on. In this context it should be noted that 37% of the Isw2 protein could not me 
covered in the in-depth LC-MS/MS analysis and this missing part contains 32% of the 
total serine and threonine residues. It is therefore possible that a dominant site regulated 
by TORC1 of Isw2 escaped the in-depth LC-MS/MS analysis.  
Next, to gain some more information about the regulation of Isw2 activity by 
TORC1, the gene expression of INO1 and SIP4 has been investigated by quantitative real 
time PCR. Both genes were chosen as reporters because their expression is up-regulated 
in presence of rapamycin [42] as well as in isw2∆ mutants [142]. As expected, treatment 
with rapamycin of the WT strain as well as deletion of ISW2 led to an increase in both 
mRNAs (Figure 3.14C). However the combined effect of ISW2 deletion and rapamycin 
treatment led to an even more pronounced increase in Ino1 and Sip4 mRNAs (Figure 
3.14C). Thus, it seems that the effect of TORC1 and Isw2 on INO1 and SIP4 expression 
occurs via two distinct pathways. 
 
Results 
 
 90
 
 
 
Figure 3.14: Functional analysis of Isw2. (A) Evaluation of the functionality of the ISW2 mutant strains 
and (B) evaluation of their rapamycin sensitivity. (C) Gene expression of INO1 and SIP4 in response to 
rapamycin treatment and ISW2 deletion.  
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3.3.3. In Vitro Kinase Assay of Selected Regulated Phosphoproteins 
 
Because rapamycin acutely inhibits the activity of TORC1 [21], proteins whose 
extent of phosphorylation decrease following rapamycin treatment, qualify, in theory, as 
direct substrates for TORC1. Among the regulated phosphoproteins that were chosen for 
validation, four had a decreased extent of phosphorylation upon rapamycin treatment 
(Nap1, Reg1, Vtc2 and Vtc3, Table 3.5 and 3.8). Thus, it was important to check whether 
these proteins can become directly phosphorylated by TORC1. Among the candidate 
proteins, Nap1 qualifies particularly well as a direct TORC1 substrate since it contains 
two rapamycin-sensitive TP sites, a motif that has been shown to be often phosphorylated 
by (m)TORC1 [66, 143]. 
To examine whether TORC1 can directly phosphorylate the candidate proteins, 
they were immunoprecipitated from yeast cells and incubated in vitro with recombinant 
mTOR in presence of radioactive ATP. For an activity test, the canonical in vivo substrate 
4E-BP was incubated with recombinant mTOR. 4E-BP was robustly phosphorylated by 
mTOR (Figure 3.15A, left panel) and phosphorylation of 4E-BP was abolished with the 
mTOR-specific inhibitor PP242 (Figure 3.15A, left panel). Similarly, the direct yeast 
TORC1 substrate Sch9-HA isolated from rapamycin-treated cells was also efficiently 
phosphorylated by mTOR (Figure 3.15A, right panel). Next, the candidate proteins Nap1-
HA, Reg1-HA, Vtc2-HA and Vtc3-HA were in vitro phosphorylated with mTOR. 
Recombinant mTOR specifically phosphorylated Nap1-HA and Vtc2-HA, while Reg1-
HA and Vtc3-HA became also phosphorylated when mTOR was completely inhibited 
with PP242 (Figure 3.15B). This is most likely due to co-precipitating PP242-resistant 
protein kinases. The presence of additional protein kinases in the immunoprecipitates was 
suspected because peptides from casein kinase II were found in the immunoprecipitates 
of Reg1-HA (data not shown). Since Reg1 contains several phosphorylation sites 
conforming to the casein kinase II motif (e.g. S490, S614 and S485) it can be assumed 
that the mTOR-independent phosphorylation is caused by casein kinase II. Also 
interesting was that Vtc2-HA was apparently stabilized by mTOR phosphorylation 
(Figure 3.15B). Indeed, when Vtc2-HA was incubated at 30°C in absence of mTOR for 
different time points, protein aggregates were observed at the boundary between the 
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stacking and the running gels (Figure 3.15C). The use of protease inhibitor did not have 
any effect on the stabilization of the protein (Figure 3.15C). 
 
 
Protein Phosphopeptide sequence Av. Ratio ± SD 
Nap1 
SSMQIDNAPT20PHNTPASVLNPSYLK 0.42 
SSMQIDNAPTPHNT24PASVLNPSYLK 0.59 ± 0.00 
SSMQIDNAPT20PHNT24PASVLNPSYLK 0.47 ± 0.10 
SSMQIDNAPT20PHNT24PAS27VLNPSYLK 0.10 
LGS76LVGQDSGYVGGLPK 0.88 ± 0.10 
IIS140GQEQPKPEQIAK 1.41 ± 0.52 
Reg1 
S75MGLLDEYIDPTK 1.02 ± 0.10 
S570DSGVHSPITDNSSVASSTTSR 0.41 ± 0.04 
RTLS769LGK 0.80 
S773GSTNSLYDLAQPSLSSATPQQK 1.04 ± 0.15 
S773GSTNS778LYDLAQPSLSSATPQQK 0.97 
S773GSTNSLY780DLAQPSLSSATPQQK 0.97 
SGS775T776NSLYDLAQPSLSSATPQQK 0.77 ± 0.06 
SGS775TNSLY780DLAQPSLSSATPQQK 0.71 
SGST776NSLYDLAQPSLSSATPQQK 0.93 
SGST776NS778LYDLAQPSLSSATPQQK 0.97 
Vtc2 
SNFNTAS182EPLASASK 0.37 ± 0.02 
SNFNTAS182EPLAS187ASK 0.07 
FSSIVS196NDIDMNFR 0.40 
RLS583NLK 0.24 ± 0.03 
ITSQGDLEADGS615S616DEETEQEPHSK 0.91 ± 0.06 
LMGVDS657EEEEIELPPGVK 0.96 ± 0.06 
Vtc3 
SSVDS43WSER 0.82 ± 0.05 
LS195HFSNLEDASFK 1.13 
LSHFS198NLEDASFK 0.74 ± 0.22 
SNSLS269SDGNSNQDVEIGK 0.96 
SNSLSS270DGNSNQDVEIGK 0.99 
LSKIS592VPDGK 0.54 ± 0.15 
HVIADLEDHES621S622DEEGTALPK 1.00 ± 0.29 
 
 
Table 3.8: List of selected candidate proteins that become significantly dephosphorylated upon rapamycin 
treatment. Phosphopeptides in bold are significantly less phosphorylated in presence of rapamycin. Two TP 
sites are present in Nap1 (T20 and T24) whereas the PKA consensus site is clearly evident in Vtc2 (S583). 
For additional information see also Table 3.5.  
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Figure 3.15: In vitro kinase assay of selected candidate proteins whose extent of phosphorylation decrease 
following rapamycin treatment. Kinase assay was with recombinant mTOR. (A) The physiological mTOR 
substrates 4E-BP and Sch9 are robustly phosphorylated in vitro by mTOR. PP242 indicates treatment with 
the mTOR-specific inhibitor. The panels labeled with 32P indicate autoradiographies and those labeled just 
with the protein name designate the Coomassie-stained substrates. Tor-32P indicates autophosphorylation  
of the mTOR kinase. (B) In vitro phosphorylation of HA-tagged Nap1, Vtc3, Reg1 and Vtc2. The labeling 
of the panels is as in (A). (C) Vtc2 is prone to aggregation at 30°C. The migration of the protein is indicated 
by Vtc2, while the arrow shows the appearance of protein aggregates. 
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Nap1-HA was robustly and specifically phosphorylated by mTOR in vitro. The 
specificity was given by the fact that no phosphorylation of Nap1 occurred when mTOR 
was completely inhibited with PP242 or when mTOR was omitted from the in vitro 
kinase assay (Figure 3.16A). Furthermore, higher phosphorylation by mTOR was seen 
when Nap1-HA was either isolated from rapamycin-treated cells or when the 
immunoprecipitate was dephopshorylated by λ protein phosphatase (Figure 3.16B). At 
this point, it was fundamental to know if in vitro phosphorylation of Nap1-HA by mTOR 
occurs at the same sites as those observed in the phosphoproteome. 
 
 
 
 
 
Figure 3.16: (A) In vitro phosphorylation of HA-Nap1 by mTOR. (B) Prior treatment of HA-Nap1 by 
rapamycin or λ protein phosphatase increases its in vitro phosphorylation by mTOR. 
 
 
 
For this, Nap1-HA was isolated from a 4 l culture, immunoprecipitated, and 
dephosphorylated by λ protein phosphatase for maximal phosphorylation by mTOR. To 
enable the tracing of both unlabelled phosphate in the mass spectrometer and 
radioactively labeled phosphate during liquid chromatography, the ratio of cold ATP to 
32P-labelled ATP was titrated and optimal incorporation of 32P into Nap1-HA was 
achieved with 30 µM cold ATP (data not shown). For efficient phosphorylation of Nap1-
HA, BSA was required to stabilize mTOR during the kinase assay (data not shown). In 
vitro phosphorylated Nap1-HA was digested with trypsin and the digest was fractionated 
by RP-HPLC. The radioactively labeled phosphopeptides were located in the fractions by 
liquid scintillation counting and the peak of the radioactivity was analyzed by LC-
MS/MS (Figure 3.17).  
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 HPLC peptide mapping of Nap1 phosphorylated in vitro by mTOR revealed one 
major peak of radioactivity that was preceded by a broad, less intense peak (Figure 
3.17B). Overall recovery of the radioactivity was approximately 80%. The two 
radioactive fractions (a, b in Figure 3.17B) were analysed by LC-MS/MS. In the first 
peak of radioactivity (peak a) the phosphopeptide IIS140GQEQPKPEQIAK was 
identified, whereas the second fraction (peak b) contained the peptides 
LGS76LVGQDSGYVGGLPK and LGSLVGQDS82GYVGGLPK. The same results were 
obtained when the Nap1 digest was subjected to RP-HPLC fractionation after 
phosphopeptide enrichment via IMAC (data not shown). In the PP242-treated kinase 
assay, virtually no radioactivity was eluted from the column (Figure 3.17A/B). In 
accordance, the ion intensities of the individual phosphopeptides were also strongly 
reduced in the sample treated with PP242 (while the ion intensities of other Nap1-HA 
peptides did not show a comparably significant reduction) (Figure 3.17C). Figure 3.17D 
summarized the results from the in vitro phosphomapping and the phosphoproteomic 
analysis. 
 
 
 
Results 
 
 96
 
 
Figure 3.17: Identification of the phosphorylation sites on Nap1-HA after in vitro phosphorylation by 
mTOR. (A) Recovery of radioactivity along the purification steps used to isolate radiolabeled peptides. (B). 
RP-HPLC elution of radioalabeled peptides from in vitro phosphorylated HA-Nap1 digested with trypsin. 
The fractions a, b1 and b2 were subjected to LC-MS/MS analysis (C) LC-MS/MS analysis of fractions b1 
and b2. The same protein amount for both untreated and PP242-treated Nap1-HA was measured as shown 
by two non-phosphorylated Nap1-HA peptides. The snapshot shows the elution peaks of the two in vitro 
phosphorylated Nap1-HA peptides. (D) Schematic overview of the phosphorylation sites identified in Nap1 
in the phosphoproteomic analysis (full and open arrows) and after in vitro phosphorylation (open arrows). 
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These findings are surprising because in the phosphoproteome the N-terminal 
phospho-sites (T20, T24, and S27) were those down-regulated upon rapamycin treatment, 
while S76 and S140 were not affected by the treatment (Table 3.8). Consequently, it was 
essential to investigate the in vivo phosphorylation of S76, S82 and S140 to be really sure 
that no change was occurring at these positions. For this an in-depth LC-MS/MS analysis 
was performed, where Nap1-HA was first isolated by immunoprecipitation and then 
digested with different proteases to map in a reliable way S76, S82 and S140 (Figure 
3.18A). Moreover, such experiment would have been helpful to map the N-terminal 
phospho-sites and confirm their regulation upon rapamycin treatment. Unfortunately the 
N-terminal part of Nap1-HA could be only detected in the unphosphorylated form, 
making impossible to confirm the regulation of T20, T24 and S27. The same result was 
obtained using a genomically-tagged Nap1-HA strain (data not shown), thus the absence 
of these phospho-sites was very likely not due to overexpression problems. The 
possibility that those sites were erroneously identified in the phosphoproteome could be 
also ruled out because, manual investigation of the full MS spectra and MS/MS spectra 
obtained in phosphoproteomic analysis clearly showed that these sites are phosphorylated 
and that they are more phosphorylated in the untreated samples. This was further 
supported by other phosphoproteomes where those N-terminal sites were found in Nap1. 
On the other hand, S76, S82 and S140 could be consistently mapped but, as shown in the 
phosphoproteome, their phosphorylation remained unaffected over three different 
rapamycin treatment times (Figure 3.18B). Furthermore, in agreement with the large-
scale phosphorylation stoichiometry analysis published by Wu et al. [141], the 
phosphorylation occupancy at S76, S82 and S140 was lower than 1% (Figure 3.18C and 
Table 3.7), suggesting that they probably play a minor physiological role.  
In conclusion, even though Nap1-HA could be phosphorylated in vitro by mTOR, 
the in vitro phosphorylation sites do not correspond to those found regulated in the 
phosphoproteomic analysis. On the other hand, the rapamycin-sensitive phospho-sites 
found in the phosphoproteome do not seem to be directly phosphorylated by mTOR and, 
for technical reason, could not be identified in the in-depth LC-MS/MS analysis. 
Nevertheless, the in vitro phosphorylation sites on Nap1 conform rather well with the 
known (m)TOR consensus motif. Especially S76 and S140, the two main mTOR 
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phosphorylation sites in vitro, are surrounded by hydrophobic residues (I/G/L/V), which 
agrees with the (m)TOR preference to phosphorylate either S/TP sites or hydrophobic 
motifs [66, 143]. 
 
 
 
 
Figure 3.18: In-depth LC-MS/MS analysis of in vivo phosphorylated Nap1-HA. (A) By using different 
proteases, about 80% of Nap1 could be sequenced (residues in red). The expected phosphorylation sites are 
marked in blue. Time course of the phosphorylation fold change (B) and the site occupancy (C) of Nap1-
HA following rapamycin treatment. 
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4. Discussion 
 
Yeast cells grown under favorable conditions accumulate cellular mass, whereas 
cells grown under unfavorable growth conditions arrest the cell cycle and become 
quiescent. This means that yeasts, like other unicellular or multicellular organisms, are 
able to sense nutrient cues and to adapt cell growth accordingly. The highly-conserved 
kinase TORC1 plays a central role in nutrient sensing and in transducing these signals to 
downstream effectors to eventually regulate cell growth. Active TORC1 promotes 
anabolic processes like ribosome biogenesis, translation initiation and nutrient uptake and 
represses catabolic processes like autophagy and stress response. Given its central role in 
the regulation of cell growth and the many readouts regulated by TORC1, it is surprising 
that up to date only three well characterized substrates of TORC1 have been identified in 
the yeast S. cerevisiae, i.e. Tap42, Sch9 and Sfp1 [32, 65, 66]. Furthermore, the signaling 
pathways linking TORC1 to its known readouts are still incompletely understood. To 
shed some light on the signaling cascades regulated by TORC1 and to get some insights 
in novel TORC1 targets, a phosphoproteomic approach was established to globally 
analyze the phosphorylation changes induced by rapamycin, a specific inhibitor of 
TORC1. 
 
 
4.1. Production of a Rapamycin-sensitive Yeast Phosphoproteome 
 
The strategy used in the present study to quantify rapamycin-induced 
phosphorylation changes was based on stable isotope labeling with amino acid in cell 
culture (SILAC) [117]. To increase the statistical significance of each quantified 
phosphopeptide hit, four biological replicates were performed and in total 2,607 unique 
phosphorylation sites from 972 phosphoproteins could be quantified (Figure 3.4B and 
Appendix IV). In each of the four experiments, on average, 1,145 phosphopeptides could 
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be identified, a significantly lower number than the one obtained in the qualitative 
phosphoproteomic analysis (1,672 phosphopeptides per experiment) (Figure 3.2B and 
Appendix I-II). Since the two procedures were almost identical, the higher number of 
identified phosphopeptides in the qualitative phosphoproteome must be due to the SILAC 
labeling. This is very likely a consequence of the higher sample complexity generated by 
SILAC labeling, where for each peptide two signals are recorded in the survey scan. As a 
result, the higher complexity of the SILAC samples probably led to undersampling of the 
phosphoproteome.  
An alternative to SILAC is the chemical labeling of peptides with the iTRAQ 
reagents [115]. In contrast to SILAC the derivatization of the same peptide with two 
different iTRAQ tags does not change the overall molecular mass of the peptide. In the 
present study, iTRAQ labeling was initially chosen to quantify rapamycin-induced 
changes in phosphorylation. Due to the disappointingly low number of phosphopeptides 
identified, the iTRAQ method was not pursued further (Appendix III). A possible reason 
for the low yield of phosphopeptides is the increase in the charge states of iTRAQ-
labeled peptides in comparison to the unlabeled peptides, which severely complicates the 
analysis of the fragmentation spectra [116]. A second explanation relates to the 
unfavorable conditions used during the iTRAQ labeling procedure. For derivatization, the 
peptides are incubated with the iTRAQ reagent in 100% ethanol, which can reasonably 
lead to severe losses of the hydrophilic phosphopeptides.  
An alternative technique to SILAC is label-free quantitation. This technique is 
based on the comparison of precursor ion intensities across multiple LC-MS/MS runs and 
it can be used for the simultaneous comparison of many conditions. Because label-free 
quantitation requires that every biological sample is measured separately, inter-
experimental variation can become relatively high. Moreover, label-free quantitation 
works best when the same sample is measured several times by LC-MS/MS, which 
obviously puts a high demand on the instrument’s measurement time. Another label-free 
quantitation can be done by spectral counting. This method uses the number of MS/MS 
spectra assigned to a protein/peptide as an estimation of protein/peptide abundance [144]. 
However, since spectral counting relies on peptide identification, it is unsuitable for 
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large-scale phosphoproteomic analysis because of undersampling of such complex 
peptide mixtures.  
Recently another quantitative rapamycin-sensitive yeast phosphoproteome was 
published [34], which was based on the label-free technology rather than SILAC labeling 
of cells. In that study 2,260 phosphopeptides from 751 phosphoproteins were quantified. 
This compares very well to the quantitative phosphoproteome in the present study (2,382 
phosphopeptides from 972 phosphoproteins). Although the two methods gave 
comparable phosphoproteome coverages, the overlap between the regulated 
phosphoproteins of the two studies was marginal (Figure 3.7). Only 12% of the down-
regulated and 13% of the up-regulated phosphoproteins were common to the two studies. 
The poor overlap can, in part, be explained by the different growth conditions and 
technical approaches employed in the two studies: the duration of rapamycin treatment 
(30 versus 20 minutes), the protein digestion regimes (in-solution versus in-gel 
digestion), the different phosphopeptide enrichment techniques (TiO2 versus IMAC), and 
the bioinformatics pipeline employed to analyze the quantitative mass spectrometric data 
(SuperHirn versus MaxQuant). 
 
 
4.2. Dissection of Rapamycin-induced Changes in Expression and 
Rapamycin-induced Changes in Phosphorylation  
 
Of the total 972 phosphoproteins quantified in this study, the phosphorylation 
states of 130 phosphoproteins were significantly altered by rapamycin treatment. Among 
them, 78 were more (i.e. up-regulated) and 55 less phosphorylated (i.e. down-regulated) 
upon rapamycin treatment (Table 3.1 and 3.2). The 78 proteins whose extent of 
phosphorylation was increased upon rapamycin treatment cannot be direct TORC1 
substrates, since inhibition of TORC1 by rapamycin should cause a decrease in 
phosphorylation of direct targets. On the contrary, the 55 down-regulated 
phosphoproteins are potential direct TORC1 substrates.  
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However, before concluding that a change in phosphorylation is due to a 
difference in the activity of the upstream protein kinase/phosphatase, it should be noted 
that TORC1 not only modulates the activity of phosphatases and kinases but it also 
controls the activity of several transcription factors (e.g. Fhl1, Gln3, Maf1, Msn2/4, 
Rtg1/3, and Sfp1). Thus, rapamycin treatment also elicits changes in protein expression. 
The impact on transcription obviously depends on the duration of the treatment: short 
treatments leave distal TORC1 readouts, like gene transcription, unaffected. Early 
transcriptomic studies in yeast treated with rapamycin revealed that the effect of 
rapamycin on the mRNA levels are very fast (<20 minutes) [41, 42, 145]. As a result, one 
must be aware that every rapamycin-sensitive phosphoproteome is a snapshot of two 
effects, i.e. proteins whose expression or phosphorylation is affected by rapamycin 
treatment.  
There are several solutions to distinguish between the two effects. The first is the 
measurement of a sample before and after phosphopeptide enrichment to measure both 
expression and phosphorylation changes (Appendix IV-V). Unfortunately the overlap 
between the proteome and phosphoproteome can be very small and, in the present study, 
only 34% of the proteins could be observed in both analyses (Table 3.1 and 3.2). The 
second solution relies on the identification of more than one phosphopeptide per 
phosphoprotein. If all phosphopeptides derived from the same protein change the same 
way, for example all are up-regulated, this is a good evidence for an expressional rather 
than phosphorylation change. This cannot be used in every instance, because there are 
proteins which are affected at several sites by rapamycin treatment (e.g. Atg13, Maf1, 
and Sch9). In addition, in the present study only 53% of the phosphoproteins were 
identified with multiple phosphopeptides (Appendix IV). For all the other 
phosphoproteins identified with only a single phosphopeptide it is impossible to know a 
priori whether the measured change is a consequence of altered expression or altered 
phosphorylation. Finally, the phosphoproteomic data can be compared with 
transcriptomic data to check whether rapamycin treatment affects the mRNA level of a 
specific gene. In the present study, 25% of the regulated phosphoproteins displayed 
similar changes at their mRNA levels upon rapamycin treatment (Table 3.1 and 3.2), 
suggesting that the phosphorylation changes measured for these proteins were probably 
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caused by changes in their gene expressions rather than in their phosphorylations. Some 
examples are described in more detail below.  
Among the up-regulated phosphoproteins there are the permeases Can1, Dip5, 
Mep2, Ptr2, and Put4, which have also up-regulated mRNA levels upon rapamycin 
treatment [41, 42] (Table 3.1). Similarly but in the opposite direction, Gnp1 was found 
down-regulated both in the present phosphoproteome and in previously published 
transcriptomes [41, 42] (Table 3.2). These observations are probably a consequence of 
the transcriptional changes caused by rapamycin. Nitrogen starvation, via TORC1 
inhibition, triggers the expression of several low-specificity permeases, like Put4 (Pro 
permease), Mep2 (NH4+ permease) and Ptr2 (di/tripeptide transporter), whereas high-
affinity permeases like Gnp1 are internalized from the plasma membrane and degraded. 
Interestingly, the rapamycin effect on Can1, Dip5 and Ptr2 seen in the phosphoproteome 
and transcriptome could be also seen in the proteome, where their protein levels were 
increased after rapamycin treatment (Table 3.3). Also up-regulated in the proteome were 
the permeases Agp1 and Gap1, two low-affinity and broad-specificity amino acid 
permeases able to import almost all 20 amino acids (Table 3.3). These observations 
suggests that the phosphorylation changes measured for Can1, Dip5, Ptr2 and probably 
Mep2 and Put4, are due to altered gene expression rather than to a difference in the 
activity of the upstream protein kinases/phosphatases. Surprisingly, this was not the case 
for Gnp1, because its protein level was unaffected after 20 minutes of rapamycin 
treatment (Appendix V). This is clearly in contrast with the decreased Gnp1 mRNA level 
measured in transcriptomic studies and suggests that the decrease in Gnp1 
phosphorylation is not an indirect consequence of a decrease in GNP1 gene expression. It 
should be however noted that a decrease in Gnp1 mRNA will probably results, at a later 
time point, in a decrease in Gnp1 protein level. This hypothesis is further supported by a 
global analysis showing that there is a delayed correlation between mRNA and protein 
level changes after rapamycin treatment [146]. However, a rapamycin treatment of only 
20 minutes is most likely too short to elicit a significant change in protein expression. 
Combining all information from transcriptome, proteome and phosphoproteome the 
decrease in Gnp1 phosphorylation is perhaps a signal to trigger its endocytosis. This is 
also evidenced by the fact that the regulated phospho-site in Gnp1 is predicted to face the 
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cytosol, where it could act as signal to modulate Gnp1 stability at the plasma membrane. 
These examples underline the importance of analyzing protein expression and 
phosphorylation simultaneously, to rule out that a change observed in protein 
phosphorylation is brought about by increased mRNA levels.  
The two enzymes Tps3 and Tsl1 are up-regulated both in the phosphoproteome 
and in previously published transcriptomes [41, 42] (Table 3.1). However, similar to 
Gnp1, these changes are not caused by expression changes because the protein levels of 
Tps3 and Tsl1 are not affected by rapamycin treatment (Appendix V), probably because 
20 minutes rapamycin treatment are not enough to cause a significant change in the 
proteins levels of Tps2 and Tsl1. Interestingly, an increase in the abundance of the two 
enzymes would make fits with their involvement in trehalose biosynthesis which, like 
glycogen, is a storage carbohydrate needed to endure nutrient starvation periods [147].  
The proteins Gdh2 and Dcs2 were hyperphosphorylated upon rapamycin 
treatment (Table 3.1). This is very likely to be caused by increased mRNA levels since 
their expression is under the control of the transcription factors Gln3 [148-150] and 
Msn2/4 [151], respectively, which are both activated by rapamycin treatment. This can be 
partially confirmed at the protein level for the protein Dcs2, where a slight increase in 
expression (1.60 ± 0.04) was observed upon rapamycin treatment (Appendix V). 
Finally, the proteins Esf1, Lhp1 and Zuo1 were down-regulated in the 
phosphoproteome and in previously published transcriptomes [41, 42] (Table 3.2). These 
proteins influence processes (pre-rRNA processing (Esf1), tRNA maturation (Lhp1), 
ribosome biogenesis (Zuo1)) that are positively regulated by TORC1. At a first glance it 
would be logical to conclude that the change in phosphorylation observed for these 
proteins is a consequence of the change in their mRNA levels. However within the time 
frame of the experiment (20 minutes rapamycin treatment) their protein levels remain 
unaffected (Appendix V). As a result the dephosphorylation of the three proteins upon 
rapamycin treatment could very well play a role in modulating their functions. Similarly 
to Gnp1, prolonging the treatment with rapamycin will almost certainly decrease Tps3 
and Tsl1 protein levels as a consequence of a decrease in their mRNA levels.  
Interestingly, for some proteins an inverse correlation between phosphorylation 
and mRNA change was observed (Table 3.1 and Table 3.2). Two prominent examples are 
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Kin2 and Tif5. Kin2 is a serine/threonine protein kinase involved in exocytosis. In a 
recent interactomic study, Kin2 was shown to physically associate with Kog1, a TORC1 
subunit. Kin2 also interacts with Ksp1 and Kdx1, which themselves associate physically 
with Tor1, Kog1, Lst8, and Tco89 [129]. Whether Kin2 is part of TORC1 signaling is 
very likely but it does not seem to be a direct substrate of TORC1, since an increase 
rather than a decrease in phosphorylation at S888 was observed in the phosphoproteomic 
analysis. The second protein with an opposite change in phosphorylation and mRNA 
abundance is Tif5 (also know as eIF5). Tif5 is the GTP activating protein for eIF2 
necessary for joining the 40S and 60S ribosomal subunits. This is a particularly 
interesting observation because TORC1 regulates translation initiation at multiple steps 
and could therefore very well signal to Tif5. The fact that altered phosphorylation was 
found on Tif4632 (also known as eIF4G) and Eap1, a putative yeast orthologue of 
mammalian 4E-BPs, supports this idea (Table 3.1 and 3.2). 
 
 
4.3. Targeted Analysis of Selected Candidate Proteins Reveals their 
Involvement in TORC1 Signaling 
 
At this point it was interesting to validate some of the proteins found in the 
present phosphoproteomic analysis. For this, seven up-regulated (Hal5, Isw2, Kkq8, 
Ldb19, Mtc1, Noc2, and Sec7) and four down-regulated (Nap1, Reg1, Vtc2, and Vtc3) 
phosphoproteins were chosen. For validation single deletions were generated and the 
rapamycin sensitivity and glycogen accumulation of the null mutants were checked. 
These two criteria were chosen because many TORC1 effectors have altered rapamycin 
sensitivity [6, 43, 66, 147] when deleted.  
The two assays revealed that some of the proteins chosen for validation are 
involved in TORC1 signaling. For instance the mutants hal5∆, isw2∆, kkq8∆, ldb19∆, and 
reg1∆ had increased rapamycin sensitivity (Figure 3.8), while the mutants mtc1∆, nap1∆, 
vtc2∆, and vtc3∆ were equally sensitive as the wild type. Similarly, the mutants hal5∆, 
isw2∆, ldb19∆, and reg1∆ accumulated more glycogen than wild type cells (Figure 3.9). 
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Since for some deletion strains only wild type behavior was observed, a third experiment 
was performed to reveal the effect of rapamycin on the phosphorylation state of the 
candidate proteins. The change in phosphorylation of the tagged proteins was monitored 
by a shift in migration during SDS-PAGE (Figure 3.10). Surprisingly, the majority of the 
proteins did not show any alteration in electrophoretic mobility following rapamycin 
treatment. This can be, in part, explained by the high molecular weight of the analyzed 
proteins but could also be a consequence of small phosphorylation changes induced by 
the rapamycin treatment, which are not able to elicit a mobility shift of the intact protein 
(see below). Nevertheless for the proteins Ldb19, Kkq8 and to some extent Sec7, a 
migration shift upon rapamycin treatment was observed. Phosphatase treatment abolished 
their mobility shift, demonstrating that it was caused by a change in protein 
phosphorylation.  
 In summary, the three assays used show that five out of eleven phosphoproteins 
are probably part of TORC1 signaling, i.e. Hal5, Isw2, Kkq8, Ldb19, and Reg1. But are 
the phosphorylation sites identified in the phosphoproteome involved in the signaling 
process? Are there additional regulated phosphorylation sites in these proteins to the one 
found in the phosphoproteome? To answer these questions, five proteins were chosen for 
in-depth phosphomapping: three proteins that fulfilled all validation criteria (i.e. Isw2, 
Kkq8, and Ldb19) and two proteins that did not (i.e. Mtc1 and Noc2). It should be noted 
that the phosphoproteomic analysis already revealed that these proteins contain 
rapamycin-sensitive sites but an in-depth phosphomapping was required to check whether 
additional and maybe more relevant sites were present. This concern arises because 
several TORC1 effectors were found to be regulated at multiple rather than at single 
phosphorylation sites: six rapamycin-sensitive sites in Sch9 [66], seven in Maf1 [34] and 
eight sites in Atg13 [152]. Furthermore, since in the phosphoproteomic analysis very 
complex samples were subjected to LC-MS/MS analysis, only a few MS/MS spectra per 
phosphopeptide were acquired, thereby increasing the risk of mislocalization of the 
phosphorylation site.  
In-depth LC-MS/MS analysis allowed extensive sequence coverage of all five 
phosphoproteins. Starting from immunoprecipitates five different proteases were used to 
cover from 50% to 80% of the entire protein sequences. This is a striking improvement 
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over the phosphoproteomic analyses, where only a few phosphopeptides per protein 
could be identified. This is also an important prerequisite to reduce the risk that major 
regulated phospho-sites escape phosphomapping. This also highlights one of the caveats 
of nowadays phosphoproteomics. The vast majority of all phosphoproteomic workflows 
are based on protein digestion with trypsin. This obviously precludes the identification of 
certain phospho-sites because the phosphopeptides obtained by trypsinolysis are either 
too short or too long to be retained by reverse-phase chromatography.  
For all five phosphoproteins except Noc2, several sites could be identified in the 
in-depth LC-MS/MS analysis in addition to those already mapped in the 
phosphoproteome (Figure 3.11). With twelve phosphorylation sites, Kkq8 was 
particularly highly phosphorylated. Out of twelve sites, ten could be quantified. The 
remaining two phospho-sites could not be quantified due to the high numbers of lysine 
and arginine residues which, upon trypsin cleavage, generates many partially cleaved 
peptides that hamper label-free quantitation. The phosphorylation sites affected most by 
rapamycin treatment were S1079 of Isw2, T795 of Ldb19, S266 of Mtc1, S70 of Noc2 
and S63/S66 of Kkq8 (Figure 3.11). In addition, some phospho-sites that were weakly 
regulated were identified at position S1073 of Isw2, T619 of Ldb19, S72 of Mtc1 and 
S37 of Kkq8 (Figure 3.11). Surprisingly, the site occupancy of the rapamycin-sensitive 
sites rarely exceeded 50%. Nevertheless, for both Ldb19 and Kkq8 the change in 
phosphorylation following rapamycin treatment was enough to elicit a gel migration shift 
(Figure 3.10). This observation raised two different questions. Are the phosphorylation 
stoichiometries measured in the in-depth LC-MS/MS analysis a good estimation of the 
true phospho-site occupancy? Can these phosphorylation sites play a biological role even 
though they have low to moderate occupancies? These two aspects will be considered in 
the next section.  
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4.3.1. Identification of Physiologically Relevant Phosphorylation Sites 
 
It is a common belief that the functional significance of a phosphorylation site 
depends on its fractional stoichiometry. This is a presumption that lacks experimental 
evidence. There are however, some reasons in favor of this idea. For example, there is a 
bioenergetic argument: it is reasonable to assume that a highly phosphorylated site has a 
biological function because just keeping a site occupied is a mere waste of ATP. The 
contrary is not necessarily true, since a low stoichiometry site could well be non-
functional but, since it is not very abundant, there is little to no evolutionary pressure to 
eliminate it.  
The concept that a cell contains non-functional, low occupancy phosphorylation 
sites is in contrast to the observation that several phospho-sites are well conserved among 
different organisms, and many of them have low to moderate stoichiometries. For 
example, a comparison of human and mouse orthologues revealed that 88% of the 
phosphoserine and 85% of the phosphothreonine sites are conserved [153]. Moreover, a 
recent study comparing the evolutionary conservation of high, moderate and low 
occupancy phospho-sites in different yeast species, showed that low occupancy sites are 
on average more conserved than high stoichiometry sites [141].  
Concerning the phosphorylation stoichiometries obtained in the present in-depth 
LC-MS/MS analysis, it seems that the rapamycin-regulated phospho-sites have generally 
low to moderate occupancies. This is particularly striking for S1073 of Isw2, S70 of 
Noc2, S72 of Mtc1, T619 of Ldb19 and S37 of Kkq8. At a first glance this would argue 
against their physiological relevance but there are at least four arguments suggesting that 
they may play a role in modulating protein function. (1) The yeast cells used for these 
experiments were not synchronized. Therefore, the measured phosphorylation state of 
each protein corresponds to an average of all different phosphorylation states observable 
throughout the cell cycle. This issue has been addressed in some phosphoproteomic 
analysis that showed dramatic changes in the phosphorylation throughout the cell cycle 
when synchronized cells were used [154]. (2) The effect of rapamycin could be restricted 
to a certain fraction of the total protein molecules present in the cell, which are however 
averaged during cell lysis. This is the case when a protein is present in different 
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subcellular compartments but only one of them physically interacts with the TORC1 
network. This sounds plausible because many proteins are found at different locations in 
the cell: TORC2 itself has been reported to localize at the plasma membrane [131], in 
intracellular membrane compartments [24], in the cytoplasm [155] and to associate with 
ribosomes [156]. The Snf1 kinase localizes to the nucleus, the cytoplasm and the vacuole 
depending on the associating β-subunits [157]. (3) The five phosphoproteins validated 
were all more phosphorylated when yeast cells were treated with rapamycin for 15 
minutes. It is possible (and interesting to pursue) that a prolonged rapamycin treatment 
could lead to increased phosphorylation at those sites.  (4) The method used to calculate 
the phosphorylation stoichiometries in this study may underestimate the true in vivo 
occupancy because it assumes that no difference exist in the ionization and detection 
efficiencies of phosphorylated and unphosphorylated peptides.  
The impact of a phosphate group on the ionization efficiency of a phosphopeptide 
has long been debated and contradictory results have been reported. There are three 
approaches to circumvent this problem. The first approach relies on the empirical 
determination of so-called response ratios of a phosphopeptide and its unphosphorylated 
cognate using synthetic peptide standards spiked in known quantities [158]. These ratios 
are subsequently used to correct the phosphorylation stoichiometries obtained by dividing 
the phosphopeptide intensity by the sum of the intensities of the phosphopeptide and its 
non-phosphorylated counterpart. This approach has the disadvantage that the response 
ratios vary according to the experimental set-up and need to be determined for each 
phosphopeptide. This limits its applicability for large-scale studies. The second strategy 
is based on absolute quantification (AQUA) of peptides, which are synthesized with 
incorporated stable isotopes and can be spiked into a sample in known quantities [159]. 
The spiked peptides and phosphopeptides can then be used to quantify in absolute terms 
the phosphorylation stoichiometry. Again, the use of AQUA peptides is limited to known 
phosphorylations and cannot be used for large-scale studies. The third method requires 
that a sample is split in two fractions, which are then differentially labeled with isotopic-
coded tags. One of the two fractions is then dephosphorylated before being pooled with 
the untreated fraction [160-163]. This method is used to calculate the phospho-site 
occupancy simply by subtracting the intensity of the non-phosphorylated peptide from 
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the sum of the intensity of the dephosphorylated phosphopeptide and the non-
phosphorylated peptide. In this way all calculations are done using the non-
phosphorylated ion species so that the problem associated with different ionization 
efficiencies is circumvented.  
In a recent study, where this last method was employed on a large-scale [141], 
similar results to those obtained in the present in-depth LC-MS/MS analysis were 
reported (Table 3.7). This suggests that the low phosphorylation stoichiometries 
measured for S1073 of Isw2, S70 of Noc2, S72 of Mtc1, T619 of Ldb19 and S37 of Kkq8 
are not a consequence of differences in the ionization efficiencies between a peptide and 
its cognate phosphopeptide. In more general terms this also demonstrates that, under the 
LC-MS/MS conditions used in present in-depth LC-MS/MS analysis, ionization 
efficiency differences do not significantly affect the calculation of phosphorylation 
stoichiometries. As a result the direct comparison of the ion tracings of a phosphopeptide 
and its unphosphorylated cognate seems to be a reliable way to estimate phospho-site 
occupancy levels. Interestingly, even though very similar, the phosphorylation 
stoichiometries obtained in the present study were on average slightly lower than those 
obtained by Wu et al. This can be explained by the fact that in that study the 
phosphopeptides were dephosphorylated, which means that for multiply phosphorylated 
peptides the phosphorylation stoichiometries could be overestimated because the 
contribution of each phospho-isoform is summed up and cannot be distinguished in the 
final stoichiometry value.  
 
 
4.4. Biological Relevance of the Selected Candidate Proteins  
 
In the two previous sections four assays, namely rapamycin sensitivity and 
glycogen accumulation of the single deletion strains, SDS-PAGE migration shift upon 
rapamycin treatment, and in depth-LC-MS/MS phosphomapping were applied to 
establish a link between the candidate proteins Hal5, Isw2, Kkq8, Ldb19, Reg1, Sec7, 
Mtc1 and Noc2 and TORC1. Furthermore, it has been shown that the phosphorylation 
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stoichiometries obtained in the in-depth LC-MS/MS analysis are a very good 
approximation of the real in vivo phospho-site occupancies. The question that 
immediately arises is which roles these proteins play in the TORC1 signaling network? In 
the next sections, the implications of some of the validated phosphoproteins in TORC1 
signaling will be presented. 
 
 
4.4.1. Isw2 and Ino1 Link TORC1 Signaling to Inositol Metabolism 
 
Among the validated candidates, Isw2 is very interesting. Isw2 is an ATP-
dependent chromatin remodeling factor [164]. It is involved in repressing INO1 [132], 
early meiotic genes [165] and MATa-specific genes [166] in haploid and MATα cells. To 
perform these functions, Isw2 associates with Itc1 to form the so-called ISW2 complex 
[167]. Several lines of evidence suggest that TORC1 indirectly controls Isw2, which in 
turn regulates INO1 expression. ISW2 deletion, as shown in this study, results in 
rapamycin sensitivity and glycogen accumulation (Figure 3.8 and 3.9). Deletion of INO1 
causes, in turn, a decrease in glycogen accumulation [137]. The proteomic analysis 
revealed that INO1 expression is controlled by TORC1, since rapamycin treatment 
resulted in an elevated Ino1 protein level (Table 3.3). Elevated mRNA levels have also 
been reported for Ino1 upon rapamycin treatment (Figure 3.14C) [42]. At the molecular 
level, both the phosphoproteomic analysis and the in-depth phosphomapping showed that 
TORC1 inhibition stimulates Isw2 phosphorylation at S1079 (Figure 3.11). Interestingly, 
LC-MS/MS analysis of Isw2 showed that Itc1, the second subunit of the ISW2 complex, 
was exclusively present in Isw2 immunoprecipitates from untreated cells (data not 
shown). These data suggest that TORC1 indirectly regulates Isw2 phosphorylation and by 
this also the association of Isw2 and Itc1. In presence of rapamycin the Isw2/Itc1 
complex dissociates and is no longer able to repress INO1 transcription. A possible model 
fitting these observations is illustrated in Figure 4.1. 
 If TORC1 would regulate INO1 expression exclusively through Isw2, the Ino1 
mRNA levels in isw2∆ cells treated with rapamycin should be the same as those 
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measured in untreated isw2∆ cells. Surprisingly this was not the case and rapamycin-
treated isw2∆ cells displayed a stronger derepression of INO1 expression in comparison 
with the untreated isw2∆ cells (Figure 3.14C). The fact that ISW2 deletion and rapamycin 
treatment are additive on INO1 expression could be due to two independent signaling 
branches impinging on INO1, i.e. TORC1 and Isw2. Alternatively, TORC1 could signal 
to INO1 both in an Isw2-dependent and independent manner.  
It is interesting to note that besides Isw2 and Ino1 the phosphorylation of the 
inositol transporter Itr1 and the inositol pyrophosphate synthase Kcs1 were significantly 
affected by rapamycin treatment. The phosphorylation of Itr1 was increased, while Kcs1 
phosphorylation was decreased upon rapamycin treatment (Table 3.1 and 3.2). Thus there 
is evidence that TORC1 regulates inositol metabolism. 
To shed additional light on the regulation of INO1 by Isw2 and TORC1, it is 
important to investigate whether INO1 deletion can compensate the ISW2 deletion in 
regards to glycogen accumulation. Equally important would be to determine whether 
INO1 deletion causes resistance to rapamycin and whether this phenotype can 
compensate the increased sensitivity of isw2∆ cells. Finally, to get a complete picture of 
the link between TORC1 and the ISW2 complex, the kinase or phosphatase connecting 
TORC1 to Isw2 must be identified. This could be done by monitoring T1079 
phosphorylation of Isw2-HA expressed in different yeast strains carrying single kinase 
and phosphatase deletions. Particular attractive are the null mutants of kinases and 
phosphatases which are active and inactive, respectively, when TORC1 is inhibited. 
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Figure 4.1: Model of TORC1-dependent INO1 expression through the control of Isw2/Itc1 association. 
 
 
4.4.2. Ldb19 and Aly2 are Involved in the Regulation of Amino Acid Permeases by 
TORC1 
 
Among the phosphoproteins analyzed in more details, the arrestin-related 
ubiquitin-ligase adaptor Ldb19 is an interesting candidate. Ldb19 (also known as Art1) 
has two PY domains that target the E3 ubiquitin-ligase Rsp5 to its substrates (e.g. Can1) 
for subsequent degradation [128]. Ldb19 is mono-ubiquitinated, as seen by the presence 
of two bands in SDS PAGE that are 7-8 kDa apart (Figure 3.10). Both isoforms are 
phosphorylated in a rapamycin-dependent fashion, suggesting that ubiquitination of 
Ldb19 is independent of TORC1. The link between Ldb19 and TORC1 signaling was 
revealed in a recent report showing that another arrestin-related ubiquitin-ligase adaptor, 
Aly2 (also known as Art3), is directly phosphorylated by the TORC1 target Npr1 [168]. 
Aly2 is necessary to mediate the recycling of Gap1 back from the endosome to the Trans 
Golgi Network [168]. Therefore it is conceivable that a similar mechanism exists linking 
TORC1 and Ldb19 to regulate the trafficking of Can1.  
In the present phosphoproteomic analysis, S155 phosphorylation in Aly2 was 
moderately increased upon rapamycin treatment (1.68 ± 0.28). This change was however 
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not statistically significant based on the stringent statistical criteria chosen for this study. 
It would be intriguing to confirm in vitro phosphorylation of Aly2 by Npr1 and to check 
whether S155 is the regulated phospho-site. It should be noted that S155 
(…RTLS155DNE…) is not located within the known Npr1 consensus motif (K/RSxxK/R) 
[169]. However, since the Npr1 consensus sequence was derived with a set of synthetic 
peptides, it remains possible that Npr1 is able to phosphorylate S155 in vivo. Similar 
considerations apply to Ldb19. Like Aly2, the two regulated phospho-sites in Ldb19 
(…EDIT619PVN… and …HVLT795PHS…) do not conform to the known Npr1 consensus 
site but this should be confirmed in an in vitro phosphorylation assay. Figure 4.2 depicts 
a model explaining the TORC1-dependent regulation of Gap1 and Can1 ubiquitination 
via Aly2 and Ldb19, respectively. 
Other observations linking Ldb19 to TORC1 came from localization studies of 
GFP-tagged Ldb19. The protein perfectly co-localizes with Sec7 [128], the guanine 
nucleotide exchange factor (GEF) for ARF proteins. This is intriguing for two reasons. 
Firstly, in the phosphoproteomic analysis a strikingly increase in Sec7 phosphorylation at 
S772 was measured after rapamycin treatment (Table 3.1). This phosphorylation site is 
closely located to the so-called Sec7 domain (residues 824-1010) [170], which is 
responsible for the ARF GEF catalytic activity of Sec7. Secondly, Sec7 contains a C-
terminal domain responsible for the interaction with the E3 ubiquitin-ligase Rsp5 [171]. 
The fact that so many proteins involved in membrane trafficking and permease sorting 
(i.e. Ldb19, Aly2, Npr1, Sec7 and Bul1) were found differentially phosphorylated in the 
phosphoproteomic analysis upon rapamycin treatment is astonishing and should be 
further investigated (Table 3.1 and 3.2). In particular, the two rapamycin-sensitive sites in 
Ldb19 should be mutated and the rapamycin sensitivity and glycogen accumulation of 
such mutants should be investigated. Furthermore it is intriguing to see if these Ldb19 
phospho-mutants can still co-localize with Sec7 in vivo.  
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Figure 4.2: Model of TORC1-dependent Gap1 and Can1 ubiquitination via (A) Aly2 and (B) Ldb19. 
 
 
 
4.4.3. TORC1 Indirectly Regulates Nap1 and Gin4 Phosphorylations 
 
Among the phosphoproteins chosen for further validation there were Nap1, Reg1, 
Vtc2 and Vtc3. The corresponding deletion mutants, except reg1∆, had normal 
rapamycin sensitivity and glycogen accumulation (Figure 3.8 and 3.9). Since these 
proteins are less phosphorylated in rapamycin-treated cells, they qualify for in vitro 
kinase assays to check whether they become directly phosphorylated by recombinant Tor.  
Nap1, a pleiotropic protein involved in microtubule dynamics, bud 
morphogenesis and histones transport [172, 173], was specifically phosphorylated by Tor 
in vitro (Figure 3.15B and 3.16). Several lines of evidence suggest that TORC1 signals to 
Nap1. (1) In the phosphoproteome, Nap1 phosphorylation on T20, T24 and S27 
decreased in response to rapamycin treatment (Table 3.2). (2) T20 and T24 are TP sites 
that are typically phosphorylated by (m)TORC1 consensus motifs [66, 143]. (3) In a 
recent yeast interactomic study, Nap1 was shown to physically interact with Tor1 and 
other Tor1-associated proteins [129]. (4) The nap1∆ strain is more sensitive to rapamycin 
[135] and it has abnormal cellular localization of the Gin4 kinase. (5) The gin4∆ strain in 
turn is more resistant to rapamycin and accumulates less glycogen than wild-type [137]. 
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(6) In the present phosphoproteomic analysis Gin4 phosphorylation responded to 
rapamycin treatment: S502 became less, and S666 more phosphorylated (Table 3.1 and 
Table 3.2). All these data, and the fact that recombinant Tor phosphorylates Nap1 in 
vitro, suggest that TORC1 signals to Nap1 (and Gin4).  
To confirm the phosphorylation sites found in the present phosphoproteome, in-
depth phosphomapping of Nap1 was carried out. Unfortunately, even though the region 
of the protein that contains T20, T24 and/or S27 could be easily recovered by 
trypsinolysis, phosphorylation at these sites could never be detected in 
immunoprecipitates of Nap1 (Figure 3.18). Identical results were obtained when Nap1 
was expressed from a multi-copy plasmid or from a genomically tagged strain (data not 
shown). Also, in the case of very low-level phosphorylation, phosphopeptide enrichment 
did not indicate any phosphorylation at these N-terminal sites (data not shown). A 
possible explanation of these conflicting findings is that the N-terminal phospho-sites 
identified in the phosphoproteome are incorrect. This is, however, very unlikely because 
the same phospho-sites were found in several other phosphoproteomic studies [92, 110, 
174, 175]. Moreover, manual inspection of the phosphoproteomic data confirmed the 
presence of the three phosphorylation sites and their rapamycin regulation. Correct 
identification was supported by the high Mascot scores (~50-60) of the MS/MS spectra. 
Another possibility to explain the lack of the phosphorylated residues is inadvertent 
dephosphorylation during the immunoprecipitation. To alleviate the problem, Nap1-HA 
could be immunoprecipitated for a shorter time or, alternatively, cell lysis could be 
carried out in a strongly denaturing SDS buffer to stop unwanted dephosphorylation.  
Nevertheless, even though the regulated phospho-sites identified in the 
phosphoproteome could not be identified in the subsequent in-depth LC-MS/MS analysis, 
the fact that Tor phosphorylates Nap1 in vitro left the possibility open whether Nap1 is a 
true TORC1 substrate. One way out of the dilemma was to identify the sites 
phosphorylated in vitro by recombinant Tor. For this, in vitro phosphorylated Nap1 was 
digested and analyzed by LC-MS/MS. Surprisingly, identification of the fractions by LC-
MS/MS that contained radioactively-labeled Nap1 phosphopeptides revealed that the in 
vitro phosphorylation sites are S76, S82 and S140 (Figure 3.17). This rules the possibility 
out that T20, T24 and S27 become phosphorylated in vitro. Moreover, this data suggests 
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that in vitro phosphorylation of Nap1 by recombinant Tor is not physiologically relevant, 
as both the phosphoproteomic and the subsequent in-depth LC-MS/MS analysis showed 
that the sites S76, S82 and S140 are not affected by rapamycin treatment (Table 3.8 and 
Figure 3.18). 
These results suggest that, even though physically interacting, Nap1 is not a direct 
substrate of TORC1. Nevertheless, genetic and biochemical evidences support the view 
that Nap1 is part of the TORC1 network and that the kinase Gin4 is also involved in this 
signaling branch. In addition, even though they could not be identified in the in-depth 
LC-MS/MS analysis, T20, T24 and S27 remain very likely rapamycin-sensitive sites, 
since they were consistently and significantly found regulated in the phosphoproteomic 
analysis (Figure 3.2). In a recent global phosphorylation stoichiometry survey [141], the 
occupancy of these sites has been estimated around 25%, which makes them attractive 
physiological sites for a regulation by TORC1. Finally the observation that Nap1 is 
phosphorylated in vitro at S76, S82 and S140, a non-physiological event, confirms the 
preference of Tor toward the phosphorylation of hydrophobic motifs. 
 
 
4.4.4. TORC1 Impinges on Snf1 Signaling via Reg1  
 
Similar to Nap1, Reg1 was also found hypophosphorylated upon rapamycin 
treatment in the phosphoproteomic analysis, which qualified Reg1 for in vitro kinase 
assays with recombinant Tor. Interestingly, Reg1 was robustly phosphorylated in vitro 
even when Tor was incubated with its specific inhibitor PP242 (Figure 3.15B). This is 
probably due to a kinase co-immunoprecipitating with Reg1. Since Reg1 contains in its 
C-terminus several residues conforming to the canonical casein kinase II (CK II) 
consensus site, it is likely that the in vitro phosphorylation of Reg1 is caused by active 
CK II stably associating with Reg1 during immunoprecipitation. This was further 
supported by the identification by LC-MS/MS of peptides from all four CK II subunits in 
Reg1 immunoprecipitates (data not shown). 
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Reg1 remains an interesting candidate despite the fact that it is not a direct 
TORC1 substrate. Its deletion influenced both rapamycin sensitivity and glycogen 
accumulation (Figure 3.8 and 3.9). Furthermore, its role in activating the Snf1 kinase 
makes Reg1 a likely TORC1 effector. Reg1 is necessary for Snf1 inactivation by 
dephosphorylation of the essential T210 [133]. Interestingly, even though TORC1 
primarily senses the level of amino acids and Snf1 is necessary for growth in the absence 
of glucose, it was shown that TORC1 signals to Snf1 because T210 is phosphorylated in 
a rapamycin-dependent manner [134]. Therefore, it seems that both glucose depletion and 
TORC1 inhibition up-regulate Snf1 activity and, as a result, it is likely that Reg1 is 
inhibited under such conditions. This renders S570 phosphorylation an activating event. 
To demonstrate this hypothesis all rapamycin-sensitive phosphorylation sites in Reg1 
should be mapped and the activity of Snf1 should be investigated in cells lacking those 
phosphorylation sites. This could be addressed, for example, by measuring the expression 
of Snf1-sensitive genes (like Adr1, Mig1, and Sip4) in a Reg1 S/T-to-A mutant.  
 
 
4.4.5. The VTC Proteins Link TORC1 and Microautophagy 
 
Similar to Nap1, the vacuolar protein Vtc2 was also specifically phosphorylated 
by Tor in vitro (Figure 3.15B). Vtc2 is unusual because its protein level was dependent 
on its phosphorylation state. Phosphorylation of Vtc2 stabilizes the protein. This is a 
common feature among protein kinases that have been found to be thermally unstable 
when certain residues are not phosphorylated [176, 177]. This also agrees with the 
observation that Vtc2 is prone to aggregation when it is alone incubated at 30°C (Figure 
3.15C). The effect of TORC1 on Vtc2 is intriguing when considering the sub-cellular 
localization and physiological function of Vtc2. Vtc2 together with Vtc1, Vtc3 and Vtc4 
forms the so-called vacuolar transporter chaperone (VTC) complex [178]. The VTC 
complex is involved in microautophagy, a process of direct invagination of the vacuolar 
membrane into the vacuolar lumen. This process compensates for the massive influx of 
membranes caused by macroautophagy. In the phosphoproteome, both Vtc2 and Vtc3 
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were less phosphorylated upon rapamycin treatment (Table 3.2), while Vtc1 and Vtc4 
could not be detected. This agrees with their membrane topology, since Vtc1 and Vtc4 
are integral membrane proteins, whereas the majority of Vtc2 and Vtc3 proteins do not 
span the vacuolar membrane [179]. As a result, it is likely that Vtc1 and Vtc4, but not 
Vtc2 and Vtc3, are lost by aggregation when the cell extract is heated to 95°C prior to gel 
electrophoresis. In the phosphoproteome, Vtc2 was found to be differentially 
phosphorylated at S182, S187, S196 and S583 (Table 3.2). These residues are located 
within the cytosolic part of Vtc2 (residues 1-693) and are therefore physically accessible 
to TORC1 all the more that TORC1 was found to be localized to the outer vacuolar 
membrane [131, 155, 180]. Furthermore, the involvement of the VTC proteins in TORC1 
signaling is also highlighted by the finding that their sub-cellular localization is affected 
by rapamycin treatment or nitrogen starvation [181]. To shed more light into the 
regulation of the VTC proteins, and more specifically Vtc2, by TORC1, exhaustive 
phosphomapping of all in vivo phosphorylation sites should be done. In parallel the in 
vitro phosphorylated sites on Vtc2 should be mapped. Next it would be intriguing to 
check whether the mutation of those regulated phospho-sites is impairing 
microautophagy and affecting the subcellular localization change induced by rapamycin 
treatment.  
 
 
4.5. Novel Less Characterized TORC1 Targets Identified in the 
Quantitative Phosphoproteomic Analysis 
 
Recently a global protein kinase and phosphatase interaction network in yeast has 
been published [129]. In this study it was found that TORC1 physically interacts with 
Cdc14, Fmp48, Kdx1, Ksp1, Mks1, Nap1, Nnk1, Npr1, Rck1, Rtg3, Sky1, and Tax4. 
Interestingly six of these proteins (Ksp1, Mks1, Nap1, Npr1, Rtg3, and Sky1) were also 
found in the present phosphoproteome to be affected at the phosphorylation level by 
rapamycin treatment (Table 3.1 and Table 3.2). All of them except Rtg3 were less 
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phosphorylated in presence of rapamycin, suggesting that they may be direct TORC1 
substrates.  
Ksp1 is a serine/threonine protein kinase required for haploid filamentous growth 
(Bharuca 2008). In the present study Ksp1 was found to be phosphorylated by PKA in a 
TORC1-specific manner (Figure 3.6), which was in agreement with the 
phosphoproteomic experiments that revealed a down-regulation in phosphorylation at 
S827 and S884 (RRLS827MEQ and RRSS884ANE) upon rapamycin treatment (Table 3.2) 
[122]. However, Ksp1 was found regulated at two additional sites in the 
phosphoproteomic analysis, for instance T525 and/or S529 (DFFT525PPS529VQH) (Table 
3.2). The first of them is surrounded by hydrophobic residues and is a TP site, which 
would agree with the hypothetical (m)TORC1 consensus motif [66, 143]. To verify this 
hypothesis, an in vitro kinase assay using recombinant Tor should be performed and, in 
case of a positive outcome, the in vitro phosphorylated sites should be mapped to confirm 
that phosphorylation is really occurring at these specific residues. Interestingly, if Ksp1 
will be eventually shown to be a direct TORC1 substrate, it will be one of the many 
proteins targeted by both TORC1 and PKA. Furthermore, since yeast filamentation 
requires Snf1 phosphorylation, Ksp1 could be involved in its regulation. 
Mks1 was already shown to be involved in TORC1 signaling as a negative 
regulator of RTG gene expression [49, 182] and it was found less phosphorylated at S518 
in the phosphoproteomic analysis (Table 3.2). This site (RRQS518MDI) conforms very 
well to the know PKA consensus motif [122], which has been however never shown to be 
directly targeted by TORC1 [66, 143].  
 Sky1 is a mRNA splicing factor and, considering that 90% of mRNA splicing is 
devoted to process RP mRNAs [26], it would be reasonable that TORC1 directly 
impinges on this protein as an alternative way to regulate ribosome biogenesis. However 
the regulated phospho-sites identified in the phosphoproteome (S445/S449) do not 
conform to the known TORC1 consensus motif (Table 3.2) [66, 143]. Interestingly, a 
second protein involved in mRNA processing, Ccr4, was found less phosphorylated upon 
rapamycin treatment (Table 3.2). Ccr4 is a component of the CCR4-NOT transcriptional 
complex, responsible for deadenylation-dependent mRNA decay, which may explain 
how TORC1 regulates mRNA stability.  
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